<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0410200180
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Bortezomib BOS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BORTEZOMIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous, Subcutaneous
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1523.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Boston Oncology Arabia" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX32
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Bortezomib BOS contains the active substance bortezomib, a so-called &lsquo;proteasome inhibitor&rsquo;. Proteasomes play an important role in controlling cell function and growth. By interfering with their function, bortezomib can kill cancer cells.</p><p>Bortezomib BOS is used for the treatment of multiple myeloma (a cancer of the bone marrow) in patients older than 18 years:</p><p>- alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.</p><p>- In combination with the medicines melphalan and prednisolone, for patients whose disease has not been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell transplantation.</p><p>- in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment).</p><p>Bortezomib BOS is used for the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously treated and for whom blood stem cell transplantation is unsuitable</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Bortezomib BOS:</strong></p><p>- if you are allergic to bortezomib, boron or to any of the other ingredients of this medicine (listed in section 6)</p><p>- if you have certain severe lung or heart problems.</p><p><em>&nbsp;</em></p><p><strong>Warnings and Precautions</strong></p><p><strong>You should tell your doctor if you have any of the following</strong></p><p>&middot;&nbsp; low numbers of red or white blood cells</p><p>&middot;&nbsp; bleeding problems and/or low number of platelets in your blood</p><p>&middot;&nbsp; diarrhoea, constipation, nausea or vomiting</p><p>&middot;&nbsp; fainting, dizziness or light-headedness in the past</p><p>&middot;&nbsp; kidney problems</p><p>&middot;&nbsp; moderate to severe liver problems</p><p>&middot;&nbsp; numbness, tingling, or pain in the hands or feet (neuropathy) in the past</p><p>&middot;&nbsp; heart or blood pressure problems</p><p>&middot;&nbsp; shortness of breath or cough</p><p>&middot;&nbsp; seizures</p><p>&middot;&nbsp; shingles (localised including around the eyes or spread across the body)</p><p>&middot;&nbsp; symptoms of tumor lysis syndrome such as muscle cramping, muscle weakness, confusion, visual loss or disturbances and shortness of breath</p><p>&middot;&nbsp; memory loss, trouble thinking, difficulty with walking or loss of vision. These may be signs of a serious brain infection and your doctor may suggest further testing and follow-up.</p><p>&nbsp;</p><p>You will have to take regular blood tests before and during your treatment with Bortezomib BOS, to check your blood cell counts regularly.</p><p>If you have mantle cell lymphoma and are given the medicine rituximab with Bortezomib BOS you should tell your doctor:</p><p>&middot;&nbsp; if you think you have hepatitis infection now or have had it in the past. In a few cases, patients who have had hepatitis B might have a repeated attack of hepatitis, which can be fatal. If you have a history of hepatitis B infection you will be carefully checked by your doctor for signs of active hepatitis B.</p><p>&nbsp;</p><p>You must read the package leaflets of all medicinal products to be taken in combination with Bortezomib BOS for information related to these medicines before starting treatment with Bortezomib BOS. When thalidomide is used, particular attention to pregnancy testing and prevention requirements is needed (see Pregnancy and breast-feeding in this section).</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Bortezomib BOS should not be used in children and adolescents because it is not known how the medicine will affect them.</p><p>&nbsp;</p><p><strong>Other medicines and Bortezomib BOS</strong></p><p>Please tell your doctor, or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor if you are using medicines containing any of the following active substances:</p><p>- ketoconazole, used to treat fungal infections</p><p>ritonavir, used to treat HIV infection</p><p>- rifampicin, an antibiotic used to treat bacterial infections</p><p>- carbamazepine, phenytoin or phenobarbital used to treat epilepsy</p><p>- St. John&rsquo;s Wort (Hypericum perforatum), used for depression or other conditions</p><p>- oral antidiabetics</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>You should not use Bortezomib BOS if you are pregnant, unless clearly necessary.</p><p>Both men and women receiving Bortezomib BOS must use effective contraception during and for up to 3 months after treatment. If, despite these measures, pregnancy occurs, tell your doctor immediately.</p><p>You should not breast-feed while using Bortezomib BOS. Discuss with your doctor when it is safe to restart breast-feeding after finishing your treatment.</p><p>Thalidomide causes birth defects and foetal death. When Bortezomib BOS is given in combination with thalidomide you must follow the pregnancy prevention programme for thalidomide (see package leaflet for thalidomide).</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Bortezomib BOS might &nbsp;cause tiredness , dizziness, fainting, or blurred vision. Do not drive or operate tools or machines if you experience such side effects; even if you do not, you should still be cautious</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will work out your dose of Bortezomib BOS according to your height and weight (body surface area). The usual starting dose of Bortezomib BOS is 1.3 mg/m<sup>2</sup> body surface area twice a week.</p><p>Your doctor may change the dose and total number of treatment cycles, depending on your response to the treatment on the occurrence of certain side effects and on your underlying conditions (e.g. liver problems).</p><p>&nbsp;</p><p><em>Progressive multiple myeloma</em></p><p>When Bortezomib BOS is given alone, you will receive 4 doses of Bortezomib BOS intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a 10-day &lsquo;rest period&rsquo; without treatment. This 21-day period (3 weeks) corresponds to one treatment cycle. You might receive up to 8 cycles (24 weeks).</p><p>&nbsp;</p><p>You may also be given Bortezomib BOS together with the medicines pegylated liposomal doxorubicin or dexamethasone.</p><p>&nbsp;</p><p>When Bortezomib BOS is given together with pegylated liposomal doxorubicin, you will receive Bortezomib BOS intravenously or subcutaneously as a 21-day treatment cycle and pegylated liposomal doxorubicin 30 mg/m<sup>2</sup> is given on day 4 of the Bortezomib BOS 21-day treatment cycle as an intravenous infusion after the Bortezomib BOS.</p><p>You might receive up to 8 cycles (24 weeks).</p><p>&nbsp;</p><p>When Bortezomib BOS is given together with dexamethasone, you will receive Bortezomib BOS intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 20 mg is given orally on days 1, 2, 4, 5, 8, 9, 11, and 12, of the Bortezomib BOS, 21-day treatment cycle. You might receive up to 8 cycles (24 weeks).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><em>Previously untreated multiple myeloma</em></p><p>If you have not been treated before for multiple myeloma, and you are not suitable for blood stem cell transplantation you will receive Bortezomib BOS together with two other medicines; melphalan and prednisone.</p><p>&nbsp;</p><p>In this case, the duration of a treatment cycle is 42 days (6 weeks). You will receive 9 cycles (54 weeks).</p><p>&middot;&nbsp; In cycles 1 to 4, Bortezomib BOS is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.</p><p>&middot;&nbsp; In cycles 5 to 9, Bortezomib BOS is administered once weekly on days 1, 8, 22 and 29.</p><p>melphalan (9 mg/m<sup>2</sup>) and prednisone (60 mg/m<sup>2</sup>) are both given orally on days 1, 2, 3 and 4 of the first week of each cycle.</p><p><strong>&nbsp;</strong></p><p>If you have not been treated before for multiple myeloma, and you are suitable for blood stem cell transplantation you will receive Bortezomib BOS intravenously or subcutaneously together with the medicines dexamethasone, or dexamethasone and thalidomide, as induction treatment.</p><p>&nbsp;</p><p>When Bortezomib BOS is given together with dexamethasone, you will receive Bortezomib BOS intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib BOS &nbsp;21-day treatment cycle.</p><p>You will receive 4 cycles (12 weeks).</p><p>&nbsp;</p><p>When Bortezomib BOS is given together with thalidomide and dexamethasone, the duration of a treatment cycle is 28 days (4 weeks).</p><p>&nbsp;</p><p>Dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib BOS 28-day treatment cycle and thalidomide is given orally daily at 50 mg up to day 14 of the first cycle, and if tolerated the thalidomide dose is increased to 100 mg on days 15-28 and may be further increased to 200 mg daily from the second cycle onwards.</p><p>&nbsp;</p><p>You might receive up to 6 cycles (24 weeks).</p><p><em>&nbsp;</em></p><p><em>Previously untreated mantle cell lymphoma </em></p><p>If you have not been treated before for mantle cell lymphoma you will receive Bortezomib BOS intravenously or subcutaneously together with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone .Bortezomib BOS is given intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a &lsquo;rest period&rsquo; without treatment. The duration of a treatment cycle is 21 days (3 weeks). You might receive up to 8 cycles (24 weeks).</p><p>The following medicinal products are given on day 1 of each Bortezomib BOS &nbsp;21-day treatment cycle as intravenous infusions:</p><p>Rituximab at 375 mg/m<sup>2</sup>, cyclophosphamide at 750 mg/m<sup>2</sup> and doxorubicin at 50 mg/m<sup>2</sup>.</p><p>Prednisone is given orally at 100 mg/m<sup>2 </sup>on days 1, 2, 3, 4 and 5 of the Bortezomib BOS treatment cycle.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>How Bortezomib BOS is given</strong></p><p>This medicine is for intravenous or subcutaneous use. Bortezomib BOS will be administered by a health care professional experienced in the use of cytotoxic medicines.</p><p>Bortezomib BOS powder has to be dissolved before administration. This will be done by a healthcare professional. The resulting solution is then either injected into a vein or under the skin. Injection into a vein is rapid, taking 3 to 5 seconds. Injection under the skin is in either the thighs or the abdomen.</p><p><strong>&nbsp;</strong></p><p><strong>If you are given too much</strong><strong> Bortezomib BOS</strong></p><p>As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much. In the unlikely event of an overdose, your doctor will monitor you for side effects</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these effects may be serious.</p><p>If you are given Bortezomib BOS for multiple myeloma or mantle cell lymphoma, tell your doctor straight away if you notice any of the following symptoms:</p><p>- muscle cramping, muscle weakness</p><p>- confusion, visual loss or disturbances, blindness, seizures, headaches</p><p>- shortness of breath, swelling of your feet or changes in your heart beat, high blood pressure, tiredness, fainting</p><p>- coughing and breathing difficulties or tightness in the chest.</p><p>&nbsp;</p><p>Treatment with Bortezomib BOS can very commonly cause a decrease in the numbers of red and white blood cells and platelets in your blood. Therefore, you will have to take regular blood tests before and during your treatment with Bortezomib BOS, to check your blood cell counts regularly. You may experience a reduction in the number of:</p><p>-&nbsp; platelets, which may make you be more prone to bruising, or to bleeding without obvious injury (e.g., bleeding from your bowels, stomach, mouth and gum or bleeding in the brain or bleeding from the liver)</p><p>- &nbsp;red blood cells, which can cause anaemia, with symptoms such as tiredness and paleness</p><p>- &nbsp;white blood cells may make you more prone to infections or flu-like symptoms.</p><p>&nbsp;</p><p>If you are given Bortezomib BOS for the treatment of multiple myeloma the side effects you may get are listed below:</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p>&middot;&nbsp; Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet, due to nerve damage</p><p>&middot;&nbsp; Reduction in the number of red blood cells and or white blood cells (see above)</p><p>&middot;&nbsp; Fever</p><p>&middot;&nbsp; Feeling sick (nausea) or vomiting, loss of appetite</p><p>&middot;&nbsp; Constipation with or without bloating (can be severe)</p><p>&middot;&nbsp; Diarrhoea: if this happens, it is important that you drink more water than usual. Your doctor may give you another medicine to control diarrhoea</p><p>&middot;&nbsp; Tiredness (fatigue), feeling weak</p><p>&middot;&nbsp; Muscle pain, bone pain</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp; Low blood pressure, sudden fall of blood pressure on standing which may lead to fainting</p><p>&middot;&nbsp; High blood pressure</p><p>&middot;&nbsp; Reduced functioning of your kidneys</p><p>&middot;&nbsp; Headache</p><p>&middot;&nbsp; General ill feeling, pain, vertigo, light-headedness, a feeling of weakness or loss of consciousness</p><p>&middot;&nbsp; Shivering</p><p>&middot;&nbsp; Infections, including pneumonia, respiratory infections, bronchitis, fungal infections, coughing with phlegm, flu like illness</p><p>&middot;&nbsp; Shingles (localised including around the eyes or spread across the body)</p><p>&middot;&nbsp; Chest pains or shortness of breath with exercise</p><p>&middot;&nbsp; Different types of rash</p><p>&middot;&nbsp; Itching of the skin, lumps on the skin or dry skin</p><p>&middot;&nbsp; Facial blushing or tiny broken capillaries</p><p>&middot;&nbsp; Redness of the skin</p><p>&middot;&nbsp; Dehydration</p><p>&middot;&nbsp; Heartburn, bloating, belching, wind, stomach pain, bleeding from your bowels or stomach</p><p>&middot;&nbsp; Alteration of liver functioning</p><p>&middot;&nbsp; A sore mouth or lip, dry mouth, mouth ulcers or throat pain</p><p>&middot;&nbsp; Weight loss, loss of taste</p><p>&middot;&nbsp; Muscle cramps, muscle spasms, muscle weakness, pain in your limbs</p><p>&middot;&nbsp; Blurred vision</p><p>&middot;&nbsp; Infection of the outermost layer of the eye and the inner surface of the eyelids (conjunctivitis)</p><p>&middot;&nbsp; Nose bleeds</p><p>&middot;&nbsp; Difficulty or problems in sleeping, sweating, anxiety, mood swings, depressed mood, restlessness or agitation, changes in your mental status, disorientation</p><p>&middot;&nbsp; Swelling of body, to include around eyes and other parts of the body</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp; Heart failure, heart attack, chest pain, chest discomfort, increased or reduced heart rate</p><p>&middot;&nbsp; Failing of your kidneys</p><p>&middot;&nbsp; Inflammation of a vein, blood clots in your veins and lungs</p><p>&middot;&nbsp; Problems with blood clotting</p><p>&middot;&nbsp; Insufficient circulation</p><p>&middot;&nbsp; Inflammation of the lining around your heart or fluid around your heart</p><p>&middot;&nbsp; Infections including urinary tract infections, the flu, herpes virus infections, ear infection and cellulitis</p><p>&middot;&nbsp; Bloody stools, or bleeding from mucosal membranes, e.g., mouth, vagina</p><p>&middot;&nbsp; Cerebrovascular disorders</p><p>&middot;&nbsp; Paralysis, seizures, falling, movement disorders, abnormal or change in, or reduced sensation (feeling, hearing, tasting, smelling), attention disturbance, trembling, twitching</p><p>&middot;&nbsp; Arthritis, including inflammation of the joints in the fingers, toes, and the jaw</p><p>&middot;&nbsp; Disorders that affect your lungs, preventing your body from getting enough oxygen. Some of these include difficulty breathing, shortness of breath, shortness of breath without exercise, breathing that becomes shallow, difficult or stops, wheezing</p><p>&middot;&nbsp; Hiccups, speech disorders</p><p>&middot;&nbsp; Increased or decreased urine production (due to kidney damage), painful passing of urine or blood/proteins in the urine, fluid retention</p><p>&middot;&nbsp; Altered levels of consciousness, confusion, memory impairment or loss</p><p>&middot;&nbsp; Hypersensitivity</p><p>&middot;&nbsp; Hearing loss, deafness or ringing in the ears, ear discomfort</p><p>&middot;&nbsp; Hormone abnormality which may affect salt and water absorption</p><p>&middot;&nbsp; Overactive thyroid gland</p><p>&middot;&nbsp; Inability to produce enough insulin or resistance to normal levels of insulin</p><p>&middot;&nbsp; Irritated or inflamed eyes, excessively wet eyes, painful eyes, dry eyes, eye infections, discharge from the eyes, abnormal vision, bleeding of the eye</p><p>&middot;&nbsp; Swelling of your lymph glands</p><p>&middot;&nbsp; Joint or muscle stiffness, sense of heaviness, pain in your groin</p><p>&middot;&nbsp; Hair loss and abnormal hair texture</p><p>&middot;&nbsp; Allergic reactions</p><p>&middot;&nbsp; Redness or pain at the injection site</p><p>&middot;&nbsp; Mouth pain</p><p>&middot;&nbsp; Infections or inflammation of the mouth, mouth ulcers, oesophagus, stomach and intestines, sometimes associated with pain or bleeding, poor movement of the intestines (including blockage), abdominal or oesophageal discomfort, difficulty swallowing, vomiting of blood</p><p>&middot;&nbsp; Skin infections</p><p>&middot;&nbsp; Bacterial and viral infections</p><p>&middot;&nbsp; Tooth infection</p><p>&middot;&nbsp; Inflammation of the pancreas, obstruction of the bile duct</p><p>&middot;&nbsp; Genital pain, problem having an erection</p><p>&middot;&nbsp; Weight increase</p><p>&middot;&nbsp; Thirst</p><p>&middot;&nbsp; Hepatitis</p><p>&middot;&nbsp; Injection site or injection device related disorders</p><p>&middot;&nbsp; Skin reactions and disorders (which may be severe and life threatening), skin ulcers</p><p>&middot;&nbsp; Bruises, falls and injuries</p><p>&middot;&nbsp; Inflammation or haemorrhage of the blood vessels that can appear as small red or purple dots (usually on the legs) to large bruise-like patches under the skin or tissue</p><p>&middot;&nbsp; Benign cysts</p><p>&middot;&nbsp; A severe reversible brain condition which includes seizures, high blood pressure, headaches, tiredness, confusion, blindness or other vision problems.</p><p><strong>&nbsp;</strong></p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><p>&middot;&nbsp; Heart problems to include heart attack, angina</p><p>&middot;&nbsp; Flushing</p><p>&middot;&nbsp; Discoloration of the veins</p><p>&middot;&nbsp; Inflammation of the spinal nerve</p><p>&middot;&nbsp; Problems with your ear, bleeding from your ear</p><p>&middot;&nbsp; Underactivity of your thyroid gland</p><p>&middot;&nbsp; Budd&ndash;Chiari syndrome (the clinical symptoms caused by blockage of the hepatic veins)</p><p>&middot;&nbsp; Changes in or abnormal bowel function</p><p>&middot;&nbsp; Bleeding in the brain</p><p>&middot;&nbsp; Yellow discolouration of eyes and skin (jaundice)</p><p>&middot;&nbsp; Serious allergic reaction (anaphylactic shock) signs of which may include difficulty breathing, chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised<strong> </strong>lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse</p><p>&middot;&nbsp; Breast disorders</p><p>&middot;&nbsp; Vaginal tears</p><p>&middot;&nbsp; Genital swelling</p><p>&middot;&nbsp; Inability to tolerate alcohol consumption</p><p>&middot;&nbsp; Wasting, or loss of body mass</p><p>&middot;&nbsp; Increased appetite</p><p>&middot;&nbsp; Fistula</p><p>&middot;&nbsp; Joint effusion</p><p>&middot;&nbsp; Cysts in the lining of joints (synovial cysts)</p><p>&middot;&nbsp; Fracture</p><p>&middot;&nbsp; Breakdown of muscle fibers leading to other complications</p><p>&middot;&nbsp; Swelling of the liver, bleeding from the liver</p><p>&middot;&nbsp; Cancer of the kidney</p><p>&middot;&nbsp; Psoriasis like skin condition</p><p>&middot;&nbsp; Cancer of the skin</p><p>&middot;&nbsp; Paleness of the skin</p><p>&middot;&nbsp; Increase of platelets or plasma cells (a type of white cell) in the blood</p><p>&middot;&nbsp; Blood clot in small blood vessels (thrombotic microangiopathy)</p><p>&middot;&nbsp; Abnormal reaction to blood transfusions</p><p>&middot;&nbsp; Partial or total loss of vision</p><p>&middot;&nbsp; Decreased sex drive</p><p>&middot;&nbsp; Drooling</p><p>&middot;&nbsp; Bulging eyes</p><p>&middot;&nbsp; Sensitivity to light</p><p>&middot;&nbsp; Rapid breathing</p><p>&middot;&nbsp; Rectal pain</p><p>&middot;&nbsp; Gallstones</p><p>&middot;&nbsp; Hernia</p><p>&middot;&nbsp; Injuries</p><p>&middot;&nbsp; Brittle or weak nails</p><p>&middot;&nbsp; Abnormal protein deposits in your vital organs</p><p>&middot;&nbsp; Coma</p><p>&middot;&nbsp; Intestinal ulcers</p><p>&middot;&nbsp; Multi-organ failure</p><p>&middot;&nbsp; Death</p><p>&nbsp;</p><p>If you are given Bortezomib BOS together with other medicines for the treatment of mantle cell lymphoma the side effects you may get are listed below:</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p>&middot;&nbsp; Pneumonia</p><p>&middot;&nbsp; Loss of appetite</p><p>&middot;&nbsp; Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet, due to nerve damage</p><p>&middot;&nbsp; Nausea and vomiting</p><p>&middot;&nbsp; Diarrhoea</p><p>&middot;&nbsp; Mouth ulcers</p><p>&middot;&nbsp; Constipation</p><p>&middot;&nbsp; Muscle pain, bone pain</p><p>&middot;&nbsp; Hair loss and abnormal hair texture</p><p>&middot;&nbsp; Tiredness, feeling weak</p><p>&middot;&nbsp; &nbsp;Fever</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>&middot;&nbsp; Shingles (localized including around the eyes or spread across the body)</p><p>&middot;&nbsp; Herpes virus infections</p><p>&middot;&nbsp; Bacterial and viral infections</p><p>&middot;&nbsp; Respiratory infections, bronchitis, coughing with phlegm, flu like illness</p><p>&middot;&nbsp; Fungal infections</p><p>&middot;&nbsp; Hypersensitivity (allergic reaction)</p><p>&middot;&nbsp; Inability to produce enough insulin or resistance to normal levels of insulin</p><p>&middot;&nbsp; &nbsp;Fluid retention</p><p>&middot;&nbsp; Difficulty or problems in sleeping</p><p>&middot;&nbsp; Loss of consciousness</p><p>&middot;&nbsp; Altered level of consciousness, confusion</p><p>&middot;&nbsp; Feeling dizzy</p><p>&middot;&nbsp; Increased heartbeat, high blood pressure, sweating,</p><p>&middot;&nbsp; Abnormal vision, blurred vision</p><p>&middot;&nbsp; Heart failure, heart attack, chest pain, chest discomfort, increased or reduced heart rate</p><p>&middot;&nbsp; High or low blood pressure</p><p>&middot;&nbsp; Sudden fall of blood pressure upon standing which may lead to fainting</p><p>&middot;&nbsp; Shortness of breath with exercise</p><p>&middot;&nbsp; Cough</p><p>&middot;&nbsp; Hiccups</p><p>&middot;&nbsp; Ringing in the ears, ear discomfort</p><p>&middot;&nbsp; Bleeding from your bowels or stomach</p><p>&middot;&nbsp; Heartburn</p><p>&middot;&nbsp; Stomach pain, bloating</p><p>&middot;&nbsp; Difficulty swallowing</p><p>&middot;&nbsp; Infection or inflammation of the stomach and intestines</p><p>&middot;&nbsp; Stomach pain</p><p>&middot;&nbsp; Sore mouth or lip, throat pain</p><p>&middot;&nbsp; Alteration of liver function</p><p>&middot;&nbsp; Itching of skin</p><p>&middot;&nbsp; Redness of skin</p><p>&middot;&nbsp; Rash</p><p>&middot;&nbsp; Muscle spasms</p><p>&middot;&nbsp; Infection of the urinary tract</p><p>&middot;&nbsp; Pain in limbs</p><p>&middot;&nbsp; Swelling of body, to include eyes and other parts of the body</p><p>&middot;&nbsp; Shivering</p><p>&middot;&nbsp; Redness and pain at injection site</p><p>&middot;&nbsp; General ill feeling</p><p>&middot;&nbsp; Weight loss</p><p>&middot;&nbsp; Weight increase</p><p>&nbsp;</p><p>&nbsp;<strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp; Hepatitis</p><p>&middot;&nbsp; Severe allergic reaction (anaphylactic reaction) signs of which may include difficulty breathing, chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse</p><p>&middot;&nbsp; &nbsp;Movement disorders, paralysis, twitching</p><p>&middot;&nbsp; Vertigo</p><p>&middot;&nbsp; Hearing loss, deafness</p><p>&middot;&nbsp; Disorders that affect your lungs, preventing your body from getting enough oxygen. Some of these include difficulty breathing, shortness of breath, shortness of breath without exercise, breathing that becomes shallow, difficult or stops, wheezing</p><p>&middot;&nbsp; Blood clots in your lungs</p><p>&middot;&nbsp; Yellow discoloration of the eyes and skin (jaundice)</p><p>Lump in the eyelid (chalazion), red and swollen eyelids</p><p><strong>&nbsp;</strong></p><p><strong>Rare side effects (may affect up to 1 in 1000 people)</strong></p><p>&middot;&nbsp; Blood clot in small blood vessels (thrombotic microangiopathy</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date stated on the vial and the carton after EXP.</p><p>Store below 30&deg;C. Keep the vial in the outer carton in order to protect from light.</p><p>The reconstituted solution should be used immediately after preparation. If the reconstituted solution is not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. However, the reconstituted solution is stable for 8 hours at 25&deg;C stored in the original vial and/or a syringe, with a total storage time for the reconstituted medicine not exceeding 8 hours prior to administration.</p><p>Bortezomib BOS is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp; The active substance is<strong> </strong>Bortezomib</p><p>&middot;&nbsp; The other ingredient is<strong>- </strong>mannitol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Bortezomib BOS is a white to off-white cake or powder. It is packed in 10 mL USP Type -1 glass vial stoppered with 13 mm rubber stoppers and sealed with 13 mm aluminum seals.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MAH and Secondary packaging:</p><p>Boston Oncology Arabia</p><p>Sudair Industrial City,</p><p>Sudair, Saudi Arabia</p><p>&nbsp;</p><p>Full Manufacturing and Primary Packaging:</p><p>Gland Pharma Limited</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last revised in May 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>بورتيزوميب بي او اس</strong> على المادة الفعالة بورتيزوميب، التي تدعى &quot;صاد بورتيسوم&quot;. وهذه المادة تلعب دوراً هاماً في التحكم بوظيفة ونمو الخلية. فمن خلال التدخل بوظيفتيهما تستطيع مادة بورتيزوميب قتل الخلايا السرطانية.</p><p dir="RTL">يُستخدم <strong>بورتيزوميب بي او اس</strong> لمعالجة السرطان المتعدد للنخاع الشوكي (سرطان نقي العظام)، لدى المرضى فوق 18 عاماً من العمر:</p><p dir="RTL">&nbsp;</p><p dir="RTL">- بمفرده أو مع الأدوية دوكسوروبيسين الشحمي المشوه أو ديكساميثازون، للمرضى الذين يتفاقم مرضهم (التدريجي) بعد تلقي على الأقل علاج مسبق واحد والذين لم يكن زراعة الخلايا الجذعية للدم عندهم ناجحاً أو غير مناسب لهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">- بالمشاركة مع الأدوية ميلفالان وبريدنيزولون، للمرضى الذين لم يتم علاج مرضهم من قبل وغير مناسبين للعلاج الكيميائي بجرعات عالية مع زراعة الخلايا الجذعية للدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">- بالمشاركة مع الأدوية ديكساميثازون أو ديكساميثازون مع ثاليدوميد، للمرضى الذين لم يتم علاج مرضهم من قبل وقبل تلقي جرعة عالية من العلاج الكيميائي مع زراعة الخلايا الجذعية للدم (العلاج التعريفي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم <strong>بورتيزوميب</strong><strong> بي او اس</strong> لمعالجة سرطان الغدد الليمفاوية في الخلايا الوعائية (نوع من السرطان يؤثر على العقد الليمفاوية) في المرضى فوق 18 عاماً من العمر أو أكبر بالمشاركة مع الأدوية ريتوكسيماب، سايكلوفوسفاميد، دوكسوروبيسين وبريدنيزون، للمرضى الذين لم يتم علاج مرضهم مسبقاً والذين لم يكن زراعة الخلايا الجذعية للدم مناسباً لهم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ بورتيزوميب بي او اس:</strong></p><p dir="RTL">&bull; إذا كنت تتحسس من بورتيزوميب، بورون أو أية مكونات أخرى لهذا المستحضر (المدرجة في البند 6)</p><p dir="RTL">&bull; إذا كانت لديك مشاكل معينة شديدة في الرئتين أو في القلب.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>يجب أن تخبر طبيبك إذا كان لديك أيّاً مما يلي:</strong></p><p dir="RTL">&bull; تعداد منخفض في خلايا الدم الحمراء أو البيضاء</p><p dir="RTL">&bull; مشاكل نزف، و/أو تعداد منخفض للصفيحات في دمك</p><p dir="RTL">&bull; إسهال، إمساك، غثيان أو إقياء</p><p dir="RTL">&bull; إغماء، دوخة أو دُوار في الماضي</p><p dir="RTL">&bull; مشاكل في الكلى</p><p dir="RTL">&bull; مشاكل معتدلة أو شديدة في الكبد</p><p dir="RTL">&bull; خَدَر، تنميل، أو ألم في اليدين أو القدمين (اعتلال عصبي) في الماضي</p><p dir="RTL">&bull; مشاكل في القلب أو ضغط الدم</p><p dir="RTL">&bull; قصر تنفس أو سعال</p><p dir="RTL">&bull; نوبات</p><p dir="RTL">&bull; داء المنطقة (موضعي ويشمل ما حول العينين أو منتشر في أنحاء الجسم)</p><p dir="RTL">&bull; أعراض متلازمة تحلل الورم مثل تشنج العضلات، ضعف العضلات، ارتباك، فقدان الرؤية أو اضطرابات وقصر في التنفس</p><p dir="RTL">&bull; فقدان الذاكرة، تفكير مضطرب، صعوبة في المشي، أو فقدان الرؤية. ربما تكون هذه علامات التهاب خطير في الدماغ ويمكن لطبيبك أن يقترح إجراء مزيد من الفحص والمتابعة.</p><p dir="RTL">ينبغي عليك أن تجري فحوصاً دورية للدم قبل وأثناء معالجتك بدواء <strong>بورتيزوميب بي او اس</strong>، للتحقق بشكل دوري من تعداد خلايا دمك.</p><p dir="RTL">إذا كان لديك سرطان في الغدد اللمفاوية للخلية الغشائية ويُعطى لك دواء ريتوكسيماب مع <strong>بورتيزوميب بي او اس</strong> يجب أن تخبر طبيبك:</p><p dir="RTL">&bull; إذا كنت تظن بأن لديك الآن التهاب كبد أو قد حصل معك في الماضي. في بعض الحالات، المرضى الذين أصيبوا بالتهاب الكبد (ب) يمكن أن تتكرر عندهم هجمة التهاب الكبد، والتي يمكن أن تكون مميتة. فإذا كان لديك تاريخ التهاب الكبد &quot;ب&quot; ينبغي أن يتم فحصك بدقة من قبل طبيبك للتحقق من العلامات النشطة لالتهاب الكبد (ب).</p><p dir="RTL">يجب عليك قراءة نشرات كل المستحضرات الطبية التي تأخذها بالمشاركة مع <strong>بورتيزوميب بي او اس</strong> للحصول على المعلومات العائدة لهذه الأدوية قبل البدء بالمعالجة بدواء <strong>بورتيزوميب بي او اس.</strong> وعند استخدام ثاليدوميد، يجب الاهتمام خاصة بفحص الحمل ومتطلبات المنع اللازمة (راجع الحمل والإرضاع في هذا القسم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب عدم استخدام <strong>بورتيزوميب بي او اس</strong> لدى الأطفال والمراهقين لأنه من غير المعروف كيف سيؤثر هذا الدواء عليهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وبورتيزوميب بي او اس</strong></p><p dir="RTL">يرجى إخبار طبيبك، أو الصيدلي إذا كنت تأخذ، أو قد أخذت مؤخراً أو يمكن أن تأخذ أية أدوية أخرى.</p><p dir="RTL">وبخاصة، أخبر طبيبك إذا كنت تستخدم أدوية تحتوي على أيٍّ من المواد الفعالة التالية:</p><p dir="RTL">- كيتوكونازول، المستخدم لمعالجة التهاب الفطور</p><p dir="RTL">- ريتونافير، المستخدم لمعالجة التهاب نقص المناعة البشرية</p><p dir="RTL">- ريفامبيسن، مضاد حيوي يستخدم لمعالجة الالتهابات البكتيرية</p><p dir="RTL">- كاربامازيبين، فينيتوئين أو فينوباربيتال المستخدمة لمعالجة الصرع</p><p dir="RTL">- نبتة القديس جون (هايبيريكوم بيرفوراتوم)، المستخدمة للاكتئاب أو حالات أخرى</p><p dir="RTL">- أدوية فموية لمعالجة السكري</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">يجب عدم استخدام <strong>بورتيزوميب بي او اس</strong> إذا كنتِ حاملاً، مالم يكن ذلك ضرورياً.</p><p dir="RTL">يجب على كلٍّ من الرجال والنساء الذين يتناولون <strong>بورتيزوميب بي او اس</strong> أن يستعملوا مانع حمل فعال أثناء المعالجة وحتى بعد مضي ثلاثة أشهر على المعالجة. وإذا حدث الحمل، بالرغم من هذه التدابير، أخبر طبيبك فوراً.</p><p dir="RTL">يجب عليكِ عدم إرضاع طفلكِ أثناء استخدام <strong>بورتيزوميب بي او اس</strong>. ابحثي مع طبيبكِ متى يكون استئناف الرضاعة آمناً بعد انتهاء معالجتك.</p><p dir="RTL">يسبب ثاليدومايد تشوهات خلقية وموت الجنين. عندما يُعطى <strong>بورتيزوميب بي او اس</strong> بالمشاركة مع ثاليدوميد يجب عليكِ اتباع برنامج الوقاية من الحمل (راجعي نشرة العبوة من أجل ثاليدوميد).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">يمكن أن يسبب <strong>بورتيزوميب بي او اس</strong> إعياء، دوخة، إغماء أو رؤية مشوشة. لا تقود أو تشغل الأدوات أو الآلات إذا واجهت مثل هذه التأثيرات الجانبية؛ حتى وإن لم تلاحظها، ينبغي عليك أن تكون حذراً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيحدد طبيبك جرعتك من بورتيزوميب<strong> بي او اس</strong> بحسب طولك ووزنك (مساحة سطح الجسم). الجرعة الأولية الاعتيادية من <strong>بورتيزوميب بي او اس</strong> هي<strong> 1</strong>،3 ملغ/م<sup>2</sup> من مساحة سطح الجسم مرتين أسبوعياً.</p><p dir="RTL">يمكن أن يغيِّر طبيبك الجرعة والعدد الإجمالي لدورات المعالجة، اعتماداً على استجابتك للمعالجة عند حدوث تأثيرات جانبية معينة وعلى أحوالك الرئيسية (مثل: مشاكل الكبد).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>سرطان النخاع الشوكي المتعدد المتقدم</em></p><p dir="RTL">عندما يُعطى <strong>بورتيزوميب بي او اس</strong> بمفرده، سوف تتلقى 4 جرعات من <strong>بورتيزوميب بي او اس</strong> في الوريد أو تحت الجلد في الأيام 1، 4، 8 و11، تعقبها &quot;فترة إستراحة&quot; لمدة 10 أيام بدون معالجة. فترة الـ 21 يوماً هذه (3 أسابيع) تعادل دورة علاجية واحدة.</p><p dir="RTL">وربما تتلقى حتى 8 دورات (24 أسبوعاً).</p><p dir="RTL">ويمكن أن تُعطى أيضاً <strong>بورتيزوميب بي او اس</strong> مع الأدوية دوكسوروبيسين الشحمي المشوه، أو ديكساميثازون.</p><p dir="RTL">عند إعطاء <strong>بورتيزوميب بي او اس</strong> مع دوكسوروبيسين الشحمي المشوه، &nbsp;المضاد للفيروسات سوف تتلقى <strong>بورتيزوميب بي او اس</strong> عن طريق الوريد أو تحت الجلد كدورة معالجة لـ 21 يوماً ودوكسوروبيسين الشحمي المشوه مقدار 30 ملغ/م<sup>2</sup> تُعطى في اليوم الرابع من دورة المعالجة بدواء <strong>بورتيزوميب بي او اس</strong> البالغة 21 يوماً كتسريب بالوريد بعد <strong>بورتيزوميب بي او اس</strong>.</p><p dir="RTL">وربما تتلقى حتى 8 دورات (24 أسبوعاً).</p><p dir="RTL">عندما يُعطى <strong>بورتيزوميب بي او اس</strong> مع ديكساميثازون، سوف تتلقى <strong>بورتيزوميب بي او اس</strong> عن طريق الوريد أو تحت الجلد كدورة معالجة لـ 21 يوماً وديكساميثازون 20 ملغ يُعطى بالفم في الأيام 1، 2، 4، 5، 8، 9، 11 و12، من دورة المعالجة بدواء <strong>بورتيزوميب بي او اس</strong> البالغة 21 يوماً.</p><p dir="RTL">وربما تتلقى حتى 8&nbsp; دورات (24 أسبوعاً).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>سرطان النخاع الشوكي المتعدد غير المعالج سابقاً</em></p><p dir="RTL">إذا لم تعالج سابقاً من سرطان النخاع الشوكي المتعدد، وأنت غير مناسب لزراعة الخلايا الجذعية في الدم، سوف تتلقى <strong>بورتيزوميب بي او اس</strong> مع دواءين آخرين، هما ميلفالان و بريدنيزون.</p><p dir="RTL">في هذه الحالة، تكون مدة دورة المعالجة 42 يوماً (6 أسابيع). وسوف تتلقى 9 دورات (54 أسبوعاً).</p><p dir="RTL">&bull; في الدورات من 1 إلى 4، يُعطى <strong>بورتيزوميب بي او اس</strong> مرتين أسبوعياً في الأيام 1، 4، 8، 11، 22، 25، 29 و 32.</p><p dir="RTL">&bull; في الدورات من 5 إلى 9، يُعطى <strong>بورتيزوميب بي او اس</strong> مرةً واحدةً أسبوعياً في الأيام 1، 8، 22 و 29.</p><p dir="RTL">ويُعطى معاً عن طريق الفم كلاً من ميلفالان (9 ملغ/م<sup>2</sup>) و بريدنيزون (60 ملغ/م<sup>2</sup>) في الأيام 1، 2، 3 و4 من الأسبوع الأول من كل دورة.</p><p dir="RTL">&bull; إذا لم تعالج سابقاً من سرطان النخاع الشوكي المتعدد، وأنت مناسب لزراعة الخلايا الجذعية في الدم فسوف تتلقى <strong>بورتيزوميب بي او اس</strong> عن طريق الوريد أو تحت الجلد مع الأدوية ديكساميثازون، أو ديكساميثازون و ثاليدوميد، كمعالجة حثية.</p><p dir="RTL">&bull; عندما يُعطى <strong>بورتيزوميب بي او اس</strong> مع ديكساميثازون، سوف تتلقى <strong>بورتيزوميب بي او اس</strong> عن طريق الوريد أو تحت الجلد كدورة معالجة لمدة 21 يوماً وتُعطى ديكساميثازون 40 ملغ عن طريق الفم في الأيام 1، 2، 3، 4، 8، 9، 10 و 11 من دورة&nbsp; المعالجة بدواء <strong>بورتيزوميب بي او اس </strong>البالغة 21 يوماً.</p><p dir="RTL">وسوف تتلقى 4&nbsp; دورات (12 أسبوعاً).</p><p dir="RTL">&bull; عندما يُعطى <strong>بورتيزوميب بي او اس</strong> مع ثاليدوميد و ديكساميثازون، تكون مدة دورة المعالجة 28 يوماً (4 أسابيع).</p><p dir="RTL">&bull; يُعطى ديكساميثازون 40 ملغ عن طريق الفم في الأيام 1، 2، 3، 4، 8، 9، 10 و 11 من دورة المعالجة 28 يوماً بدواء <strong>بورتيزوميب بي او اس</strong>، ويُعطى ثاليدوميد عن طريق الفم يومياً بمقدار 50 ملغ حتى اليوم 14 من الدورة الأولى، وعند التحمل تزاد جرعة ثاليدوميد إلى 100 ملغ في الأيام 15 &ndash; 28 وربما تُزاد أكثر إلى 200 ملغ يومياً اعتباراً من الدورة الثانية فصاعداً.</p><p dir="RTL">ربما تتلقى حتى 6 دورات (24 أسبوعاً).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>سرطان الغدد اللمفاوية للخلايا الغشائية غير المعالجة سابقاً</em></p><p dir="RTL">إذا لم تعالج سابقاً من سرطان الغدد اللمفاوية للخلية الغشائية فسوف تتلقى <strong>بورتيزوميب بي او اس</strong> عن طريق الوريد أو تحت الجلد مع الأدوية ريتوكسيماب، سايكلوفوسفاميد، دوكسوروبيسين و بريدنيزون.</p><p dir="RTL">يُعطى دواء <strong>بورتيزوميب بي او اس</strong> عن طريق الوريد أو تحت الجلد في الأيام 1، 4، 8 و11، تعقبها &quot;فترة إستراحة&quot; &nbsp;بدون معالجة. وتبلغ مدة دورة المعالجة 21 يوماً (3 أسابيع).</p><p dir="RTL">وربما تتلقى حتى 8 دورات (24 أسبوعاً).</p><p dir="RTL">وتُعطى المستحضرات الدوائية التالية في اليوم الأول من كل دورة 21 يوماً من دورات المعالجة بدواء <strong>بورتيزوميب بي او اس</strong> كتسريب وريدي:</p><p dir="RTL">يُعطى ريتوكسيماب 375 ملغ/م<sup>2</sup>، سايكلوفوسفاميد 750 ملغ/م<sup>2</sup> و دوكسوروبيسين 50 ملغ/م<sup>2</sup>.</p><p dir="RTL">يُعطى بريدنيزون عن طريق الفم بمقدار 100 ملغ/م<sup>2</sup> في الأيام 1، 2، 3، 4 و 5 من دورة المعالجة بدواء <strong>بورتيزوميب بي او اس</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يُعطى بورتيزوميب بي او اس:</strong></p><p dir="RTL">هذا الدواء معد للاستعمال عن طريق الوريد أو تحت الجلد. ويجب أن يُوصف <strong>بورتيزوميب بي او اس</strong> من قبل أخصائي الرعاية الصحية مختص باستخدام الأدوية السامة للخلايا.</p><p dir="RTL">يجب حل مسحوق <strong>بورتيزوميب بي او اس</strong> قبل إعطائه. ويتم ذلك من قبل أخصائي الرعاية الصحية. ويحقن المحلول الناتج إما في الوريد أو تحت الجلد. ويكون الحقن في الوريد سريعاً، بحيث يستغرق من 3 إلى 5 ثواني. والحقن تحت الجلد إما أن يكون في الفخذ أو في البطن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أُعطيتَ المزيد من بورتيزوميب بي او اس</strong></p><p dir="RTL">بما أن هذا الدواء يُعطى إليك من قبل طبيبك أو ممرضتك، فمن غير المحتمل أن تُعطى كمية أكبر. ففي حالة الجرعة الزائدة غير المحتملة، فإن طبيبك سيراقبك من أجل التأثيرات الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات جانبية، وإن كانت لا تحدث لكل شخص. بعض هذه التأثيرات قد تكون خطيرة.</p><p dir="RTL">إذا أُعطيتَ <strong>بورتيزوميب بي او اس</strong> من أجل سرطان الدماغ المتعدد أو من أجل سرطان الغدد اللمفاوية للخلايا الغشائية، أخبر طبيبك فوراً إذا لاحظت أياً من الأعراض التالية:</p><p dir="RTL">- تشنج العضلات، ضعف العضلات</p><p dir="RTL">- ارتباك، فقدان أو اضطرابات في الرؤية، عمى، نوبات مرضية، أوجاع رأس</p><p dir="RTL">- قصر تنفس، تورُّم في قدميك، أو تغير في ضربات قلبك، ضغط دم عالٍ، تعب، إغماء</p><p dir="RTL">- سعال وصعوبات في التنفس أو ضيق في الصدر</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تسبب المعالجة بدواء <strong>بورتيزوميب بي او اس</strong> بشكل شائع جداً نقصاً في تعداد خلايا الدم الحمراء والبيضاء والصفيحات في دمك. لذلك، يجب عليك أن تُجري فحوص دم دورية قبل وأثناء المعالجة بدواء <strong>بورتيزوميب بي او اس</strong>، للتحقق بانتظام من تعداد خلايا دمك. وقد تعاني من نقص في تعداد:</p><p dir="RTL">- الصفيحات، التي يمكن أن تجعلك أكثر عرضة للكدمات، أو النزف بدون جرح ظاهر (مثل: نزيف من الأمعاء الغليظة، المعدة، الفم واللثة أو نزف في الدماغ أو نزف من الكبد)</p><p dir="RTL">- خلايا الدم الحمراء، التي يمكن أن تُسبب فقر الدم، مع أعراض مثل التعب والشحوب</p><p dir="RTL">- خلايا الدم البيضاء، التي يمكن أن تجعلك أكثر عرضة للالتهابات أو لأعراض شبيهة بالأنفلونزا.</p><p dir="RTL">إذا أُعطيتَ <strong>بورتيزوميب بي او اس</strong> لمعالجة سرطان الدماغ المتعدد، فإن التأثيرات الجانبية التي يمكن أن تحدث لك هي المدرجة أدناه:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية شائعة جداً (يمكن أن تؤثر في أكثر من 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&bull; حساسية، خدر، تنميل أو إحساس بحرقة الجلد، أو ألم في اليدين أو القدمين، بسبب تلف عصبي</p><p dir="RTL">&bull; انخفاض في تعداد خلايا الدم الحمراء و/أو خلايا الدم البيضاء (راجع أعلاه)</p><p dir="RTL">&bull; حمى</p><p dir="RTL">&bull; إحساس بالمرض (غثيان) أو إقياء، فقدان شهية</p><p dir="RTL">&bull; إمساك مع أو بدون انتفاخ (يكاد يكون شديداً)</p><p dir="RTL">&bull; إسهال: إذا حدث ذلك، من المهم شرب المزيد من الماء أكثر من المعتاد. ويمكن أن يعطيك طبيبك دواءً آخر لضبط الإسهال</p><p dir="RTL">&bull; تعب (إعياء)، شعور بالضعف</p><p dir="RTL">&bull; ألم عضلات، ألم عظام</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية شائعة (يمكن أن تؤثر حتى في 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&bull; انخفاض ضغط الدم، هبوط مفاجئ بضغط الدم عند الوقوف الذي قد يؤدي إلى الإغماء</p><p dir="RTL">&bull; ضغط دم عالٍ</p><p dir="RTL">&bull; انخفاض وظائف الكليتين</p><p dir="RTL">&bull; وجع رأس</p><p dir="RTL">&bull; شعور عام بالمرض، ألم، إعياء، دوار، شعور بالضعف أو فقدان الوعي</p><p dir="RTL">&bull; رجفان</p><p dir="RTL">&bull; اصابات، تشمل ذات الرئة، التهابات تنفسية، التهاب الشعب الهوائية، التهابات فطرية، سعال مع بلغم، مرض شبيه بالأنفلونزا</p><p dir="RTL">&bull; داء المنطقة (موضعي يشمل ما حول العينين أو منتشر في أنحاء الجسم)</p><p dir="RTL">&bull; آلام صدر أو قصر في التنفس مع الرياضة</p><p dir="RTL">&bull; أنواع مختلفة من الطفح الجلدي</p><p dir="RTL">&bull; حكة الجلد، كتل على الجلد أو جلد جاف</p><p dir="RTL">&bull; احمرار وجه أو شعيرات دموية مقطعة صغيرة</p><p dir="RTL">&bull; احمرار جلد</p><p dir="RTL">&bull; تجفاف</p><p dir="RTL">&bull; حرقة قلبية، انتفاخ، تجشؤ، ريح، ألم معدة، نزف من الأمعاء الغليظة أو المعدة</p><p dir="RTL">&bull; تغير وظائف الكبد</p><p dir="RTL">&bull; فم أو شفة متقرحة، فم جاف، تقرحات في الفم أو ألم في الحلق</p><p dir="RTL">&bull; فقدان الوزن، فقدان التذوق</p><p dir="RTL">&bull; تقلصات عضلية، تشنجات عضلية، ضعف عضلات، ألم في أطرافك</p><p dir="RTL">&bull; رؤية مشوشة</p><p dir="RTL">&bull; اصابة الطبقة الخارجية للعين والسطح الداخلي للأجفان (التهاب الملتحمة)</p><p dir="RTL">&bull; نزيف الأنف</p><p dir="RTL">&bull; صعوبة أو مشاكل في النوم، تعرُّق، قلق، تأرجح المزاج، مزاج مكتئب، انعدام الراحة أو الهيجان، تغيرات في الوضعية العقلية، تشوش</p><p dir="RTL">&bull; تورُّم الجسم، يشمل ما حول العينين وأجزاء أخرى من الجسم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة (يمكن أن تؤثر حتى في 1 من كل 100 شخص)</strong></p><p dir="RTL">&bull; فشل قلب، هجمة قلبية، ألم صدر، اضطراب في الصدر، تزايد أو تناقص في سرعة القلب</p><p dir="RTL">&bull; فشل كليتيك</p><p dir="RTL">&bull; التهاب وريد، جلطات دموية &nbsp;في أوردتك ورئتيك</p><p dir="RTL">&bull; مشاكل مع تجلط الدم</p><p dir="RTL">&bull; دورة دموية غير كافية</p><p dir="RTL">&bull; التهاب البطانة حول قلبك أو سائل حول قلبك</p><p dir="RTL">&bull; اصابات تشمل التهابات المجاري البولية، انفلونزا، فيروس داء المنطقة، إصابة في الأذن والتهاب خليوي</p><p dir="RTL">&bull; غائط دموي، أو نزف من الأغشية المخاطية، مثل: الفم، المهبل</p><p dir="RTL">&bull; اضطرابات في الأوعية الدماغية</p><p dir="RTL">&bull; شلل، نوبات، سقوط، اضطرابات الحركة، إحساس غير طبيعي أو تغير أو إنخفاض في الإحساس (الإحساس، السمع، التذوق، الشم)، اضطراب الإنتباه، رجفان، وخز</p><p dir="RTL">&bull; التهاب المفاصل، بما في ذلك التهاب مفاصل أصابع اليدين، القدمين، والفك</p><p dir="RTL">&bull; اضطرابات تؤثر في رئتيك، تمنع جسمك من الحصول على أكسجين كافٍ. بعض هذه التأثيرات تشمل صعوبة التنفس، قصر التنفس، قصر تنفس بدون رياضة، تنفس يصبح ضحلاً، صعوبة أو توقف، اللهاث</p><p dir="RTL">&bull; الفواق، اضطرابات في الكلام</p><p dir="RTL">&bull; تزايد أو تناقص إدرار البول (بسبب تلف الكليتين)، مرور مؤلم للبول أو دم/بروتينات في البول، إحتباس سوائل</p><p dir="RTL">&bull; مستويات متغيرة في الوعي، إرتباك، إعتلال أو فقدان في الذاكرة</p><p dir="RTL">&bull; حساسية عالية</p><p dir="RTL">&bull; فقدان السمع، صمم أو طنين في الأذنين، اضطراب الأذن</p><p dir="RTL">&bull; شذوذ هرموني يمكن أن يؤثر في امتصاص الملح والماء</p><p dir="RTL">&bull; فرط نشاط الغدة الدرقية</p><p dir="RTL">&bull; عدم القدرة على إنتاج إنسولين كافٍ أو مقاومة لمستويات الإنسولين الطبيعية</p><p dir="RTL">&bull; عيون متهيجة أو ملتهبة، عيون رطبة بشكل مفرط، عيون مؤلمة، عيون جافة، التهابات العين، سيلان العيون، رؤية غير طبيعية، نزف العين</p><p dir="RTL">&bull; تورُّم الغدد اللمفاوية</p><p dir="RTL">&bull; تصلب المفاصل أو العضلات، إحساس بالتثاقل، ألم في أريبة الفخذ</p><p dir="RTL">&bull; فقدان الشعر ونسيج شعري غير طبيعي</p><p dir="RTL">&bull; ردود فعل تحسسية</p><p dir="RTL">&bull; إحمرار أو ألم في موقع الحقن</p><p dir="RTL">&bull; ألم الفم</p><p dir="RTL">&bull; اصابات أو التهاب في الفم، تقرحات الفم، المريء، المعدة والأمعاء، تترافق أحياناً مع ألم أو نزف، حركة أمعاء ضعيفة (بما في ذلك الإنسداد)، اضطراب في البطن أو المريء، صعوبة البلع، إقياء دم</p><p dir="RTL">&bull; اصابات جلدية</p><p dir="RTL">&bull; اصابات بكتيرية أو فيروسية</p><p dir="RTL">&bull; اصابة في الأسنان</p><p dir="RTL">&bull; التهاب البنكرياس، إنسداد قناة الصفراء</p><p dir="RTL">&bull; ألم تناسلي، مشاكل الإنتصاب</p><p dir="RTL">&bull; زيادة الوزن</p><p dir="RTL">&bull; العطش</p><p dir="RTL">&bull; التهاب كبد</p><p dir="RTL">&bull; اضطرابات عائدة لموقع الحقن أو جهاز الحقن</p><p dir="RTL">&bull; ردود فعل واضطرابات جلدية (يمكن أن تكون شديدة ومهددة للحياة)، تقرحات جلدية</p><p dir="RTL">&bull; كدمات، سقوط وجروح</p><p dir="RTL">&bull; التهاب أو نزف الأوعية الدموية التي يمكن أن تظهر كنقط حمراء أو أرجوانية (عادة على الساقين) إلى بقع كبيرة شبيهة بالكدمات تحت الجلد أو النسيج</p><p dir="RTL">&bull; خلايا حميدة</p><p dir="RTL">&bull; حالة عكسية شديدة للدماغ تشمل نوبات، إرتفاع ضغط الدم، أوجاع رأس، تعب، إرتباك، عمى أو مشاكل أخرى في الرؤية</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; <strong>تأثيرات جانبية نادرة (يمكن أن تؤثر حتى في 1 من كل 1000 شخص)</strong></p><p dir="RTL">&bull; مشاكل قلبية تشمل هجمة قلبية، ذبحة صدرية</p><p dir="RTL">&bull; إحمرار الوجه</p><p dir="RTL">&bull; تغيير لون الأوردة</p><p dir="RTL">&bull; التهاب العصب الشوكي</p><p dir="RTL">&bull; مشاكل في أذنك، نزف من أذنك</p><p dir="RTL">&bull; هبوط نشاط الغدة الدرقية</p><p dir="RTL">&bull; متلازمة بود- كياري (أعراض إكلينيكية ناجمة عن إنسداد أوردة الكبد)</p><p dir="RTL">&bull; تغيرات في وظيفة الأمعاء الغليظة أو أداء غير طبيعي</p><p dir="RTL">&bull; نزف دماغ</p><p dir="RTL">&bull; إصفرار العيون والجلد (يرقان)</p><p dir="RTL">&bull; رد فعل تحسسي خطير (صدمة تحسسية) قد تشمل علاماتها صعوبة التنفس، ألم أو ضيق صدر، و/أو شعور بالدوخة / الإغماء، حكة شديدة في الجلد أو وجود كتل مرتفعة على الجلد، تورُّم الوجه، الشفاه، اللسان و/أو الحلق، والتي قد تُسبب صعوبة البلع، تدهور الصحة</p><p dir="RTL">&bull; اضطرابات ثديية</p><p dir="RTL">&bull; سيلان مهبلي</p><p dir="RTL">&bull; تورُّم تناسلي</p><p dir="RTL">&bull; عدم القدرة على تحمل إستهلاك الكحول</p><p dir="RTL">&bull; هدر، أو فقدان كتلة الجسم</p><p dir="RTL">&bull; شهية متزايدة</p><p dir="RTL">&bull; ناسور</p><p dir="RTL">&bull; ارتشاح مفاصل</p><p dir="RTL">&bull; خلايا في بطانة المفاصل (خلايا سائلة زلقة)</p><p dir="RTL">&bull; كسر</p><p dir="RTL">&bull; تعطل ألياف العضلات يؤدي إلى مضاعفات أخرى</p><p dir="RTL">&bull; تورُّم الكبد، نزف من الكبد</p><p dir="RTL">&bull; سرطان الكلى</p><p dir="RTL">&bull; صدفية مثل حالة الجلد</p><p dir="RTL">&bull; سرطان الجلد</p><p dir="RTL">&bull; شحوب الجلد</p><p dir="RTL">&bull; زيادة الصفيحات أو خلايا البلازما (نوع من الخلايا البيضاء) في الدم</p><p dir="RTL">&bull; تجلط الدم في الأوعية الدموية الصغيرة (اعتلال الأوعية الدقيقة الخثاري)</p><p dir="RTL">&bull; رد فعل غير طبيعي لعمليات نقل الدم</p><p dir="RTL">&bull; فقدان جزئي أو كلي للرؤية</p><p dir="RTL">&bull; تناقص الدافع الجنسي</p><p dir="RTL">&bull; سيلان اللعاب</p><p dir="RTL">&bull; عيون منتفخة</p><p dir="RTL">&bull; حساسية للضوء</p><p dir="RTL">&bull; تنفس سريع</p><p dir="RTL">&bull; ألم في الشرج</p><p dir="RTL">&bull; حصى بالمرارة</p><p dir="RTL">&bull; فتق</p><p dir="RTL">&bull; جروح</p><p dir="RTL">&bull; أظافر متقصفة أو ضعيفة</p><p dir="RTL">&bull; رواسب بروتينية غير طبيعية في أعضائك الحيوية</p><p dir="RTL">&bull; كوما</p><p dir="RTL">&bull; تقرحات معوية</p><p dir="RTL">&bull; فشل متعدد في الأعضاء</p><p dir="RTL">&bull; الموت</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أُعطيتَ <strong>بورتيزوميب بي او اس</strong> مع أدوية أخرى لمعالجة سرطان الغدد اللمفاوية للخلايا الغشائية، فإن التأثيرات الجانبية التي قد تحدث لك هي المدرجة أدناه:</p><p dir="RTL"><strong>تأثيرات جانبية شائعة جداً (يمكن أن تؤثر في أكثر من 1 من كل 10 أشخاص</strong>)</p><p dir="RTL">&bull; ذات الرئة</p><p dir="RTL">&bull; فقدان الشهية</p><p dir="RTL">&bull; حساسية، خدر، تنميل أو إحساس بحرقة الجلد، أو ألم في اليدين أو القدمين، بسبب تلف عصبي</p><p dir="RTL">&bull; غثيان وإقياء</p><p dir="RTL">&bull; إسهال</p><p dir="RTL">&bull; تقرحات الفم</p><p dir="RTL">&bull; إمساك</p><p dir="RTL">&bull; ألم عضلات، ألم عظام</p><p dir="RTL">&bull; فقدان الشعر ونسيج شعري غير طبيعي</p><p dir="RTL">&bull; تعب، شعور بالضعف</p><p dir="RTL">&bull; حمى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية شائعة (يمكن أن توثر حتى في 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&bull; داء المنطقة (موضعي يشمل ما حول العينين أو منتشر في أنحاء الجسم)</p><p dir="RTL">&bull; فيروس داء المنطقة</p><p dir="RTL">&bull; اصابات بكتيرية وفيروسية</p><p dir="RTL">&bull; اصابات تنفسية، التهاب الشعب الهوائية، سعال مع بلغم، مرض شبيه بالأنفلونزا</p><p dir="RTL">&bull; اصابات فطرية</p><p dir="RTL">&bull; حساسية عالية (رد فعل تحسسي)</p><p dir="RTL">&bull; عدم القدرة على إنتاج إنسولين كافٍ أو مقاومة لمستويات الإنسولين الطبيعية</p><p dir="RTL">&bull; إحتباس سوائل</p><p dir="RTL">&bull; صعوبة أو مشاكل في النوم</p><p dir="RTL">&bull; فقدان الوعي</p><p dir="RTL">&bull; تغير مستوى الوعي، إرتباك</p><p dir="RTL">&bull; شعور بالدوخة</p><p dir="RTL">&bull; تزايد ضربات القلب، ضغط دم مرتفع، تعرق</p><p dir="RTL">&bull; رؤية غير طبيعية، رؤية مشوشة</p><p dir="RTL">&bull; فشل قلب، هجمة قلبية، ألم صدر، إضطراب الصدر، تزايد أو تناقص سرعة القلب</p><p dir="RTL">&bull; ضغط دم مرتفع أو منخفض</p><p dir="RTL">&bull; هبوط مفاجئ في ضغط الدم عند الوقوف قد يؤدي إلى الإغماء</p><p dir="RTL">&bull; قصر تنفس مع الرياضة</p><p dir="RTL">&bull; سعال</p><p dir="RTL">&bull; فواق</p><p dir="RTL">&bull; طنين في الأذنين، إضطراب الأذنين</p><p dir="RTL">&bull; نزف من الأمعاء الغليظة أو المعدة</p><p dir="RTL">&bull; حرقة القلب</p><p dir="RTL">&bull; ألم معدة، إنتفاخ</p><p dir="RTL">&bull; صعوبة البلع</p><p dir="RTL">&bull; اصابة أو التهاب المعدة والأمعاء</p><p dir="RTL">&bull; ألم معدة</p><p dir="RTL">&bull; فم أو شفة متقرحة، ألم الحلق</p><p dir="RTL">&bull; تغير وظيفة الكبد</p><p dir="RTL">&bull; حكة الجلد</p><p dir="RTL">&bull; إحمرار الجلد</p><p dir="RTL">&bull; طفح جلدي</p><p dir="RTL">&bull; تشنجات عضلية</p><p dir="RTL">&bull; اصابة في المجرى البولي</p><p dir="RTL">&bull; ألم في الأطراف</p><p dir="RTL">&bull; تورُّم الجسم، يشمل العيون وأجزاء أخرى من الجسم</p><p dir="RTL">&bull; رجفان</p><p dir="RTL">&bull; إحمرار وألم في موقع الحقن</p><p dir="RTL">&bull; شعور عام بالمرض</p><p dir="RTL">&bull; فقدان الوزن</p><p dir="RTL">&bull; زيادة الوزن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة ( يمكن أن تؤثر حتى في 1 من كل 100 شخص)</strong></p><p dir="RTL">&bull; التهاب الكبد</p><p dir="RTL">&bull; رد فعل تحسسي شديد (رد فعل الحساسية) قد تشمل علاماته صعوبة في التنفس، ألم صدر أو ضيق صدر، و/أو شعور بالدوخة/ &nbsp;الإغماء، حكة شديدة في الجلد أو كتل مرتفعة على الجلد، تورُّم الوجه، الشفتين، اللسان و/أو الحلق، مما قد يسبب صعوبة في البلع، تدهور الصحة</p><p dir="RTL">&bull; اضطرابات الحركة، شلل، وخز</p><p dir="RTL">&bull; دوار</p><p dir="RTL">&bull; فقدان السمع، صمم</p><p dir="RTL">&bull; اضطرابات تصيب رئتيك، تمنع جسمك من الحصول على أكسجين كافٍ. بعض هذه الاضطرابات تشمل صعوبة في التنفس، قصر في التنفس، قصر في التنفس بدون الرياضة، التنفس يصبح ضحلاً، صعوبة&nbsp; أو توقف، اللهاث</p><p dir="RTL">&bull; جلطات دموية في رئتيك</p><p dir="RTL">&bull; إصفرار بلون العيون والجلد (يرقان)</p><p dir="RTL">&bull; نتوء في الجفن (بردة)، وجفون حمراء منتفخة</p><p dir="RTL"><strong>تأثيرات جانبية نادرة ( يمكن أن تؤثر حتى في 1 من كل 1000 شخص)</strong></p><p dir="RTL">&bull; تجلط الدم في الأوعية الدموية الصغيرة (اعتلال الأوعية الدقيقة الخثاري)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تستعمل هذا الدواء بعد انتهاء صلاحيته المذكورة على القارورة والكرتونة بعد EXP.</p><p dir="RTL">احفظه بدرجة حرارة دون 30 مئوية. واحفظ القارورة في الكرتونة الخارجية لحماية المستحضر من الضوء.</p><p dir="RTL">يجب استخدام المحلول المعاد تحضيره فوراً بعد التحضير. إذا لم يستخدم المحلول المعاد تحضيره فوراً، فإن فترات التخزين للإستعمال وللأحوال التي تسبق الاستخدام تقع على عاتق المستخدم. ومع ذلك، فالمحلول المعاد تحضيره يبقى ثابتاً لمدة 8 ساعات بدرجة حرارة 25 مئوية محفوظاً في القارورة الأصلية و/أو المحقنة، بمدة تخزين إجمالية للدواء المعاد تحضيره لا تتعدى 8 ساعات قبل إعطائه.</p><p dir="RTL">إن <strong>بورتيزمويب بي او اس</strong> معد للاستخدام لمرة واحدة فقط. إن أي مستحضر أو مواد مخلفة لم تُستخدم يجب التخلص منها وفقاً للشروط المحلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; المادة الفعالة هي بورتيزوميب</p><p dir="RTL">&bull; المكونات الأخرى هي مانيتول</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن <strong>بورتيزمويب بي او اس</strong> هو مسحوق أبيض إلى أبيض مائل للصفرة. وهو معبأ بقارورة زجاجية سعة 10 مل من النوع&ndash;1 وفق الدستور الأمريكي مغلقة بسدادات مطاطية قطر 13 ملم ومختومة بأختام ألمنيوم قطر 13 ملم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مالك حقوق التسويق والتغليف الثانوي:</p><p dir="RTL">شركة بوستن اونكولجي العربية</p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p><p dir="RTL">ب&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصنيع الكامل والتغليف الأولي:</p><p dir="RTL">قلاند فارما</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            د - تمت مراجعة هذه النشرة لآخر مرة في أيار 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bortezomib TBM
Bortezomib for Injection, 3.5 mg/vial
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bortezomib.........3.5 mg
After reconstitution, 1 ml of solution for subcutaneous injection contains 2.5 mg bortezomib. After reconstitution, 1 ml of solution for intravenous injection contains 1 mg bortezomib. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection
White to off white intact or fractured lyophilized cake or powder
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bortezomib TBM as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.</p><p>Bortezomib TBM in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.<br />Bortezomib TBM in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Bortezomib TBM in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bortezomib TBM treatment must be initiated under supervision of a physician experienced in the treatment of cancer patients; however Bortezomib TBM may be administered by a healthcare professional experienced in use of chemotherapeutic agents.<br />Bortezomib TBM must be reconstituted by a healthcare professional (see section 6.6).</p><p>Posology for treatment of progressive multiple myeloma (patients who have received at least one prior therapy)<br />Monotherapy<br />Bortezomib TBM is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21-day treatment cycle. This 3-week period is considered a treatment cycle. It is recommended that patients</p><p><img alt="page3image20316160" width="0.720000" height="227.700000" src="blob:https://sdi.sfda.gov.sa/5ee18d33-7fa7-4755-991a-4b9947d22072" /></p><p>receive 2 cycles of Bortezomib TBM following a confirmation of a complete response. It is also recommended that responding patients who do not<br />achieve a complete remission receive a total of 8 cycles of Bortezomib TBM therapy. At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>Dose adjustments during treatment and re-initiation of treatment for monotherapy</p><p>Bortezomib TBM treatment must be withheld at the onset of any Grade 3 non-haematological or any Grade 4 haematological toxicities, excluding neuropathy as discussed below (see also section 4.4). Once the symptoms of the toxicity have resolved, Bortezomib TBM treatment may be re- initiated at a 25% reduced dose (1.3 mg/m2&nbsp;reduced to 1.0 mg/m2; 1.0 mg/m2&nbsp;reduced to 0.7 mg/m2). If the toxicity is not resolved or if it recurs at the lowest dose, discontinuation of Bortezomib TBM must be considered unless the benefit of treatment clearly outweighs the risk.</p><p>Neuropathic pain and/or peripheral neuropathy<br />Patients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in Table 1 (see section 4.4). Patients with pre-existing severe neuropathy may be treated with Bortezomib TBM only after careful risk/benefit assessment.<br />Table 1: Recommended* posology modifications for bortezomib-related neuropathy</p><p>&nbsp;</p><table><tbody><tr><td><p>Severity of neuropathy</p><img alt="page3image20324224" width="107.580000" height="1.020000" src="blob:https://sdi.sfda.gov.sa/ef672434-41c1-41e0-b3ec-8d2c7bec14bb" /></td><td><p>Posology Modication</p><img alt="page3image20325184" width="98.100000" height="1.020000" src="blob:https://sdi.sfda.gov.sa/8e0ac821-70ef-4a99-ab50-4ab5c03cd0ae" /></td></tr><tr><td><p>Grade 1 (asymptomatic; loss of deep tendon reflexes or paresthesia) without pain or loss of function</p><img alt="page3image20324992" width="194.340000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/2b65f37e-1292-41b7-ae1b-54271ab3fc74" /><img alt="page3image20325952" width="203.820000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a5c7a132-a56b-4b40-a064-23657b94fc18" />&nbsp;<img alt="page3image20325376" width="36.660000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/069a0a96-7bbe-406d-968d-f7bd5d135e09" /></td><td><p>None</p></td></tr><tr><td><p>Grade 1 with pain or Grade 2 (moderate symptoms; limiting instrumental Activities of Daily Living (ADL)**)</p><img alt="page3image20326336" width="176.220000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f956b2de-b40b-47e5-8249-8d179dfd26d3" /><img alt="page3image20327104" width="201.000000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/d9e71056-c2cc-4780-afed-355f516a14f9" />&nbsp;<img alt="page3image20326528" width="99.900000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/889d4933-79a7-4706-8496-55d4787b60f8" /></td><td><p>Reduce Bortezomib TBM to 1.0 mg/m2<br />or<br />Change Bortezomib TBM treatment schedule to 1.3 mg/m2&nbsp;once per week</p><img alt="page3image20327872" width="174.000000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/7e8d8157-31c2-4e3d-a55e-1e4eaca132b9" />&nbsp;<img alt="page3image20327488" width="219.060000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/35c643db-340b-4b07-a426-1a8d2a3ff959" /></td></tr><tr><td><p>Grade 2 with pain or Grade 3 (sever symptoms; limiting self care ADL***)</p><img alt="page3image20328832" width="158.520000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/1e3b3188-d10d-4d87-92ec-ae7181d196b9" />&nbsp;<img alt="page3image20329408" width="165.060000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/8c6eef40-da57-4e31-84e3-6d0527e8efe7" /></td><td><p>Withhold Bortezomib TBM therapy until symptoms of toxicity have resolved. When toxicity resolves reinitiate with a reduced dose of Bortezomib TBM at 0.7 mg/m2&nbsp;once per week.</p><img alt="page3image20329792" width="181.500000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/980ced89-1b60-4386-b676-55d2506976c6" />&nbsp;<img alt="page3image20329600" width="188.760000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/73e9e769-aed5-4e1b-9e82-c52e9f661573" /><img alt="page3image20330176" width="216.600000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c9cf9848-d61f-4a9a-b64f-23301cd712a5" /></td></tr><tr><td><img alt="page3image13758608" width="215.160000" height="51.120000" src="blob:https://sdi.sfda.gov.sa/5dd75a2b-aca4-44fc-b983-34a41d5b5521" /><p>Grade 4 (life-threatening consequences; urgent intervention indicated) and/or severe autonomic neuropathy</p><img alt="page3image20331328" width="175.620000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/87e165ff-c3a1-49f6-81bd-be729fd97c0c" /><img alt="page3image20331520" width="204.420000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/db56f319-8833-4e06-8de4-98191c774024" /></td><td><p>Discontinue Bortezomib TBM</p><img alt="page3image20331712" width="134.400000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/a2d7852e-72c2-4d2e-8a36-ab7272bbb170" /></td></tr></tbody></table><p><img alt="page3image20435072" width="0.720000" height="140.160000" src="blob:https://sdi.sfda.gov.sa/2bb2fce0-418b-4843-9eb3-327901452f40" />&nbsp;<img alt="page3image20437952" width="0.720000" height="192.060000" src="blob:https://sdi.sfda.gov.sa/95a1e04b-d015-422b-b90b-4504bdd9d952" /></p><p>*Grading based on NCI Common Terminology Criteria CTCAE v4 .0* Based on posology modifications in Phase II and III multiple myeloma studies and post-marketing experience. Grading based on NCI Common Toxicity Criteria CTCAE v 4.0.<br />&dagger;&nbsp;Instrumental ADL: refers to preparing meals, shopping for groceries or clothes, using</p><p>telephone, managing money etc;<br />&Dagger;***&nbsp;Self care ADL: refers to bathing, dressing and undressing, feeding self, using the toilet, taking m medications, and not bedridden</p><p>Combination therapy with pegylated liposomal doxorubicin</p><p>Bortezomib TBM is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/ m2&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21- day treatment cycle. This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>Pegylated liposomal doxorubicin is administered at 30 mg/m2&nbsp;on day 4 of the Bortezomib TBM treatment cycle as a 1 hour intravenous infusion administered after the Bortezomib TBM injection.</p><p><img alt="page3image20435456" width="275.460000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/91323297-d39e-40dd-846b-a0cecd09b442" />&nbsp;<img alt="page3image20446592" width="151.380000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/6dc33c68-1b97-4505-80a8-4f2d0ffb9cba" /><img alt="page3image20434112" width="428.460000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/cb736b5c-d2fb-430a-b10a-6413a09a4dae" />&nbsp;<img alt="page3image20434304" width="127.200000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/db872910-9403-4ba8-b042-e16b65c3cea0" /><img alt="page3image20446016" width="347.580000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/58d92ba6-f6e1-4f35-a849-cc3ed3700b81" />&nbsp;<img alt="page3image20445632" width="132.480000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/94784e82-2f75-43af-a35f-33299196ca38" /><img alt="page3image20446976" width="401.520000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/7cfc7bf1-aff7-43d8-84f9-c8e2a76e618b" />&nbsp;<img alt="page3image20445824" width="125.520000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/5c09346c-386f-4270-b50f-15ef65b51b73" /><img alt="page3image20391488" width="262.980000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/954e892e-2df9-4be6-a6c8-db018ebf1cc6" />&nbsp;<img alt="page3image20396672" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c18cf093-5d56-4352-a19a-1983f1755b14" /><img alt="page3image20391296" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bda84692-d68e-45dc-a2ef-7eb81e8ee8f3" /><img alt="page3image20390336" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0abcfed9-4e5e-4aac-be0d-3645a971a549" />&nbsp;<img alt="page3image20391872" width="244.740000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/22300594-dbb6-4f8b-aaf7-a643fd0ca65b" /><img alt="page3image20389184" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/21eab9a7-389f-4afe-ac7c-7b866a45251c" /><img alt="page3image20221888" width="434.940000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a6081983-84da-48ee-ac10-97e056202479" /></p><p>sa-spc</p><p>Pg. 3</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page4image20021440" width="0.720000" height="677.340000" src="blob:https://sdi.sfda.gov.sa/c8e2b139-5130-489c-ac0b-508b258063ca" /></p><p>Up to 8 cycles of this combination therapy can be administered as long as patients have not progressed and tolerate treatment. Patients achieving a complete response can continue treatment for at least 2 cycles after the first evidence of complete response, even if this requires treatment for more than 8 cycles. Patients whose levels of paraprotein continue to decrease after 8 cycles can also continue for as long as treatment is tolerated and they continue to respond.</p><p>For additional information concerning pegylated liposomal doxorubicin, see the corresponding Summary of Product Characteristics</p><p>Dose adjustments for combination therapy for patients with progressive multiple myeloma</p><p>For Bortezomib TBM dosage adjustments for combination therapy follow dose modification guidelines described under monotherapy above.</p><p>Posology for previously untreated multiple myeloma patients not eligible for haematopoietic stem cell transplantation<br />Combination therapy with melphalan and prednisone<br />Bortezomib TBM is administered via intravenous or subcutaneous injection in combination with oral melphalan and oral prednisone as shown in Table 2. A 6-week period is considered a treatment cycle. In Cycles 1-4, Bortezomib TBM is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32. In Cycles 5-9, Bortezomib TBM is administered once weekly on days 1, 8, 22 and 29. At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>Melphalan and prednisone should both be given orally on days 1, 2, 3 and 4 of the first week of each Bortezomib TBM treatment cycle.<br />Nine treatment cycles of this combination therapy are administered.</p><p>Table 2: Recommended posology for Bortezomib TBM in combination with melphalan and prednisone</p><p>Twice Weekly Bortezomib TBM (Cycles 1-4)<br />Week 1 2 3 4 5 6</p><p><img alt="page4image20021632" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/4471ede1-2769-42c1-bb0a-5336a76ddfc4" /><img alt="page4image20021824" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/d7f4d94d-2caf-4387-bfec-9e4427a43f2f" /><img alt="page4image20022016" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/4e6654ba-aabf-4202-b4c1-03b877975d41" /><img alt="page4image20022208" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/6a85cb5b-621f-41ab-9145-f45a84b56ca8" />&nbsp;<img alt="page4image20022400" width="327.720000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/19433dd7-6c05-44c6-995b-a8f21ae56d0f" /><img alt="page4image20022592" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/8b000e6e-2017-424e-8b6d-0ad03f990e07" />&nbsp;<img alt="page4image20022784" width="159.720000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/7d094011-a3e8-4b42-862d-4500637d9459" /><img alt="page4image20022976" width="397.800000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/d5a9aef1-aa37-4efa-a162-33afb4dd3f11" /><img alt="page4image20023168" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ba3e241f-b507-4eb2-842a-eefe73d5138d" />&nbsp;<img alt="page4image20023360" width="210.420000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/357f35cb-ce47-4f96-b27e-4f355932531a" /><img alt="page4image20023552" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/afcfd0fa-a002-4e14-8918-c2c6e118c9f6" />&nbsp;<img alt="page4image20023744" width="83.940000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/2415a052-96a8-4769-82f8-f9fcb4d3381a" />&nbsp;<img alt="page4image20023936" width="235.500000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/84d11762-7dbd-4060-bf21-2dc1969fe639" /><img alt="page4image20024128" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0625d68e-4fd2-4534-a497-2eb5214806e4" /><img alt="page4image20024320" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bc194a1c-78b8-45c8-87a3-3fcac4a4916c" /><img alt="page4image20024512" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b9a1afa9-c60b-4d39-831d-f0779823ae8c" /><img alt="page4image20024704" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/d0aeb2dd-4486-4ebd-8951-ba4971a0a26f" /><img alt="page4image20024896" width="340.560000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/782a294c-0270-4034-88d0-51ce517d9ccb" /><img alt="page4image20025088" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/fb4e0aba-caff-4912-b3ae-87aed5e27cb1" />&nbsp;<img alt="page4image20025280" width="174.360000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c8da3b6f-0390-49e1-a1db-6b8717d3ed0e" /><img alt="page4image20025472" width="298.380000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/88eb81e8-6dee-4819-b9af-5f17c63a7f69" />&nbsp;<img alt="page4image20025664" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/73beb346-4a20-4f7f-85e3-d9e673b43dba" /><img alt="page4image20025856" width="48.900000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/92cec127-521a-47e4-8306-0a7a1beca8b2" />&nbsp;<img alt="page4image20026048" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/c548f749-617e-4615-a208-1dfd3b47a93c" />&nbsp;<img alt="page4image20026240" width="171.660000" height="0.840000" src="blob:https://sdi.sfda.gov.sa/5f9ccd7c-24c9-409b-b467-9c9449869a5f" /><img alt="page4image20026432" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2a97765a-8cb3-4539-88c0-bede81c0b43a" /><img alt="page4image20026624" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/90677ed0-3d68-469c-b054-29d250cde4a1" /></p><p>Bz TBM (1.3 mg/m2)</p><p>M (9 mg/m2) P(60 mg/m2)</p><p>Day -- -- Day 1 4 Day Day Day Day</p><p>Day Day 8 11 -- --</p><p>rest period rest</p><p>Day Day Day Day rest 22 25 29 32 period</p><p>-- -- -- -- rest period</p><p><img alt="page4image20026816" width="31.740000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/15238a3f-a3f3-477f-9876-4b33e8186b63" />&nbsp;<img alt="page4image20027008" width="43.500000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/a8c6b991-8680-415b-b4bb-d63c09eecac8" />&nbsp;<img alt="page4image20027200" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f5f1cf12-1a03-4a34-9181-289344c6d3cb" />&nbsp;<img alt="page4image20027392" width="46.980000" height="0.420010" src="blob:https://sdi.sfda.gov.sa/9c8bfb5e-1454-4b2e-a215-d056f2cf4ba9" /></p><p>1234 period</p><p><img alt="page4image20027584" width="46.260000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/956dba8e-5681-4ca6-9a89-6a5e2c698991" />&nbsp;<img alt="page4image20027776" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/324f852a-c37b-479f-8cd3-cdabd70e0c26" /></p><p>Once Weekly Bortezomib TBM (Cycles 5-9)<br />Week 1 2 3 4 5 6</p><p><img alt="page4image20027968" width="168.720000" height="0.840000" src="blob:https://sdi.sfda.gov.sa/504367d6-9f6f-4d72-8c9c-cea122596b21" />&nbsp;<img alt="page4image20028160" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/0b674ed0-6bc7-4cfd-9109-2fb9eb19757b" /><img alt="page4image20028352" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/19a32ac4-671b-4723-8944-bb8c6736d422" /></p><p>Bz TBM (1.3 mg/m2) M (9 mg/m2) P(60 mg/m2)</p><p>Day -- -- Day 18 Day Day Day Day --</p><p>1234</p><p>rest Day Day rest period 22 29 period rest -- -- rest period period</p><p><img alt="page4image20028544" width="31.740000" height="0.420000" src="blob:https://sdi.sfda.gov.sa/4f5be3ad-78dd-4e83-9186-9217dbb6b5c0" />&nbsp;<img alt="page4image20028736" width="45.720000" height="0.420000" src="blob:https://sdi.sfda.gov.sa/d1aef586-e776-42e3-aeb2-3be672914839" />&nbsp;<img alt="page4image20028928" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/da9600be-c3eb-407f-a4b8-d7229ab0c058" />&nbsp;<img alt="page4image20029120" width="46.980000" height="0.420000" src="blob:https://sdi.sfda.gov.sa/db14b26a-3012-4fc9-ac51-fbc63832983e" />&nbsp;<img alt="page4image20029312" width="46.260000" height="0.420000" src="blob:https://sdi.sfda.gov.sa/6d8a75a7-b83a-437a-9f4f-4873b81844e5" />&nbsp;<img alt="page4image20029504" width="63.780000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/8c3c56f7-a306-47f0-b530-03b78b412176" />&nbsp;<img alt="page4image20029696" width="56.220000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/7cea9181-2c50-4a49-a582-a0130065bd07" /><img alt="page4image20029888" width="36.840000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/d4768d51-e0cb-4f0c-b599-76c5f1bc7122" />&nbsp;<img alt="page4image20030080" width="68.520000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/e5ebd5e6-8959-40f8-b159-f948c679a7a4" />&nbsp;<img alt="page4image20030272" width="63.300000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/5ff0da3d-98cd-4c1a-bb17-7592456120e2" />&nbsp;<img alt="page4image20030464" width="40.560000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/a66aae27-8922-4ac8-b7b1-02bfe2cb70d1" /></p><p>Bz TBM=Bortezomib TBM; M=melphalan, P=prednisone</p><p><img alt="page4image20030656" width="210.480000" height="0.420000" src="blob:https://sdi.sfda.gov.sa/345a2e14-bfb9-4ea3-aecc-7482504e7520" /></p><p>Dose adjustments during treatment and re-initiation of treatment for combination therapy with melphalan and prednisone<br />Prior to initiating a new cycle of therapy:<br />&bull; Platelet counts should be &ge; 70 x 109/l and the absolute neutrophils count should be &ge; 1.0 x 109/l</p><p>&bull; Non-haematological toxicities should have resolved to Grade 1 or baseline.<br />Table 3: Posology modifications during subsequent cycles of&nbsp;Bortezomib TBM&nbsp;therapy in combination with melphalan and prednisone</p><p>Toxicity Dose modification or delay</p><p>Hematological toxicity during a cycle:</p><p><img alt="page4image20030848" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3a0909cf-f021-4407-b599-73765475cabf" />&nbsp;<img alt="page4image20031040" width="117.300000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0e1777e0-794b-475f-bae3-c6f23284348b" />&nbsp;<img alt="page4image20031232" width="181.200000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/e40b45c5-208c-413e-8c01-64ad7f481d63" /><img alt="page4image20031424" width="430.200000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/619c3f4e-95d7-4ebe-8cae-085157191435" />&nbsp;<img alt="page4image20031616" width="337.680000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/647e94fe-5b85-4bdb-aa9b-295d9d190b2e" /><img alt="page4image20031808" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4590e333-018f-4833-a267-b1fbc1a74a33" />&nbsp;<img alt="page4image20032000" width="196.740000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/dbf253ef-1dee-436e-ab40-cebc1f8e87c5" /><img alt="page4image20032192" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5c475686-c872-4280-bef4-eebac02888da" />&nbsp;<img alt="page4image20032384" width="38.520000" height="1.020000" src="blob:https://sdi.sfda.gov.sa/c351079b-c372-4e30-8847-557ba6ba5b1a" />&nbsp;<img alt="page4image20032576" width="125.580000" height="1.020000" src="blob:https://sdi.sfda.gov.sa/38d15d47-732f-484b-9a8b-b2e58cf9e576" /><img alt="page4image20032768" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/29f8a182-80ec-4708-b18c-39b02cdcd238" />&nbsp;<img alt="page4image20032960" width="169.200000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/901098f2-faeb-4560-9e63-8271b5925f17" /><img alt="page4image20033152" width="226.800000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4b81b8fc-6767-4aaa-ab62-52ebd85055c3" />&nbsp;<img alt="page4image20033344" width="217.740000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/91d74f37-e7ce-401a-8ab2-48371d0625ea" /></p><p>sa-spc</p><p>Pg. 4</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page5image20121088" width="445.500000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/46674664-413b-436a-ade9-0897744a62a9" />&nbsp;<img alt="page5image20121280" width="0.720000" height="673.440000" src="blob:https://sdi.sfda.gov.sa/c6e80b56-f635-4974-b48c-61bc689ec6ee" /></p><p>Toxicity Dose modification or delay</p><p>Hematological toxicity during a cycle:</p><p>If platelet count is &le;not above 30 &times; 109&nbsp;/L or Withhold Bortezomib TBM therapy should be ANC &le;is not above 0.75 &times; 109&nbsp;/L on a withhelddose<br />Bortezomib TBM dosing day (other than day 1)</p><p><img alt="page5image20121472" width="38.520000" height="1.020000" src="blob:https://sdi.sfda.gov.sa/d530fc5f-4975-48a8-ae41-bc41cf1eb7b1" />&nbsp;<img alt="page5image20121664" width="125.580000" height="1.020000" src="blob:https://sdi.sfda.gov.sa/3012e01a-840b-48b1-9a39-0f6b30d67745" />&nbsp;<img alt="page5image20121856" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5912e15f-770b-48ba-8208-9d77bb64d5cf" /></p><table><tbody><tr><td><p>Hematological toxicity during a cycle:<br />If prolonged Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle</p><img alt="page5image20122432" width="169.200000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f2576af1-11c0-4fee-86ba-093b62e5956a" />&nbsp;<img alt="page5image20122624" width="169.200000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/46331cd1-2113-4503-b025-19b100ce90a0" /><img alt="page5image20122816" width="159.120000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/b82ffa78-d6ed-4a60-9562-9aa2043ffb2e" />&nbsp;<img alt="page5image20123008" width="199.800000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/dd82b01e-af3d-4ed1-97db-6228fb1c056a" /></td><td><p>Consider reduction of the melphalan dose by 25% in the next cycle</p><img alt="page5image20123776" width="160.680000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/3049c8ba-657a-4b5e-845e-5097031e5a27" />&nbsp;<img alt="page5image20123968" width="132.000000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/0325e56d-bb37-42bf-8bda-1ad6f45f8a48" /></td></tr></tbody></table><p><img alt="page5image20124544" width="49.860000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/6cf755da-503c-44dd-8858-0f100f45cfec" />&nbsp;<img alt="page5image20124736" width="45.060000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/1b73680c-1c4b-459c-b0f7-23f712c9c0cf" />&nbsp;<img alt="page5image20124928" width="216.000000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ce56d3f0-fd2f-44d2-a82c-e744ddaa3cd3" />&nbsp;<img alt="page5image20125120" width="207.420000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7bcd8b15-aff3-4e48-a78d-a086d59ca080" />&nbsp;<img alt="page5image20125312" width="64.080000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/45406539-819a-4155-8b94-cc615d4a27e2" /><img alt="page5image20125504" width="216.000000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/7d544ac7-f0f8-474b-a7b0-295c3674daa4" />&nbsp;<img alt="page5image20125696" width="58.680000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/62749c52-80fc-4872-8a98-9d10d5f9c8c2" /></p><table><tbody><tr><td><p>If several Bortezomib TBM doses in a consecutive cycles are withheld (&ge; 3 doses during twice weekly administration or &ge; 2 doses during weekly administration)due to toxicity</p><img alt="page5image20126272" width="168.660000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ee5c3505-bc19-4fd3-a58c-55bca0adfd7e" />&nbsp;<img alt="page5image20126464" width="54.660000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/3ecb2588-e946-4e12-a69b-b3146d8a4276" /><img alt="page5image20126656" width="187.440000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/d2743a76-d0b9-49d0-86c2-e1cf265e960c" /><img alt="page5image20126848" width="212.220000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/298f0523-2b8b-4f38-ae12-212ff68d7d3c" /></td><td><p>Reduce Bortezomib TBM dose should beby reduced by 1 dose</p><p>level (from 1.3 mg/m2&nbsp;to 1 mg/m2, or from 1 mg/m2&nbsp;to 0.7 mg/m2)</p><img alt="page5image20127808" width="35.700000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c77d04eb-31ca-4543-8aa2-b0b6a0c09af2" />&nbsp;<img alt="page5image20128000" width="193.380000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/746bf991-0637-4545-a04a-edfb6b482361" />&nbsp;<img alt="page5image20128192" width="79.740000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/2150fb31-eb7b-4a23-aa45-6b3eb503b8f5" /><img alt="page5image20128384" width="189.600000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/dbbe767a-64b9-413d-ac6a-ac9877c20d74" /></td></tr><tr><td><p>Grade &ge;3 non-hematological toxicities</p><img alt="page5image20128960" width="126.360000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/83efcf73-8ee6-4c53-af94-6a80afb6e227" />&nbsp;<img alt="page5image20129152" width="43.080000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/01d213fd-03e7-4b0b-a338-f9d803c46b3b" /></td><td><p>Withhold Bortezomib TBM therapy should be withheld until</p><p>symptoms of toxicity have resolved to Grade 1 or baseline. Then, Bortezomib TBM may be reinitiated with one dose level reduction (from 1.3 mg/m2&nbsp;to 1 mg/m2, or from 1 mg/m2&nbsp;to 0.7 mg/m2). For Bortezomib TBM-related neuropathic pain and/or peripheral neuropathy, hold or modify Bortezomib TBM as outlined in Table 15.</p><img alt="page5image20129920" width="44.340000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ef1741d3-4b12-496e-b0b7-c75810432b05" />&nbsp;<img alt="page5image20130112" width="203.760000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c5a4e8b7-fd81-41d5-8f4c-70d4b195b3ef" />&nbsp;<img alt="page5image20130304" width="64.140000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/88496f97-23a6-444c-8879-1abcf0fb12b3" /><img alt="page5image20130496" width="171.060000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/77d2ec65-3a63-4cd4-b9a9-35fc6328636a" />&nbsp;<img alt="page5image20130688" width="197.940000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f68f406a-f0b9-4757-91cf-4a88aa62b394" /><img alt="page5image20130880" width="167.400000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/98fc77af-9164-4d36-a8b3-b41b52357b40" />&nbsp;<img alt="page5image20131072" width="183.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0460a216-11dc-4d48-b38f-fda03b925b37" /><img alt="page5image20131264" width="200.340000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/d59455ad-9f1e-41ff-ac85-872c9b368aed" />&nbsp;<img alt="page5image20131456" width="164.700000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b0f34400-a4ea-4ec2-8cf6-532f3eed7541" /><img alt="page5image20131648" width="168.360000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bfde73d0-7d59-4bfe-9ab7-321effaf70ba" /></td></tr></tbody></table><p>For additional information concerning melphalan and prednisone, see the corresponding Summary of Product Characteristics.</p><p>Posology for previously untreated multiple myeloma patients eligible for haematopoietic stem cell transplantation (induction therapy)<br />Combination therapy with dexamethasone<br />Bortezomib TBM is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21-day treatment cycle. This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>Dexamethasone is administered orally at 40 mg on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib TBM treatment cycle.<br />Four treatment cycles of this combination therapy are administered.</p><p>Combination therapy with dexamethasone and thalidomide</p><p>Bortezomib TBM is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 28-day treatment cycle. This 4-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>Dexamethasone is administered orally at 40 mg on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib TBM treatment cycle.<br />Thalidomide is administered orally at 50 mg daily on days 1-14 and if tolerated the dose is increased to 100 mg on days 15-28, and thereafter may be further increased to 200 mg daily from cycle 2 (see Table 4).</p><p>Four treatment cycles of this combination are administered. It is recommended that patients with at least partial response receive 2 additional cycles.<br />Table 4: Posology for Bortezomib TBM combination therapy for patients with previously untreated multiple myeloma eligible for haematopoietic stem cell transplantation</p><p><img alt="page5image20132608" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b47c3f98-ba69-4c46-bf89-8ee15f2bf4a4" />&nbsp;<img alt="page5image20132800" width="117.000000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/8d2a9cd6-1aa6-4959-80a7-cdd4c9430930" /><img alt="page5image20132992" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ccde144d-f26c-42cb-9f53-bb76950cd934" />&nbsp;<img alt="page5image20133184" width="152.760000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/48c93ce9-ea35-4056-9967-0c329ac7137b" /><img alt="page5image20133376" width="186.000000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/fc650b08-57d7-4636-895b-cc31b73b101a" />&nbsp;<img alt="page5image20133568" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ed18e0fe-47b9-481f-a6a2-34757384190e" /><img alt="page5image20133760" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/defc943c-6e38-4220-a458-371ca148d982" /><img alt="page5image20133952" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/740cfa0a-ca5a-4c07-9b6e-13f607ed46de" />&nbsp;<img alt="page5image20134144" width="214.500000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a4db9729-716f-4962-bc75-b24357b34845" /><img alt="page5image20134336" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3f1a301b-f6a4-43b7-a549-babd99ba49b0" />&nbsp;<img alt="page5image20134528" width="96.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/aa87a30e-57ed-48e0-8780-cd7994c7e899" /><img alt="page5image20134720" width="297.780000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/af0845a0-673d-4047-b067-56a8ba96df37" />&nbsp;<img alt="page5image20134912" width="260.520000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/76b8fccc-2b0d-4299-ab45-dd071314cdb0" /><img alt="page5image20135104" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4f9a3ea9-e0bf-4de2-8bf4-617962a18054" /><img alt="page5image20135296" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/ea789c00-1d97-473f-ac39-8b16cc8823f5" /><img alt="page5image20135488" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/c930527f-0f8b-46fd-8f63-a2acf7c063c3" />&nbsp;<img alt="page5image20135680" width="214.500000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e6ea09da-cc37-44b1-866a-fca99d68c6a0" /><img alt="page5image20152320" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/9c346b24-4d1e-4f42-91a6-7ca3f363f168" />&nbsp;<img alt="page5image20152512" width="96.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/22b47d3d-97f6-4acc-ab13-c02a14da6c49" /><img alt="page5image20152704" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/edafa6ab-c943-453c-a61d-44e597ab9a96" /><img alt="page5image20152896" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/593ce894-e1ca-461c-8fb2-eb21ec928e2e" />&nbsp;<img alt="page5image20153088" width="94.380000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/2f1d113b-fc3c-4018-807f-d086448491d6" /><img alt="page5image20153280" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/5d2d99e6-aebf-44e4-9436-4546e8690bc4" />&nbsp;<img alt="page5image20153472" width="214.680000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/da181587-7d9c-4ec4-bf13-d30c4bb38939" /><img alt="page5image20153664" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/027e2c6d-6278-451e-9453-b33b66e2d6cf" />&nbsp;<img alt="page5image20153856" width="312.540000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0ec3ddfc-f1ec-4066-87c5-389477f9945f" /></p><p>sa-spc</p><p>Pg. 5</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page6image20084224" width="445.500000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/ba1c5b4f-ca23-48ea-8c32-da151b2205be" />&nbsp;<img alt="page6image20084416" width="0.720000" height="657.840000" src="blob:https://sdi.sfda.gov.sa/69518f66-d013-4e64-98c5-9a6a30964e65" />&nbsp;<img alt="page6image20084608" width="48.660000" height="0.839970" src="blob:https://sdi.sfda.gov.sa/570f19b6-af6d-4f24-ba1a-da686cc132c6" /><img alt="page6image20084800" width="381.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4520fb0c-6439-4036-a695-c399081118c2" /></p><p>Bz TBM+ Dx</p><p>Bz TBM +Dx+T</p><p>Cycles 1 to 4<br />Week 1 2 3</p><p><img alt="page6image20084992" width="381.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/71697100-64cd-41c1-ace0-cc6bff0d0621" /></p><p>Bz TBM (1.3 mg/m2) Day 1, 4 Dx 40 mg Day 1, 2, 3, 4</p><p>Day 8, 11 Rest Period Day 8, 9, 10, 11 -</p><p><img alt="page6image20085184" width="51.360000" height="0.840030" src="blob:https://sdi.sfda.gov.sa/46935ccd-aca6-4a4d-b27e-a4b9f146b1d2" />&nbsp;<img alt="page6image20085376" width="77.760000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/3173112e-c375-4ee7-aa49-c892bf2cd079" />&nbsp;<img alt="page6image20085568" width="31.020000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/5716f491-5293-4181-94af-6e2ea44ba719" />&nbsp;<img alt="page6image20085760" width="34.860000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/53fac4c7-d089-4520-b87c-ea07ff36c048" />&nbsp;<img alt="page6image20085952" width="42.120000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/b47bd1b7-7ccf-4f84-81f8-ba1619338388" />&nbsp;<img alt="page6image20086144" width="381.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1444ed21-3931-4789-81fd-18729d144f60" />&nbsp;<img alt="page6image20086336" width="36.300000" height="0.420040" src="blob:https://sdi.sfda.gov.sa/f5792de0-b86d-4a99-ba51-6dc7585da9b1" />&nbsp;<img alt="page6image20086528" width="49.140000" height="0.420040" src="blob:https://sdi.sfda.gov.sa/63022cfe-71e4-46d7-8bf2-615f0e645969" /><img alt="page6image20151488" width="57.540000" height="0.420040" src="blob:https://sdi.sfda.gov.sa/6f4bbb7d-a675-423a-80c4-dd76e65f7e83" />&nbsp;<img alt="page6image19969920" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/50ba7025-a0a8-444c-97b5-19f444f1bb2c" /></p><p>Cycle 1<br />Week 1 2 3 4</p><p><img alt="page6image19950848" width="381.720000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/8642d104-bfb6-4711-bdc8-c0c2a0eca627" />&nbsp;<img alt="page6image19950656" width="381.720000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/05320562-01f1-41ac-bb60-97c610dd2e4e" /></p><p>Bz TBM (1.3mg/m2)</p><p>T 50 mg T 100 mga&nbsp;Dx 40 mg</p><p>Bz TBM (1.3mg/m2) T 200 mga<br />Dx 40 mg</p><p>Day 1, 4</p><p>Daily -</p><p>Day 1, 2, 3, 4</p><p>Day 1, 4 Daily<br />Day 1, 2, 3, 4</p><p>Day 8, 11</p><p>Daily<br />-<br />Day 8, 9, 10, 11</p><p>Cycles 2 to 4b</p><p>Day 8, 11 Daily<br />Day 8, 9, 10, 11</p><p>Rest Period - Daily<br />-</p><p>Rest Period Daily<br />-</p><p>Rest Period - Daily<br />-</p><p>Rest Period Daily<br />-</p><p><img alt="page6image20103168" width="34.860000" height="0.420000" src="blob:https://sdi.sfda.gov.sa/619c7d42-fdd0-41cc-84b1-23fd5a9cc519" />&nbsp;<img alt="page6image20103360" width="75.420000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/595b23ad-717d-41eb-a0c8-a7b2824759bd" />&nbsp;<img alt="page6image20103552" width="31.020000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/9e44586d-d1ff-449e-b25d-668b22bf6195" />&nbsp;<img alt="page6image20103744" width="42.120000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/661e4f3e-0e9c-4bf3-a85c-60c616bc7e71" />&nbsp;<img alt="page6image20103936" width="42.120000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/30495960-4049-47f4-b603-68f5c780b9ba" />&nbsp;<img alt="page6image20104128" width="381.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b3b5c9ca-c3f0-40f7-b1b9-8b0d6cd3cbe9" />&nbsp;<img alt="page6image20104320" width="30.720000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/d2e6c2fa-1fc7-4c43-9c60-15f175f16a1e" /><img alt="page6image20104512" width="381.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/43683548-e689-40e3-9165-caa9b0901d87" />&nbsp;<img alt="page6image20104704" width="37.860000" height="0.420040" src="blob:https://sdi.sfda.gov.sa/b6f27ca9-0b99-4794-b6fe-6a47438f40d3" />&nbsp;<img alt="page6image20104896" width="32.760000" height="0.839970" src="blob:https://sdi.sfda.gov.sa/a63fe126-63ef-4a14-82aa-7d506ac23949" /><img alt="page6image20105088" width="381.720000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/91873859-ed22-4338-a003-391144c96cc3" />&nbsp;<img alt="page6image20105280" width="49.080000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/de18673b-52a2-46fe-a535-8ce790ca4ced" />&nbsp;<img alt="page6image20105472" width="36.300000" height="0.420040" src="blob:https://sdi.sfda.gov.sa/2d391529-3ae4-4907-97fa-9e7bec58f610" />&nbsp;<img alt="page6image20105664" width="57.540000" height="0.420000" src="blob:https://sdi.sfda.gov.sa/7a604745-ec5a-4de8-aa05-389788f411fc" /><img alt="page6image20105856" width="381.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f341cf8e-92ab-42df-9a4b-d4f45df2ff01" />&nbsp;<img alt="page6image20106048" width="52.080000" height="0.839970" src="blob:https://sdi.sfda.gov.sa/ade97d7a-3ca5-47bd-b89d-fda4525dda85" /><img alt="page6image20106240" width="381.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d80b18c5-ca9e-4e3b-8feb-b725a3ffba88" />&nbsp;<img alt="page6image20106432" width="31.020000" height="0.420040" src="blob:https://sdi.sfda.gov.sa/4f42bd37-61f2-4db1-bab7-2e67c2ea74cc" />&nbsp;<img alt="page6image20106624" width="34.860000" height="0.420000" src="blob:https://sdi.sfda.gov.sa/bd9e9c56-c741-4c40-b7ae-00cd7ce8b0ed" />&nbsp;<img alt="page6image20106816" width="75.180000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/73b0be0a-fdec-4045-b536-ee1d5ddab4a4" />&nbsp;<img alt="page6image20107008" width="42.120000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/dc6b60ec-cbd8-4327-b6f4-ae80a2920490" />&nbsp;<img alt="page6image20107200" width="42.120000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/0d172b7b-e9cb-4e16-b8fe-dd0ad64de589" /><img alt="page6image20107392" width="381.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/911851eb-7ec3-464e-9824-f89c5b0d8507" />&nbsp;<img alt="page6image20107584" width="37.860000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/12eae1a1-b7be-4876-a837-7291a88f7706" /><img alt="page6image20107776" width="381.720000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/5b5d9c76-63f8-4ec4-afde-c880589524a7" />&nbsp;<img alt="page6image20107968" width="49.080000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/445cc5df-f45a-427a-b45c-d37a54274634" />&nbsp;<img alt="page6image20108160" width="57.540000" height="0.420000" src="blob:https://sdi.sfda.gov.sa/9f31afd2-960d-43b1-a06e-565f5ad40511" />&nbsp;<img alt="page6image20108352" width="36.300000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/c107f0bb-06f6-4892-a2d2-e0d1cc371639" />&nbsp;<img alt="page6image20108544" width="63.780000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/89421af0-5bb1-4ed8-b3e0-9fdc0437a5a6" />&nbsp;<img alt="page6image20108736" width="91.680000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/61fa23b7-bc6b-461a-b33c-4aebdd9f25bf" />&nbsp;<img alt="page6image20108928" width="70.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/26544237-0495-43ac-8d51-908a2f63835d" /><img alt="page6image20109120" width="77.520000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3c2897e3-0bd5-4ea2-a39e-3faab607d8e0" />&nbsp;<img alt="page6image20109312" width="70.320000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1da63736-e8b7-4a3d-bf06-488d9518fc91" />&nbsp;<img alt="page6image20109504" width="68.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8a42f619-e900-40b1-bff1-0af19ce28075" /></p><p>Bz TBM =Bortezomib TBM; Dx=dexamethasone; T=thalidomide<br />a Thalidomide dose is increased to 100 mg from week 3 of Cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2 onwards if 100 mg is tolerated.<br />b Up to 6 cycles may be given to patients who achieve at least a partial response after 4 cycles</p><p>Dosage adjustments for transplant eligible patients<br />For Bortezomib TBM dosage adjustments, dose modification guidelines described for monotherapy should be followed.<br />In addition, when Bortezomib TBM is given in combination with other chemotherapeutic medicinal products, appropriate dose reductions for these products should be considered in the event of toxicities according to the recommendations in the Summary of Product Characteristics.</p><p>Posology for patients with previously untreated mantle cell lymphoma (MCL)</p><p>Combination therapy with rituximab, cyclophosphamide, doxorubicin and prednisone (BzR-CAP)</p><p>Bortezomib TBM is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2&nbsp;body surface area twice weekly for two weeks on days 1, 4, 8, and 11, followed by a 10-day rest period on days 12-21. This 3-week period is considered a treatment cycle. Six Bortezomib TBM cycles are recommended, although for patients with a response first documented at cycle 6, two additional Bortezomib TBM cycles may be given. At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>The following medicinal products are administered on day 1 of each Bortezomib TBM 3 week treatment cycle as intravenous infusions: rituximab at 375 mg/ m2, cyclophosphamide at 750 mg/ m2&nbsp;and doxorubicin at 50 mg/ m2.<br />Prednisone is administered orally at 100 mg/m2&nbsp;on days 1, 2, 3, 4 and 5 of each Bortezomib TBM treatment cycle.</p><p>Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma</p><p>Prior to initiating a new cycle of therapy:<br />&bull; Platelet counts should be &ge;100,000 cells/&mu;L and the absolute neutrophils count (ANC) should be</p><p>&ge;1,500 cells/&mu;L<br />&bull; Platelet counts should be &ge;75,000 cells/&mu;L in patients with bone marrow infiltration or splenic</p><p>sequestration<br />&bull; Haemoglobin &ge;8 g/dL<br />&bull; Non-haematological toxicities should have resolved to Grade 1 or baseline.</p><p><img alt="page6image20109696" width="238.200000" height="0.419980" src="blob:https://sdi.sfda.gov.sa/564e90b3-a626-45b4-be1a-2b1780e77a6d" />&nbsp;<img alt="page6image20109888" width="441.840000" height="0.420010" src="blob:https://sdi.sfda.gov.sa/72b0dcfb-414d-44d6-bbff-2bf62aea033a" /><img alt="page6image20110080" width="111.960000" height="0.420010" src="blob:https://sdi.sfda.gov.sa/8ed605ad-4451-4d0a-9b29-1a498c05a2c4" />&nbsp;<img alt="page6image20110272" width="339.120000" height="0.420010" src="blob:https://sdi.sfda.gov.sa/59d2919d-23fd-4540-b07f-2af65b0c1e91" />&nbsp;<img alt="page6image20110464" width="222.720000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/36c8f364-57fd-4001-9d0a-b0274db2e375" /><img alt="page6image20110656" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f6818e47-f25b-4ae4-a850-56ce1a3d4b0b" />&nbsp;<img alt="page6image20110848" width="87.060000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/38c13865-2f6d-451d-b4fc-59d2acd3c1c8" /><img alt="page6image20111040" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/d8383bcc-1bc6-42bd-8f97-1ad85c039309" /><img alt="page6image20111232" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/68543e3a-d098-4fe5-bebb-edb366ecc0bd" /><img alt="page6image20111424" width="387.420000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bd9efca9-7cb1-4e68-85de-537e88d20e2b" />&nbsp;<img alt="page6image20111616" width="343.680000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ce328f2c-b504-4449-bba8-5cca068bdb94" /><img alt="page6image20111808" width="430.080000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7bec4b37-e201-4022-a7fc-d5aa54661c59" /><img alt="page6image20112000" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e362a154-54b3-4abc-88c2-3197e5dbb421" /><img alt="page6image20112192" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b0e68ba2-4c64-4230-8ff0-f29b5428710b" /><img alt="page6image20112384" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/9152e5a5-9032-41d4-bdd5-88d10b75b398" /><img alt="page6image20112576" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/565a27f3-4655-41e1-8506-acc76b0d20cc" /><img alt="page6image20112768" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c9aeaac1-6206-4851-98fc-0765da94d4d8" />&nbsp;<img alt="page6image20112960" width="214.500000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c088188a-0856-4764-bfa8-85d911c9447c" /><img alt="page6image20113152" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/3b127ae5-1170-4c3f-86a8-200c76ad8616" /><img alt="page6image20113344" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/d718e453-be0a-42cc-99b6-a374da1521bd" />&nbsp;<img alt="page6image20113536" width="148.440000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/522be8ec-2004-45a6-91f8-5cb0e77dde27" /><img alt="page6image20113728" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/057af967-3b53-4c6e-9819-782ee00560b6" />&nbsp;<img alt="page6image20113920" width="70.200000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/9926cb2b-5250-408b-9992-5cbff3c678e8" /><img alt="page6image20114112" width="423.180000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/2fa1a99a-959b-4566-83fc-3116e440cba0" />&nbsp;<img alt="page6image20114304" width="181.200000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/275fc36a-5c5b-4828-beb6-f36d2545de23" /><img alt="page6image20114496" width="432.540000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/d443c791-b231-4c8b-9d53-7f84a78631ec" />&nbsp;<img alt="page6image20114688" width="69.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/3b162f0c-5674-4dce-903d-472020e4617a" /><img alt="page6image20114880" width="422.100000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7c0b2ae3-3c81-4626-81a8-4cd6935e0649" />&nbsp;<img alt="page6image20115072" width="58.020000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c7f6da0f-fc1d-4c93-b7a5-be636c266d90" />&nbsp;<img alt="page6image20115264" width="104.820000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/32977b0b-e58a-4a2d-80ca-44c7b45635f8" /><img alt="page6image20115456" width="338.220000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3fca09cb-4021-4165-b3f0-63b172a0b552" /></p><p>sa-spc</p><p>Pg. 6</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page7image20167488" width="0.720000" height="669.960000" src="blob:https://sdi.sfda.gov.sa/2341dfd6-2aeb-425d-913c-e678e142c0e8" /></p><p>Bortezomib TBM treatment must be withheld at the onset of any &ge;Grade 3 Bortezomib TBM-&nbsp;related non-haematological toxicities (excluding neuropathy) or &ge;Grade 3 haematological toxicities (see also section 4.4). For dose adjustments, see Table 5 below.<br />Granulocyte colony stimulating factors may be administered for haematologic toxicity according to local standard practice. Prophylactic use of granulocyte colony stimulating factors should be considered in case of repeated delays in cycle administration. Platelet transfusion for the treatment of thrombocytopenia should be considered when clinically appropriate.</p><p>Table 5: Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma</p><p><img alt="page7image20167680" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c25156ea-d8ef-4c34-a705-1a8157781223" /><img alt="page7image20167872" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/4b214126-9f4b-4404-87d6-5d0afb5071dd" />&nbsp;<img alt="page7image20168256" width="279.180000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/5352f299-f87b-4535-b92a-7368f837009e" /><img alt="page7image20168064" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/eb40f369-d27a-404e-9275-9b400374513b" /><img alt="page7image20168448" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/599e2c90-963c-4050-906a-a75c51c9d6f6" /><img alt="page7image20080960" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/39d8dca9-87b4-44c0-9158-cd229da6ddb2" />&nbsp;<img alt="page7image20774912" width="313.440000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/d818ff12-bbaf-4a68-83c2-47f6f1bc689b" /><img alt="page7image20775104" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/8453a272-7a7d-459f-97b8-cce9f79b16fa" />&nbsp;<img alt="page7image20775296" width="45.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/17888d83-d283-4d24-9697-fbf0cc5b8975" /><img alt="page7image20775488" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/9a2832fd-f611-4364-86b3-497c30ada989" /></p><p>Toxicity</p><p>Hematological toxicity</p><p>Dose modification or delay</p><p><img alt="page7image20775680" width="34.980000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/977e7966-d550-43f6-844d-7be819aefb07" />&nbsp;<img alt="page7image20775872" width="114.120000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/2c0b54aa-ede4-4d50-8e21-53e6e50075b9" />&nbsp;<img alt="page7image20776064" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a2366ddb-c640-4fa0-9ee1-02b0c07bbe14" /></p><table><tbody><tr><td><p>&bull;&nbsp;&ge;Grade 3 neutropenia with fever, Grade 4 neutropenia lasting more than 7 days, a platelet count &lt; 10,000 cells/&mu;L</p><img alt="page7image20776640" width="177.960000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/1867a3c1-7c46-40a1-b378-a3242068feb5" /><img alt="page7image20776832" width="216.000000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/f7a9e6a0-05ce-4165-92bd-0d676971d3b0" />&nbsp;<img alt="page7image20777024" width="71.520000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/fab5fbef-347e-4894-b771-e01fed966bce" /></td><td><p>Bortezomib TBM therapy should be withheld for up to 2 weeks until the patient has an ANC &ge; 750 cells/&mu;L and a platelet count &ge; 25,000 cells/&mu;L.<br />&bull; If, after Bortezomib TBM has been held, the toxicity does not resolve, as defined above, then Bortezomib TBM must be discontinued.</p><p>&bull; If toxicity resolves i.e. patient has an ANC &ge; 750 cells/&mu;L and a platelet count &ge; 25,000 cells/&mu;L, Bortezomib TBM may be reinitiated at a dose reduced by one dose level (from 1.3 mg/m2&nbsp;to 1 mg/m2, or from 1 mg/m2&nbsp;to 0.7 mg/m2).</p><img alt="page7image20777600" width="207.420000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/9351a711-a30b-4fa5-9a7e-652c899d823f" /><img alt="page7image20777792" width="207.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/8ce8518d-d70c-4c8a-a80f-bb29c9c7e21a" /><img alt="page7image20777984" width="188.640000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f9f146db-9e47-476f-80f6-8466cb18b07e" /><img alt="page7image20778176" width="207.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e8f58e63-3a46-4f66-98cd-b2eac508cf1b" /><img alt="page7image20778368" width="207.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2912258d-51f2-472a-8446-151b8122e49d" />&nbsp;<img alt="page7image20778560" width="161.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a6ffc684-201e-44be-85c1-76571748c621" /><img alt="page7image20778752" width="207.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2e89e800-fe79-4587-8008-6f866a7a712c" /><img alt="page7image20778944" width="207.420000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/27482f9a-775c-41a6-a7d3-78aa400b83b9" /><img alt="page7image20779136" width="207.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b0cb1567-f89a-4baf-b973-d350019f1595" /><img alt="page7image20779328" width="207.420000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/0e90f2a8-691e-4c3e-8e92-c8e338a5d385" /></td></tr></tbody></table><p>&bull;&nbsp;If platelet counts &lt; 25,000 cells/&mu;L. or ANC &lt; 750 cells/ &mu;L on a Bortezomib TBM dosing day (other than Day 1 of each cycle)</p><p>Bortezomib TBM therapy should be withheld</p><p><img alt="page7image20780096" width="213.180000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/62ff2841-2e36-4659-b710-dcea4dcfcace" />&nbsp;<img alt="page7image20780288" width="182.520000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/223f711f-d705-4c75-894d-c2db1f7288f4" />&nbsp;<img alt="page7image20780480" width="201.300000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ec6b31a3-da26-49a6-9d34-6a2c913536d4" /></p><table><tbody><tr><td><p>Grade &ge; 3 non-haematological toxicities considered to be related to Bortezomib TBM</p><img alt="page7image20781056" width="206.820000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/95139b80-2a7d-47c8-9b57-6bef4235a2ac" />&nbsp;<img alt="page7image20781248" width="133.560000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/0c1aef60-23e1-4022-90de-35a0a59b21e1" /></td><td><p>Bortezomib TBM therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better. Then, Bortezomib TBM may be reinitiated at a dose reduced by one dose level (from1.3mg/m2&nbsp;to1mg/m2,orfrom1mg/m2&nbsp;to 0.7 mg/m2). For Bortezomib TBM -related neuropathic pain and/or peripheral neuropathy, hold and/or modify Bortezomib TBM as outlined in Table 1</p><img alt="page7image20782016" width="203.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/22534d52-832e-42e9-9ca9-589157431eb7" /><img alt="page7image20782208" width="202.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2f58253c-66df-40cc-9d7b-376a030466cd" />&nbsp;<img alt="page7image20782400" width="167.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/890a40f7-60f9-4802-9def-6ead23489824" /><img alt="page7image20782592" width="184.380000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ad3a2363-5fa3-4b13-9f62-a817557dd20f" /><img alt="page7image20782784" width="203.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4ea2afe1-becf-450f-9225-f10b4b63058a" />&nbsp;<img alt="page7image20782976" width="170.760000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d2182116-d500-4af7-8724-d8e9a5fd9b79" /><img alt="page7image20783168" width="188.040000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/28e2f9bd-1075-497d-9caa-1d1bbf72d17a" /><img alt="page7image20783360" width="197.220000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/740b9961-3847-45e3-a735-70ad11de9402" /></td></tr></tbody></table><p>In addition, when Bortezomib TBM is given in combination with other chemotherapeutic medicinal products, appropriate dose reductions for these medicinal products should be considered in the event of toxicities, according to the recommendations in the respective Summary of Product Characteristics.</p><p>Special populations</p><p>Elderly</p><p>There is no evidence to suggest that dose adjustments are necessary in patients over 65 years of age with multiple myeloma or with mantle cell lymphoma.<br />There are no studies on the use of Bortezomib TBM in elderly patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Therefore no dose recommendations can be made in this population.</p><p>In a study in previously untreated mantle cell lymphoma patients, 42.9% and 10.4% of patients exposed to Bortezomib TBM were in the range 65-74 years and &ge; 75 years of age, respectively. In patients aged &ge; 75 years, both regimens, BzR-CAP as well as R-CHOP, were less tolerated (see section 4.8).</p><p><img alt="page7image20784128" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/73167970-065a-4ab9-8173-0794c06a23a3" /><img alt="page7image20784320" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/77eac5f3-42b3-45dd-9be5-352bc6a56ef4" /><img alt="page7image20784512" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/9f2453ad-6992-43b8-9f71-ada792bfa9fd" />&nbsp;<img alt="page7image20784704" width="68.100000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/70465792-f224-4d3a-8379-1ec5087bc6ec" />&nbsp;<img alt="page7image20784896" width="86.460000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/79e44ef0-4f56-4ed5-9257-416d7d8fb405" />&nbsp;<img alt="page7image20785088" width="32.400000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/bfad5d61-7cf1-4893-b53b-4f44ed0573e6" /><img alt="page7image20785280" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/6ac26eed-afec-48c0-8209-c0d2351b7ffc" />&nbsp;<img alt="page7image20785472" width="240.720000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/64b3ced6-2733-4f0b-b989-65f847e1cd8b" /><img alt="page7image20785664" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/de8b95d8-d14e-4231-8e86-d4b4b60bfb5c" /><img alt="page7image20785856" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/6de117fa-b9b9-458a-a5da-27431abd7745" /><img alt="page7image20786048" width="372.060000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/d3ddfbd4-38c2-494d-bb22-c7ba566ca49d" /><img alt="page7image20786240" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/fa0beb4e-3163-4bab-91ff-4484fd765d51" /><img alt="page7image20786432" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ef2b9743-7474-477a-9bdd-666df9c2c2d4" /><img alt="page7image20786624" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ffc8df82-e6c2-4380-9fb7-f56d394313f0" />&nbsp;<img alt="page7image20786816" width="54.060000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/843c398a-3a22-43f6-8371-b16558147ca3" /></p><p>sa-spc</p><p>Pg. 7</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page8image20736896" width="0.720000" height="668.280000" src="blob:https://sdi.sfda.gov.sa/33b202cf-3d8d-4ef9-9a1f-eac55dd81a9c" /></p><p>Hepatic impairment</p><p>Patients with mild hepatic impairment do not require a dose adjustment and should be treated per the recommended dose. Patients with moderate or severe hepatic impairment should be started on Bortezomib TBM at a reduced dose of 0.7 mg/ m2&nbsp;per injection during the first treatment cycle, and a subsequent dose escalation to 1.0 mg/m2 or further dose reduction to 0.5 mg/ m2&nbsp;may be considered based on patient tolerability (see Table 6 and sections 4.4 and 5.2).</p><p>Table 6: Recommended starting dose modification for Bortezomib TBM in patients with hepatic impairment</p><p><img alt="page8image20737088" width="88.320000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/f2bc4904-7205-4c90-b372-d901a39e7067" />&nbsp;<img alt="page8image20737280" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/fe01f1ca-4bfb-45c5-b94a-31103f74fe82" /><img alt="page8image20737472" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/aff810d1-a5ab-4af7-96af-62b8566ccbe1" /><img alt="page8image20737664" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/5c704bc6-a6d1-4e49-9390-44f1ccb69448" /><img alt="page8image20737856" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f9461904-072a-4594-bdc5-4a765555c896" /><img alt="page8image20738048" width="344.220000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/a56d3390-87a4-4eb2-a1ef-c6530c285851" /><img alt="page8image20738240" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/34161907-c6c0-48a1-ba87-97646c8a10b4" />&nbsp;<img alt="page8image20738432" width="50.700000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/98b24ea9-5d60-40fc-8298-a37536f42d78" /><img alt="page8image20738624" width="447.600000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/b2249c62-4e2b-4d25-86dc-1fb9994ce377" /></p><p>Grade of hepatic impairment*&nbsp;Mild</p><p>Moderate</p><p>Bilirubin level</p><p>&le; 1.0 x ULN<br />&gt; 1.0 x -1.5 x ULN &gt;1.5x-3xULN</p><p>SGOT (AST) levels<br />&gt; ULN Any<br />Any</p><p>Modification of starting dose</p><p>None</p><p>None</p><p>ReduceBortezomibTBMto0.7mg/m2&nbsp;in the first treatment cycle.<br />Consider dose escalation to 1.0 mg/m2&nbsp;or further dose reduction to 0.5 mg/m2&nbsp;in subsequent cycles based on patient tolerability.</p><p><img alt="page8image20738816" width="72.360000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/68b32da3-d4c4-430c-bc08-60e0e0b7e6c0" />&nbsp;<img alt="page8image20739008" width="56.760000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/9c2728ca-c0be-4b1c-a74e-56a9172babdb" />&nbsp;<img alt="page8image20739200" width="61.380000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/42968c42-b48d-4cca-966a-6fc3d4ed443e" />&nbsp;<img alt="page8image20739392" width="124.200000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/1ab43c1c-33d9-443f-ac2e-43cd31208d79" />&nbsp;<img alt="page8image20739584" width="55.560000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/806320e9-6fb7-4b99-b0a1-ab68f3093796" /><img alt="page8image20739776" width="447.600000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/cbf2d1f5-bfdb-4add-8b6a-67ab23d6e239" />&nbsp;<img alt="page8image20739968" width="49.620000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/4808d832-c3a4-42ac-893f-549532f0fb4d" /><img alt="page8image20740160" width="362.220000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/69257561-b932-47e7-bf70-eb36f6c43a11" />&nbsp;<img alt="page8image20740352" width="80.160000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/071ca530-8828-4451-b12b-8ac8188a9f96" /><img alt="page8image20740544" width="447.600000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d49e395b-e8aa-4523-b010-487e95184fc5" />&nbsp;<img alt="page8image20740736" width="38.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/aba227a9-f861-46a7-b6f0-d87ffdd112ef" />&nbsp;<img alt="page8image20740928" width="72.720000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/c1aa42e1-095d-424c-93ba-e15f93c0f507" />&nbsp;<img alt="page8image20741120" width="177.780000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8e5a27d4-6157-4904-9ffa-e71d272f6aab" /></p><table><tbody><tr><td><p>Severe</p></td><td><p>&gt; 3 x ULN</p><img alt="page8image20793792" width="43.980000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/30e29081-4e67-4e53-add7-5fa8c2c73b26" /></td><td><p>Any</p></td></tr></tbody></table><p><img alt="page8image20758528" width="0.480040" height="52.920000" src="blob:https://sdi.sfda.gov.sa/cad0b0ec-01f0-4fa3-bf47-753a3d136cfe" />&nbsp;<img alt="page8image20758720" width="97.920000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/fa35c277-848d-4a54-9c85-8cc97e388687" />&nbsp;<img alt="page8image20758912" width="166.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e86e2690-d7b3-40b8-a931-154da7ecc254" />&nbsp;<img alt="page8image20759104" width="154.380000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/9d02cefa-2eb6-4c7a-9419-425139d9f260" />&nbsp;<img alt="page8image20759296" width="141.600000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d2fe3b6d-cf00-45f1-94fb-5c08753fae74" /></p><p>Abbreviations: SGOT=serum glutamic oxaloacetic transaminase; AST=aspartate aminotransferase; ULN=upper limit of the normal range.<br />* Based on NCI Organ Dysfunction Working Group classification for categorising hepatic impairment (mild, moderate, severe).</p><p>Renal impairment</p><p>The pharmacokinetics of bortezomib are not influenced in patients with mild to moderate renal impairment (Creatinine Clearance [CrCL] &gt; 20 ml/min/1.73 m2); therefore, dose adjustments are not necessary for these patients. It is unknown if the pharmacokinetics of bortezomib are influenced in patients with severe renal impairment not undergoing dialysis (CrCL &lt; 20 ml/min/1.73 m2). Since dialysis may reduce bortezomib concentrations, Bortezomib TBM should be administered after the dialysis procedure (see section 5.2).</p><p>Paediatric population</p><p>The safety and efficacy of bortezomib in children below 18 years of age have not been established (see sections 5.1 and 5.2). Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p>Method of administration<br />Bortezomib TBM is available for intravenous or subcutaneous administration.<br />Bortezomib TBM should not be given by other routes. Intrathecal administration has resulted in death.</p><p>Intravenous injection</p><p>Bortezomib TBM is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with sodium chloride 9 mg/ml (0.9%) solution for injection. At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>Subcutaneous injection</p><p><img alt="page8image20818816" width="441.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/89e9e2c1-f95b-4a3f-80be-64699dd698dd" />&nbsp;<img alt="page8image20819008" width="153.900000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e66ff78f-e10e-4695-be5f-9b52a091f169" /><img alt="page8image20819200" width="441.840000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/126c5b28-9bfc-4ea3-b561-5c20d733874d" />&nbsp;<img alt="page8image20819392" width="73.560000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/be3ee3bf-f3a9-45d9-83d4-7e36683cdc3e" />&nbsp;<img alt="page8image20819584" width="79.080000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/503df087-0222-421c-b067-cd690b3f44d6" /><img alt="page8image20819776" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/913e7aec-b42e-41cc-ad3c-e3527d0fa017" /><img alt="page8image20819968" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/19823b62-94ff-49b2-b6c3-2c41469ab593" /><img alt="page8image20820160" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a4e8c99f-dea0-42b5-be7b-201f41c414ad" /><img alt="page8image20820352" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/bab3de07-71d1-4429-9fc0-798d2910977f" /><img alt="page8image20820544" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/838f410e-a5df-4862-80fc-9eef95b80140" />&nbsp;<img alt="page8image20820736" width="196.680000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ec590205-a5b7-4b14-bff5-9bbb457939bb" />&nbsp;<img alt="page8image20820928" width="96.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f92687ec-048b-4659-a792-86106b97f998" /><img alt="page8image20821120" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/75f347cc-2cd2-4d3b-89cc-5be6de84e90f" /><img alt="page8image20821312" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3e9cacda-f9d2-4595-b280-a860cca36c31" />&nbsp;<img alt="page8image20821504" width="198.900000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/3c4c8975-e1f2-4013-9948-567f2d626670" />&nbsp;<img alt="page8image20821696" width="112.440000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/2197deeb-e768-42f4-aef8-7328a059aa61" /><img alt="page8image20821888" width="343.680000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a6a96e72-416b-4201-8ba0-9bf57ecd9f41" /><img alt="page8image20822080" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4df169e8-3a67-4845-983c-97bc70ad2bce" />&nbsp;<img alt="page8image20822272" width="93.780000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a4b32051-8bc6-4730-bac6-6edf3dd26fc8" /><img alt="page8image20822464" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/9cf020be-5e93-4b4b-9787-1d509fb46e81" /><img alt="page8image20822656" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ccd8d167-34eb-42d7-acb0-ef62768c9884" /><img alt="page8image20822848" width="413.880000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/719ae033-cb1b-4bb1-b4c2-7e1e605d9e2e" />&nbsp;<img alt="page8image20823040" width="102.300000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f5ed2e6d-1f73-4560-95f0-73f5e785cf32" /></p><p>sa-spc</p><p>Pg. 8</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page9image20722432" width="0.720000" height="674.760000" src="blob:https://sdi.sfda.gov.sa/09450a5c-46c1-4639-af27-ed4d6c62cfb5" /></p><p>Bortezomib TBM is administered subcutaneously through the thighs (right or left) or abdomen (right or left). The solution should be injected subcutaneously, at a 45-90&deg; angle. Injection sites should be rotated for successive injections.<br />If local injection site reactions occur following Bortezomib TBM subcutaneous injection, either a less concentrated Bortezomib TBM solution (Bortezomib TBM 3.5 mg to be reconstituted to 1 mg/ml instead of 2.5 mg/ml) may be administered subcutaneously or a switch to intravenous injection is recommended.</p><p>When Bortezomib TBM is given in combination with other medicinal products, refer to the Summary of Product Characteristics of these products for instructions for administration.</p><p>4.2.1 Important Dosing Guidelines</p><p>Bortezomib TBM is for intravenous or subcutaneous use only. Bortezomib TBM should not be administered by any other route.<br />Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered.</p><p>The recommended starting dose of Bortezomib TBM is 1.3 mg/m2. Bortezomib TBM may be administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL.<br />Bortezomib TBM retreatment may be considered for patients with multiple myeloma who had previously responded to treatment with Bortezomib TBM and who have relapsed at least 6 months after completing prior Bortezomib TBM treatment. Treatment may be started at the last tolerated dose (see section 4.2).</p><p>When administered intravenously, Bortezomib TBM is administered as a 3 to 5 second bolus intravenous injection.</p><p>4.2.2 Dosage in Previously Untreated Multiple Myeloma</p><p>Bortezomib TBM is administered in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles as shown in Table 1. In Cycles 1-4, Bortezomib TBM is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5-9, Bortezomib TBM is administered once weekly (days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>Table 1: Dosage Regimen for Patients with Previously Untreated Multiple Myeloma Twice Weekly Bortezomib TBM (Cycles 1-4)</p><p>Week 1 2 3 4 5 6</p><p><img alt="page9image20722624" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/102033d6-9131-496c-9f5c-e22338688066" /><img alt="page9image20722816" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/f569bd7a-c752-421f-9ed8-014443034472" />&nbsp;<img alt="page9image20723008" width="188.760000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c396ef36-31c1-4d95-a9f8-7ab866468c6f" /><img alt="page9image20723200" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/ff6331a6-e3fa-492d-9a15-aae34b9f6139" /><img alt="page9image20723392" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/a66c6074-5839-4a65-be6e-dccd61518c4f" /><img alt="page9image20723584" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/562eb02a-66f6-46ca-b83f-cb7a30e05e67" />&nbsp;<img alt="page9image20723776" width="116.400000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/f5280f6a-8d9f-4530-8293-4fc0523950f5" /><img alt="page9image20723968" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/19eb5535-f7ca-4e95-b6e8-d79cd4e55dbf" /><img alt="page9image20724160" width="391.920000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/9c88cba6-435b-419b-94dc-f8334ddd89a7" />&nbsp;<img alt="page9image20724352" width="161.640000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/173162f3-04d7-4a3c-9091-b543e14d41ed" /><img alt="page9image20724544" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/50d1c63f-b2c3-4333-81de-371ad0c58bcd" />&nbsp;<img alt="page9image20724736" width="142.620000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/68607960-9020-4ad7-9732-171a862773d7" /><img alt="page9image20724928" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/31bd2821-2b31-476b-943b-ecdc8b2a5fe2" />&nbsp;<img alt="page9image20725120" width="298.260000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0923e55c-37a5-473b-8c73-34b190b53735" /><img alt="page9image20725312" width="310.140000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f413e333-e8e2-4ff3-8ff6-56de2b263a52" />&nbsp;<img alt="page9image20725504" width="128.160000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/75e525dd-86a8-46a0-a6ca-aecb4e65c01c" /><img alt="page9image20905984" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ea5b6cc8-94b2-45a3-ac3b-d170f3578daa" />&nbsp;<img alt="page9image20906176" width="51.660000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/430389ac-e52a-4578-8608-c25a8e60ffdc" /><img alt="page9image20906368" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c275c2d1-8678-41a9-96d5-854855b380ca" /><img alt="page9image20906560" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/67533acb-a7aa-4303-b065-dda04d298ad0" /><img alt="page9image20906752" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f7d169dd-7f47-4093-af18-762c8ab32932" />&nbsp;<img alt="page9image20906944" width="97.440000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/615f696d-44bd-48c0-a593-76c071107fd2" /><img alt="page9image20907136" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c4089909-8df2-426c-9454-70ef9c72726c" />&nbsp;<img alt="page9image20907328" width="95.280000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b6f7a047-f9f8-481f-a9c3-2d7d4fa2d63d" /><img alt="page9image20907520" width="262.740000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b2e1f9a6-57c9-4f1e-9852-62795e960e01" />&nbsp;<img alt="page9image20907712" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/77aa36d6-2cce-4f4f-99b9-b4076f4bac18" /><img alt="page9image20907904" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/7334a342-658e-4787-af28-c2466256c908" /><img alt="page9image20908096" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/d381e28d-6641-4ed7-ac1e-e922ac9be3c0" /><img alt="page9image20908288" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0080f199-291c-4902-9bb2-a1b5328abc12" />&nbsp;<img alt="page9image20908480" width="81.240000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0c1829f8-eab1-4fa6-b794-590fb515f356" /><img alt="page9image20908672" width="392.880000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/7967987b-b9f0-4568-8805-b94ec02bff57" /><img alt="page9image20908864" width="461.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/72ce878b-d9d9-4d94-a25c-4b1ba2197904" />&nbsp;<img alt="page9image20909056" width="209.880000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/456ad2d0-a062-4188-b33e-0295f151e06d" /><img alt="page9image20909248" width="461.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/c90d87bd-ee84-4936-b911-12b6337cab5c" /></p><table><tbody><tr><td><p>Bortezomib TBM</p><p>(1.3 mg/m2)</p><img alt="page9image20909824" width="51.900000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/1f3ef73e-dab5-40bc-89e4-ee371e42d78c" />&nbsp;<img alt="page9image20910016" width="45.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/7d147cf2-d621-40a5-9a26-0591b668d650" /></td><td><p>Day 1</p></td><td><p>--</p></td><td><p>--</p></td><td><p>Day 4</p></td><td><p>Day 8</p></td><td><p>Day 11</p></td><td><p>rest period</p></td><td><p>Day 22</p></td><td><p>Day 25</p></td><td><p>Day 29</p></td><td><p>Day 32</p></td><td><p>rest period</p></td></tr><tr><td><p>Melphalan (9 mg/m2) Prednisone (60 mg/m2)</p><img alt="page9image20912896" width="47.040000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/d246a34d-c563-4448-abb8-02947cea629f" />&nbsp;<img alt="page9image20913088" width="37.560000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/31214412-7f5f-4ce6-9ba9-23ae8924aab4" /><img alt="page9image20913280" width="48.900000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c97120b3-8e21-42f8-85b5-ded7ab108464" />&nbsp;<img alt="page9image20913472" width="43.080000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/c14c64ce-c29b-4001-87fe-c537b122bf07" /></td><td><p>Day 1</p></td><td><p>Day 2</p></td><td><p>Day 3</p></td><td><p>Day 4</p></td><td><p>--</p></td><td><p>--</p></td><td><p>rest period</p></td><td><p>--</p></td><td><p>--</p></td><td><p>--</p></td><td><p>--</p></td><td><p>rest period</p></td></tr></tbody></table><p>Once Weekly Bortezomib TBM (Cycles 5-9 when used in combination with Melphalan and Prednisone)<br />Week 1 2 3 4 5 6</p><p><img alt="page9image20916544" width="425.340000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/849c0518-101f-47d9-a04b-90dfd970bcb0" />&nbsp;<img alt="page9image20916736" width="56.220000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bc350e14-81f8-46a1-b162-fdf2d322f8f6" /><img alt="page9image20916928" width="461.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/0cd01d8b-0c52-47c3-8c9c-1cd209aab5fd" /><img alt="page9image20917120" width="461.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/c4a4b13d-7ce8-441a-9cb9-fddbc4e4d5c0" /></p><p>Bortezomib Day -- --</p><p>Day</p><p>rest</p><p>Day</p><p>Day rest</p><p><img alt="page9image20917312" width="51.900000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/74369bfc-5cfa-4fc3-84d1-a8e9ecf22bcf" />&nbsp;<img alt="page9image20917504" width="68.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/cc91df45-d775-420b-9b6c-a21f835e9c49" />&nbsp;<img alt="page9image20917696" width="30.780000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/fca171fe-7707-4542-8cd7-565ac34c0546" />&nbsp;<img alt="page9image20917888" width="39.840000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b2e797f1-e61f-4491-a0f2-71f32b5f13ab" />&nbsp;<img alt="page9image20918080" width="34.800000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/21b3a78d-c2c9-416a-ab37-11ce2f3292dc" />&nbsp;<img alt="page9image20918272" width="31.200000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/c8601dbd-7a57-4604-9c8e-5e909a744b91" />&nbsp;<img alt="page9image20918464" width="30.780000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/5e483a1c-5cc0-4ebc-b649-0c0f87acdfb4" />&nbsp;<img alt="page9image20918656" width="30.780000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/324f8c23-7085-409d-9588-47717c240a96" />&nbsp;<img alt="page9image20918848" width="43.860000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/333ae93a-bd99-4191-a676-a43b964bdda9" /></p><p>sa-spc</p><p>Pg. 9</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page10image20933120" width="461.280000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/57fea704-df2a-4b66-aac1-d30373f2bb28" />&nbsp;<img alt="page10image20933312" width="0.720000" height="666.960000" src="blob:https://sdi.sfda.gov.sa/e78a25fa-3e46-4512-9fae-45754916260c" /></p><p>TBM 1 8 period 22 29 period (1.3 mg/m2)</p><p>Day Day Day Day -- 1234</p><p>4.2.3 Dose Modification Guidelines for Bortezomib TBM when Given in Combination with Melphalan and Prednisone<br />Prior to initiating any cycle of therapy with Bortezomib TBM in combination with melphalan and prednisone:</p><p>&nbsp;Platelet count should be at least 70 &times; 109&nbsp;/L and the absolute neutrophil count (ANC) should be at least 1.0 &times; 109&nbsp;/L<br />&nbsp;Non-hematological toxicities should have resolved to Grade 1 or baseline</p><p>Table 2: Dose Modifications during Cycles of Combination Bortezomib TBM, Melphalan and Prednisone Therapy</p><p>Toxicity Dose modification or delay</p><p><img alt="page10image20933504" width="48.600000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f9c61cfb-369d-4849-9c4e-627165b6ac57" /><img alt="page10image15161920" width="68.280000" height="76.380000" src="blob:https://sdi.sfda.gov.sa/575378fc-3474-4562-8372-108a7a463f23" />&nbsp;<img alt="page10image15162032" width="31.740010" height="76.380000" src="blob:https://sdi.sfda.gov.sa/03d1107b-06de-402a-bad5-33bc3db8ce45" />&nbsp;<img alt="page10image15162144" width="35.280000" height="76.380000" src="blob:https://sdi.sfda.gov.sa/953d0c39-c21d-4771-a0ea-45593ca2b3cb" />&nbsp;<img alt="page10image20935616" width="0.479980" height="76.380000" src="blob:https://sdi.sfda.gov.sa/fea020da-2e54-459a-9f16-47bbfa7dcc24" />&nbsp;<img alt="page10image15162256" width="31.260000" height="76.380000" src="blob:https://sdi.sfda.gov.sa/7a03ac6a-b454-43d5-82fc-42a158518718" />&nbsp;<img alt="page10image20936192" width="0.479980" height="76.380000" src="blob:https://sdi.sfda.gov.sa/7f855339-ff8b-4d02-a1c8-11da32b764a2" />&nbsp;<img alt="page10image20936384" width="0.480040" height="76.380000" src="blob:https://sdi.sfda.gov.sa/a06fb87e-af3f-4adb-bf71-9c7bf91ccc00" /></p><p>Melphalan (9 mg/m2) Prednisone (60 mg/m2)</p><p>--</p><p>rest period</p><p>--</p><p>--</p><p>--</p><p>--</p><p>rest period</p><p><img alt="page10image20936768" width="47.040000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/3159ed16-11fa-4922-84ed-184a5f20c98c" />&nbsp;<img alt="page10image20936960" width="37.560000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/94efee2e-39cb-4696-9ba7-5691aaec4dca" />&nbsp;<img alt="page10image20937152" width="48.900000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/f338ac28-d369-450f-8d19-d7dea55158b4" /><img alt="page10image20938112" width="0.480010" height="76.380000" src="blob:https://sdi.sfda.gov.sa/73b07b26-20d0-4046-a325-26e5d6dfc414" />&nbsp;<img alt="page10image20938304" width="0.480010" height="76.380000" src="blob:https://sdi.sfda.gov.sa/a08096da-b0bd-4913-ab0c-25dd9db1cdcf" />&nbsp;<img alt="page10image20938496" width="0.480010" height="76.380000" src="blob:https://sdi.sfda.gov.sa/661e53fb-cc68-4fae-88ca-31e17399b09e" />&nbsp;<img alt="page10image20955136" width="0.480010" height="76.380000" src="blob:https://sdi.sfda.gov.sa/36eccd60-6412-4465-913f-ba9eadc0f3a7" />&nbsp;<img alt="page10image20955328" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0893abf8-0560-43c0-a93f-ff733a1bb9bb" />&nbsp;<img alt="page10image20955520" width="126.480000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c93a659e-9571-44d4-b900-7e065e718d0c" /><img alt="page10image20955712" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/bbe83251-aba8-4dfb-928a-902c9e49fad3" />&nbsp;<img alt="page10image20955904" width="51.300000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/1bb1c86b-4098-4f49-b6dc-00cec750ab85" />&nbsp;<img alt="page10image20956096" width="209.460000" height="0.600040" src="blob:https://sdi.sfda.gov.sa/07155478-d0cf-4eac-b06f-31d4242bbc60" /><img alt="page10image20956288" width="173.640000" height="0.600040" src="blob:https://sdi.sfda.gov.sa/826c6a27-6750-4b1e-ac08-0f42c4ee0773" />&nbsp;<img alt="page10image20956480" width="162.060000" height="0.600040" src="blob:https://sdi.sfda.gov.sa/9485f900-d974-4ddb-a886-1a4c958d2914" />&nbsp;<img alt="page10image20956672" width="370.920000" height="0.600040" src="blob:https://sdi.sfda.gov.sa/6c0a908f-10b8-4309-982f-cb9cf680d395" /><img alt="page10image20956864" width="438.180000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/302d3c9a-2cc3-4630-b9cd-da35a18fb462" />&nbsp;<img alt="page10image20957056" width="95.640000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b0d377ac-e4b5-4d57-b1c4-7077b2bedfc6" /><img alt="page10image20957248" width="461.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/5721590e-794d-4486-98bf-773a8b7ac0cf" />&nbsp;<img alt="page10image20957440" width="38.520000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/24d8ac38-686e-4890-ab3a-110873a06ff4" />&nbsp;<img alt="page10image20957632" width="125.580000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/1d48c3dc-b105-4c3b-b549-106718de808a" /></p><table><tbody><tr><td><p>Hematological toxicity during a cycle:<br />If prolonged Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle</p><img alt="page10image20958208" width="169.200000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a3f9abc3-56f2-4fad-8862-dcec06a7f13d" />&nbsp;<img alt="page10image20958400" width="159.120000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7dc4990a-1406-4d71-84b5-73170c27be22" /><img alt="page10image20958592" width="199.800000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/02bb19fa-8d97-4677-bb65-d5a68c16d63b" />&nbsp;<img alt="page10image20958784" width="184.500000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a83425c4-3c3c-49d7-9708-59e7b233d64e" /></td><td><p>Consider reduction of the melphalan dose by 25% in the next cycle</p><img alt="page10image20959360" width="160.680000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b7f6c81f-da7b-4e27-9926-aa20d31225f9" />&nbsp;<img alt="page10image20959552" width="132.000000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/cf46364f-b98d-4304-b0ea-1954db9be9b7" /></td></tr><tr><td><p>If platelet count is not above 30 &times; 109&nbsp;/L or ANC is not above 0.75 &times; 109&nbsp;/L on a Bortezomib TBM dosing day (other than day 1)</p><img alt="page10image20959936" width="165.180000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a7a5d1c7-62ac-46eb-ad92-037d6441a8be" />&nbsp;<img alt="page10image20960128" width="51.600000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bdd6e565-05cf-44bd-8682-60495e6a6358" />&nbsp;<img alt="page10image20960320" width="99.720000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c8b73c73-c108-4171-b014-51182d94a156" /><img alt="page10image20960512" width="117.000000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/a5708ec2-bdc6-4ccb-aa9b-64776a1be604" />&nbsp;<img alt="page10image20960704" width="129.240000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/107d8eb2-ec07-4dd6-8025-d263b1b8806f" /></td><td><p>Withhold Bortezomib TBM dose</p><img alt="page10image20961280" width="145.740000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/d832ef22-ece3-4a0e-bfc6-25b7c0767cd4" /></td></tr><tr><td><p>If several Bortezomib TBM doses in consecutive cycles are withheld due to toxicity</p><img alt="page10image20961664" width="161.040000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4ff493ba-d87e-4217-9042-1b0be0aa2190" />&nbsp;<img alt="page10image20961856" width="205.860000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b1e7307f-b459-4aac-9aec-8aff43866cc3" /></td><td><p>Reduce Bortezomib TBM dose by 1 dose level (from 1.3 mg/m2&nbsp;to 1 mg/m2, or from 1 mg/m2&nbsp;to 0.7 mg/m2&nbsp;)</p><img alt="page10image20962432" width="182.040000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/66c4d17b-4ae4-4d4d-b6e4-ff2a7954c34a" />&nbsp;<img alt="page10image20962624" width="94.080000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/99c6f7e2-724f-4d8b-8a7d-b146a65338cc" />&nbsp;<img alt="page10image20962816" width="45.180000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0f671e82-0f6d-4fbe-aa7e-e23e68be7090" />&nbsp;<img alt="page10image20963008" width="38.760000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f8619943-fb45-466b-bae4-999eeb63cd13" /><img alt="page10image20963200" width="33.900000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/2c359b0a-9a49-4ab8-ae40-f06a2433c597" />&nbsp;<img alt="page10image20963392" width="56.160000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/1aab5690-075e-44e1-a0dd-3d294cf179d0" /></td></tr><tr><td><p>Grade 3 or higher non-hematological toxicities</p><img alt="page10image20963776" width="163.080000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b40927ca-438b-4797-987d-a68786848eb3" />&nbsp;<img alt="page10image20963968" width="40.320000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/be6483a7-253e-473f-be3f-2200d4a18b38" /></td><td><p>Withhold Bortezomib TBM therapy until symptoms of toxicity have resolved to<br />Grade 1 or baseline. Then, Bortezomib TBM may be reinitiated with one dose level reduction (from 1.3 mg/m2&nbsp;to 1 mg/m2, or from 1 mg/m2&nbsp;to 0.7 mg/m2). For Bortezomib TBM-related neuropathic pain and/or peripheral neuropathy, hold or modify Bortezomib TBM as outlined in Table 5.</p><img alt="page10image20964736" width="181.500000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/78ca2fd6-addf-46a6-9bd9-ac399646e219" />&nbsp;<img alt="page10image20964928" width="168.300000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/bcd8c2ca-316c-4039-acd7-a7a152feb3fc" /><img alt="page10image20965120" width="197.940000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/22b5244a-f148-48ee-9176-6c86fe37c830" /><img alt="page10image20965312" width="211.740000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0258536e-7df6-420f-9708-30a009c2da2a" />&nbsp;<img alt="page10image20965504" width="69.900000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/74b254c8-3164-49a7-98fd-cf440e7d2bfe" />&nbsp;<img alt="page10image20965696" width="47.940000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/ca80d64a-a13b-4aa1-9e66-b1bf7dd8de65" /><img alt="page10image20965888" width="75.360000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/b4e3d3f0-7062-4023-9840-87228bf64c4f" />&nbsp;<img alt="page10image20966080" width="42.180000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e6b543b6-eb26-45f5-a94b-7a33ea5a5096" />&nbsp;<img alt="page10image20966272" width="139.260000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/01af9c13-864a-49e6-8df0-a4c152b31541" /><img alt="page10image20966464" width="206.820000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/8fdb2d63-afb2-4972-8b21-df99761f74fd" /><img alt="page10image20966656" width="209.340000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/9309e256-1bfb-4088-81b2-99786276626a" />&nbsp;<img alt="page10image20966848" width="36.060000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/48368e37-f8c7-450f-a2c6-c0ddbebb77dd" /></td></tr></tbody></table><p>For information concerning melphalan and prednisone, see the corresponding Summary of product characteristics.</p><p><img alt="page10image20967808" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b83421b6-74f5-4f1d-82e8-c71dd26462ed" />&nbsp;<img alt="page10image20968000" width="65.640000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/5a5f62b5-15bb-4f63-98f6-ed9dde94de22" /></p><p>sa-spc</p><p>Pg. 10</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page11image20093120" width="0.720000" height="668.460000" src="blob:https://sdi.sfda.gov.sa/86fef129-7cc6-4dbe-b2cb-902e29483eea" /></p><p>Dose modifications guidelines for peripheral neuropathy are provided (see section 4.2).</p><p>4.2.4 Dosage in Previously Untreated Mantle Cell Lymphoma</p><p>Bortezomib TBM (1.3 mg/m2) is administered intravenously in combination with intravenous rituximab, cyclophosphamide, doxorubicin and oral prednisone (VcR-CAP) for six 3-week treatment cycles as shown in Table 3. Bortezomib TBM is administered first followed by rituximab. Bortezomib TBM is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period on Days 12-21. For patients with a response first documented at cycle 6, two additional VcR-CAP cycles are recommended. At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>Table 3: Dosage Regimen for Patients with Previously Untreated Mantle Cell Lymphoma Twice Weekly Bortezomib TBM (Six 3-Week Cycles) *</p><p>123</p><p><img alt="page11image20873216" width="384.240000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/5ae9a889-86e9-47ac-90c7-fbaed6a1940d" />&nbsp;<img alt="page11image20873408" width="288.120000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/a57a2612-fc28-43e1-88f5-4798a6210f9d" /><img alt="page11image20873600" width="136.020000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0d1d5928-ab94-4fb0-bcfd-5ccd6d7726b8" />&nbsp;<img alt="page11image20873792" width="302.280000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/8104f098-e61a-4e1d-94db-12106c4aecd6" /><img alt="page11image20873984" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/4eb9235d-73e7-4a36-9371-ea889d7203a8" /><img alt="page11image20874176" width="441.840000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/0177c636-9473-47f8-8608-e192c549ca4e" /><img alt="page11image20874368" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/3addbe35-ac91-491a-a79a-46b0ec7b9d38" /><img alt="page11image20874560" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/032ff250-8fb6-42c8-ba5a-cb4f36da4f93" /><img alt="page11image20874752" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/3cceac54-77e5-4824-b0ab-cd493e193af4" />&nbsp;<img alt="page11image20874944" width="120.420000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/1bfdd3cb-709f-4759-8d8c-c8588fef53be" /><img alt="page11image20875136" width="418.200000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0a5d601a-aa2d-47ea-bbad-d961071860ca" /><img alt="page11image20875328" width="461.280000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d0939b4a-fa02-4867-b339-eac5ac7cb9d5" />&nbsp;<img alt="page11image20875520" width="256.920000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/2f30c77b-643e-4bd1-9392-743f6346b687" /><img alt="page11image20875712" width="461.280000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/3b6a32a1-f6f7-41ef-b4cd-b566c31ba9af" /></p><table><tbody><tr><td><p>Bortezomib TBM (1.3 mg/m2)</p><img alt="page11image20876480" width="78.480000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/67851be2-93ba-437c-a83c-88bd6730624e" />&nbsp;<img alt="page11image20876672" width="45.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e0f157b2-8958-46c5-b43c-b96c54ef736e" /></td><td><p>Day 1</p></td><td><p>--</p></td><td><p>--</p></td><td><p>Day 4</p></td><td><p>--</p></td><td><p>Day 8</p></td><td><p>Day 11</p></td><td><p>rest period</p></td></tr><tr><td><p>Rituximab (375 mg/m2) Cyclophosphamide (750 mg/m2) Doxorubicin (50 mg/m2)</p><img alt="page11image20878784" width="46.440000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/84300bb1-2ff1-4b5c-9f08-53d92817f943" />&nbsp;<img alt="page11image20878976" width="48.600000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0bf2e904-0f62-4bdf-99d6-00f26fd61dea" /><img alt="page11image20879168" width="84.900000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f844ec8b-8186-4303-aab7-8e8c710d30a4" />&nbsp;<img alt="page11image20879360" width="48.600000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b6dd3278-db50-4851-8b07-edb0312d2ed9" /><img alt="page11image20879552" width="55.620000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/089d944c-7784-48b1-ad16-6de2462e5695" />&nbsp;<img alt="page11image20879744" width="43.080000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/6ca7f074-fdb6-45ec-b89a-66f59802fa64" /></td><td><p>Day 1</p></td><td><p>--</p></td><td><p>--</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>--</p></td><td><p>--</p></td><td><p>rest period</p></td></tr></tbody></table><p>Prednisone Day Day Day Day Day -- -- rest</p><p><img alt="page11image20882048" width="48.900000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/747b9d22-ff73-4d7e-9e59-65292d583a37" /></p><p>(100 mg/m2)&nbsp;1&nbsp;2 3 4 5<br />*Dosing may continue for 2 more cycles (for a total of 8 cycles) if response is first seen at cycle 6.</p><p>4.2.5 Dose Modification Guidelines for Bortezomib TBM When Given in Combination with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone<br />Prior to the first day of each cycle (other than Cycle 1):<br />&nbsp;Platelet count should be at least 100 &times; 109/L and absolute neutrophil count (ANC) should be at least 1.5 &times; 109/L</p><p>&nbsp;Hemoglobin should be at least 8 g/dL (at least 4.96 mmol/L)<br />&nbsp;Non-hematologic toxicity should have recovered to Grade 1 or baseline<br />Interrupt Bortezomib TBM treatment at the onset of any Grade 3 hematologic or non-hematological toxicities, excluding neuropathy (see Table 5 and section 4.4) For dose adjustments, see Table 4 below.</p><p>Table 4: Dose Modifications on Days 4, 8, and 11 during Cycles of Combination Bortezomib TBM, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone Therapy<br />Toxicity Dose modification or delay</p><p>Hematological toxicity</p><p>period</p><p><img alt="page11image20882240" width="48.600000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e1094d97-860c-490a-acef-9351c204e2cb" />&nbsp;<img alt="page11image20882432" width="95.760000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/dc539de8-e0f6-4c0c-8a00-071b0e6a5038" />&nbsp;<img alt="page11image20882624" width="42.540000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/297f97e6-cb97-4ac3-9173-ce8f39b6e3a2" />&nbsp;<img alt="page11image20882816" width="46.020000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e79e7183-d661-45cf-a7d3-6a3a9c7e9624" />&nbsp;<img alt="page11image20883008" width="45.360000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/24b0307d-9104-4f0b-b6db-a20d9f12d3be" />&nbsp;<img alt="page11image20883200" width="45.300000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/726b4d68-e333-4e42-93f7-904b814d2868" />&nbsp;<img alt="page11image20883392" width="45.300000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/ac589d11-c2db-42e2-8ff6-fdf53be24729" />&nbsp;<img alt="page11image20883584" width="45.360000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f6d27076-bd5d-4d9e-94f0-fbc68da384cf" />&nbsp;<img alt="page11image20883776" width="45.300000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e6eff884-22e3-4062-b782-89585b8eeb8b" />&nbsp;<img alt="page11image20883968" width="46.020000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/34d6c157-ab30-4904-bb7e-889fa41dd741" /><img alt="page11image20884160" width="433.440000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4276a9bf-dc32-4e3b-82a5-eddb9854e806" /><img alt="page11image20884352" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c30d01d7-cef3-46fd-ab55-79ee572451a2" />&nbsp;<img alt="page11image20884544" width="285.480000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/fbcbd0c8-9799-451c-a484-c42a7d914810" /><img alt="page11image20884736" width="243.420000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/005cbbbd-33bf-47bd-92a2-1057da8ea63c" />&nbsp;<img alt="page11image20884928" width="208.200000" height="0.600010" src="blob:https://sdi.sfda.gov.sa/6859f486-69ab-4a74-a358-3f2873f3f778" />&nbsp;<img alt="page11image20885120" width="229.680000" height="0.600010" src="blob:https://sdi.sfda.gov.sa/0178c11c-1690-49f6-8e0a-9a38e0ca99f4" /><img alt="page11image20885312" width="90.780000" height="0.600010" src="blob:https://sdi.sfda.gov.sa/66ced76f-4e53-424e-a628-120fd0a2e644" />&nbsp;<img alt="page11image20885504" width="298.500000" height="0.599980" src="blob:https://sdi.sfda.gov.sa/c366f1e8-4635-42a5-a66a-31fb4c675469" />&nbsp;<img alt="page11image20885696" width="351.180000" height="0.600010" src="blob:https://sdi.sfda.gov.sa/afd7652c-e433-4089-a1b9-2f4627d34a6e" /><img alt="page11image20885888" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/93fb90fc-a093-4fd5-ad35-726f9b1fc4e4" /><img alt="page11image20886080" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/3083173d-7c67-4953-a108-156a91a921be" /><img alt="page11image20886272" width="452.220000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/2256d8be-0496-491d-bcdf-c8c622c893ba" /><img alt="page11image20886464" width="359.100000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f7fe982a-02cc-4ae2-a419-083292245bd6" /><img alt="page11image20886656" width="461.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e06a1357-7dde-4b63-98bc-74b095b18df8" />&nbsp;<img alt="page11image20886848" width="38.520000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/d3afe0e9-4422-4bc7-a5b9-46911e5b2a0a" />&nbsp;<img alt="page11image20887040" width="125.580000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/e9758978-e44f-4bb4-88d1-76020767fb1d" /><img alt="page11image20887232" width="461.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d0383f09-7e3f-4f5c-9ca8-bcdc65585b37" />&nbsp;<img alt="page11image20887424" width="101.100000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/c5de4fbe-a241-479f-b37b-44c6521b483c" /></p><table><tbody><tr><td><p>Grade 3 or higher neutropenia, or a platelet count not at or above 25 &times; 109&nbsp;/L</p><img alt="page11image20888192" width="189.960000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/36f89cd8-f6a3-43fa-aa65-ea35867070f9" />&nbsp;<img alt="page11image20888384" width="129.360000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f0c64181-90c0-4417-8e6b-9bd2f7b95322" /></td><td><p>Withhold Bortezomib TBM therapy for up to 2 weeks until the patient has an ANC at or above 0.75 &times; 109/L and a platelet count at or above 25 &times; 109/L.</p><p>&nbsp;If, after Bortezomib TBM has been withheld, the toxicity does not resolve, discontinue Bortezomib TBM.<br />&nbsp;If toxicity resolves such that the patient has</p><img alt="page11image20888960" width="207.480000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/5ea24640-40b0-4d3c-af18-4c2f8105342b" /><img alt="page11image20889152" width="229.440000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/1c396d95-29d6-4cda-8583-fbf81a5032a9" /><img alt="page11image20889344" width="186.420000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/9f9fbdac-f9c1-4322-8c1a-7b3c115e2853" />&nbsp;<img alt="page11image20529152" width="179.040000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e74db6d1-779d-489d-ab6d-963b458c03e2" /><img alt="page11image20529344" width="170.820000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7840801f-14aa-4437-8aa8-59cfbbb3bf98" />&nbsp;<img alt="page11image20529536" width="134.700000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f4153107-9201-472d-b617-dfa54776be6f" /><img alt="page11image20529728" width="214.800000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/aaf25f4f-8de7-4639-a459-98ef28d17d50" /></td></tr></tbody></table><p>sa-spc</p><p>Pg. 11</p><p>Bortezomib for injection 3.5mg/vial</p><table><tbody><tr><td>&nbsp;</td><td><p>an ANC at or above 0.75 &times; 109/L and a platelet count at or above 25 &times; 109&nbsp;/L, Bortezomib TBM dose should be reduced by 1 dose level (from 1.3 mg/m2&nbsp;to 1 mg/m2, or from 1 mg/m2&nbsp;to 0.7 mg/m2)</p><img alt="page12image20856192" width="132.660000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/6fef0911-6c7a-4005-95ee-88cc1f90f2cd" />&nbsp;<img alt="page12image20856384" width="71.100000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/51a7bde4-cf82-40e6-9f17-1a6461a8f1b5" />&nbsp;<img alt="page12image20856576" width="112.560000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/872a569d-370c-4725-ac76-3d28f082f569" /><img alt="page12image20871616" width="96.540000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/cd2e254c-4241-4ad4-a095-408ddc9dc4b9" />&nbsp;<img alt="page12image20946240" width="216.300000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/6cadc7a5-7bf1-4e78-9d8b-932edec040ed" />&nbsp;<img alt="page12image20947008" width="47.940000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/d54ac881-dc66-42ed-93bb-1598596e200e" /><img alt="page12image20945664" width="75.420000" height="0.540000" src="blob:https://sdi.sfda.gov.sa/5cafa8d6-e03e-4bb7-94b0-7e24d39fc2a8" /></td></tr><tr><td><p>Grade 3 or higher non-hematological toxicities</p><img alt="page12image20562112" width="163.080000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/3fb8846b-3632-4a6e-b4f6-24fd49b55d45" />&nbsp;<img alt="page12image20562304" width="40.320000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/4d59bfe0-3b18-41c6-80a8-4cc570febf4b" /></td><td><p>Withhold Bortezomib TBM therapy until symptoms of the toxicity have resolved to Grade 2 or better. Then, Bortezomib TBM may be reinitiated with one dose level reduction (from 1.3 mg/m2&nbsp;to 1 mg/m2, or from 1 mg/m2&nbsp;to 0.7 mg/m2).</p><p>For Bortezomib TBM -related neuropathic pain and/or peripheral neuropathy, hold or modify Bortezomib TBM as outlined in Table 5.</p><img alt="page12image20562880" width="229.440000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/604efdac-b8ec-47f0-bf5d-6379a31ac61e" /><img alt="page12image20563072" width="216.900000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/326d7649-70d7-4797-b0a9-36a72ede100e" /><img alt="page12image20563264" width="229.740000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/2ceaaec3-1791-4206-9b8e-a41b259e8aaa" />&nbsp;<img alt="page12image20563456" width="161.280000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/5793b505-f2d5-43e4-8494-7b8629731d2f" /><img alt="page12image20563648" width="47.880000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/624ba4d2-c765-46cf-86ff-d1a96ab1ee19" />&nbsp;<img alt="page12image20563840" width="58.020000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/fb8e13f6-2c9e-40da-9ae3-9a737027c612" />&nbsp;<img alt="page12image20564032" width="56.160000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ffeafc4b-84cb-4558-8ebb-6f4c2d854ae3" />&nbsp;<img alt="page12image20564224" width="209.220000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/090765ee-9b5d-4a2d-980e-208f90d3016f" /><img alt="page12image20564416" width="199.260000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/757c2c1f-fa54-444e-b410-186c78bcf7d4" />&nbsp;<img alt="page12image20564608" width="179.280000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/8b0116df-494a-46ea-a370-9a0958277cba" /></td></tr></tbody></table><p><img alt="page12image20565184" width="0.720000" height="677.760000" src="blob:https://sdi.sfda.gov.sa/5db496e6-f033-402d-aba2-e24e49c3a83d" /></p><p>For information concerning rituximab, cyclophosphamide, doxorubicin and prednisone, see the corresponding Summary of product characteristics.</p><p>4.2.6 Dosage and Dose Modifications for Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma<br />Bortezomib TBM (1.3 mg/m2&nbsp;/dose) is administered twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21). For extended therapy of more than 8 cycles, Bortezomib TBM may be administered on the standard schedule or, for relapsed multiple myeloma, on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13- day rest period (Days 23 to 35). At least 72 hours should elapse between consecutive doses of Bortezomib TBM.</p><p>Patients with multiple myeloma who have previously responded to treatment with Bortezomib TBM (either alone or in combination) and who have relapsed at least 6 months after their prior Bortezomib TBM therapy may be started on Bortezomib TBM at the last tolerated dose. Retreated patients are administered Bortezomib TBM twice weekly (Days 1, 4, 8, and 11) every three weeks for a maximum of 8 cycles. At least 72 hours should elapse between consecutive doses of Bortezomib TBM. Bortezomib TBM may be administered either as a single agent or in combination with dexamethasone (see section 5).</p><p>Bortezomib TBM therapy should be withheld at the onset of any Grade 3 non-hematological or Grade 4 hematological toxicities excluding neuropathy as discussed below.(see section 4.4) Once the symptoms of the toxicity have resolved, Bortezomib TBM therapy may be reinitiated at a 25% reduced dose (1.3 mg/m2&nbsp;/dose reduced to 1 mg/m2&nbsp;/dose; 1 mg/m2&nbsp;/dose reduced to 0.7 mg/m2/dose).</p><p>For dose modifications guidelines for the peripheral neuropathy see section 4.2.7</p><p>4.2.7 Dose Modifications for Peripheral Neuropathy</p><p>Starting Bortezomib TBM subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy. Patients with pre-existing severe neuropathy should be treated with Bortezomib TBM only after careful risk-benefit assessment.<br />Patients experiencing new or worsening peripheral neuropathy during Bortezomib TBM therapy may require a decrease in the dose and/or a less dose-intense schedule.</p><p>For dose or schedule modification guidelines for patients who experience Bortezomib TBM -related neuropathic pain and/or peripheral neuropathy see Table 5.</p><p><img alt="page12image20565568" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c3b12a13-0a1a-4304-abf2-44bef57eebd6" />&nbsp;<img alt="page12image20565760" width="225.120000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/229b10f5-21b3-4f98-a90a-9b4699c3ac6f" /><img alt="page12image20565952" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/54f3c052-2019-42d4-92be-8bb9b32981e8" />&nbsp;<img alt="page12image20566144" width="76.080000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/52b4a8bc-3b21-4c64-8b3b-41133e4cc9eb" />&nbsp;<img alt="page12image20566336" width="130.080000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7f2e4524-6a51-4002-ae25-a25eeb59858c" /><img alt="page12image20566528" width="308.220000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0fe1ccfe-3aed-40ee-9cd5-a597f68d1c09" />&nbsp;<img alt="page12image20566720" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/39960c13-347a-4ea6-9adf-9f2a61047024" /><img alt="page12image20566912" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/7ed7a188-f8b7-4f60-b473-df2d44871426" /><img alt="page12image20567104" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/24e55687-85ee-4863-8e7f-d2e29aa93d74" /><img alt="page12image20567296" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/faf693de-a134-48e3-89f9-91859659d626" />&nbsp;<img alt="page12image20567488" width="81.240000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/5ffd1dc2-cae1-4d1c-9d92-3d5b3ff5dba7" /><img alt="page12image20567680" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/aec81f16-2e86-4841-8b1b-1666a0fbb0fd" /><img alt="page12image20567872" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e93a069f-0279-4886-b929-780f144a99d7" /><img alt="page12image20568064" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/eebbf10a-8e5d-48cf-8240-5d8af06446c7" /><img alt="page12image20568256" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0d1c4423-7077-4930-a372-a4870d849fdb" /><img alt="page12image20568448" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e644372f-5def-4cd8-bf4f-68e1c7cdafaf" /><img alt="page12image20568640" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/019eb0e7-552f-42a7-8dba-f8161a5b94ad" />&nbsp;<img alt="page12image20568832" width="159.120000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e200797c-ce52-4af2-b5a7-5888a8b5c0db" /><img alt="page12image20569024" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/dc48c3ff-1da0-4226-93cb-99c3bcf7782f" /><img alt="page12image20569216" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bdbe0eec-6b9a-4184-b4c8-862ca9f696b3" /><img alt="page12image20569408" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/c35ee4f1-1806-4d94-9413-6b2bfde83090" />&nbsp;<img alt="page12image20569600" width="110.940000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/83ef9890-3d4c-43be-8a4f-af9b02589bdd" />&nbsp;<img alt="page12image20569792" width="119.160000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/4bdee938-98c3-4b14-93cb-1ff56f9142d2" />&nbsp;<img alt="page12image20569984" width="70.260000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/df91f61d-ebc8-4289-aad3-c6720db67d90" /><img alt="page12image20570176" width="127.380000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/1796b456-54f3-4bff-ad2b-904e2cf09d9f" />&nbsp;<img alt="page12image20570368" width="356.160000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c57b2905-fceb-4f46-a4e3-8bb716081968" />&nbsp;<img alt="page12image20570560" width="243.480000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/89abe406-bef2-49c2-9441-2c37aa0da50a" /><img alt="page12image20570752" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/a06ddb49-ea54-40f3-a141-f13535a30cd7" /><img alt="page12image20570944" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/78eeec94-b814-44d3-b9e5-3e5e34b81d14" />&nbsp;<img alt="page12image20571136" width="287.160000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/02096ef2-5508-41ee-beb3-5bdeea23f970" /><img alt="page12image20571328" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/16bc1d2a-6473-412c-a829-8b3f838f0f01" />&nbsp;<img alt="page12image20571520" width="310.920000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/92882a1a-2bbb-4dbb-b309-53be8d1c9e15" /><img alt="page12image20571712" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/02afab0b-0f40-41a7-ae70-384cbef55893" />&nbsp;<img alt="page12image20571904" width="259.620000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/2dec4dc1-b0b5-4775-85df-88390b646053" /></p><p>sa-spc</p><p>Pg. 12</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page13image20557056" width="0.720000" height="590.700000" src="blob:https://sdi.sfda.gov.sa/0baa868e-7059-4c05-9a33-b798318a19ae" /></p><p>4.2.8 Dosage in Patients with Hepatic Impairment</p><p>Patients with mild hepatic impairment do not require a starting dose adjustment and should be treated per the recommended Bortezomib TBM dose. Patients with moderate or severe hepatic impairment should be started on Bortezomib TBM at a reduced dose of 0.7 mg/m2&nbsp;per injection during the first cycle, and a subsequent dose escalation to 1.0 mg/m2&nbsp;or further dose reduction to 0.5 mg/m may be considered based on patient tolerance (see Table 6 and section 5).</p><p>Table 6: Recommended Starting Dose Modification for Bortezomib TBM in Patients with Hepatic Impairment</p><p><img alt="page13image20557248" width="233.400000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/753bc5fc-7ca6-4177-9ac4-9d2fc079e899" />&nbsp;<img alt="page13image20557440" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/76b23cd4-6d68-484f-a736-bd5e101d528b" /><img alt="page13image20557632" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/1cdcda4f-84db-4045-93d5-5f2eaaf8c061" /><img alt="page13image20557824" width="377.340000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/1d1e6a3e-30f2-43d5-ac46-8d93daabbf1f" />&nbsp;<img alt="page13image20558016" width="60.960000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/e4f4a5a5-5473-4ed0-83ce-fec17f4f9d1f" />&nbsp;<img alt="page13image20558208" width="298.980000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/315497d3-1fc1-4a2e-9b40-9f2c1e4b37c5" /><img alt="page13image20558400" width="137.460000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/8ef05962-aa6f-4398-9fbf-8755813c8ff2" />&nbsp;<img alt="page13image20558592" width="351.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/60aad9a6-8590-4818-9c65-0470f6607211" /><img alt="page13image20558784" width="419.520000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/a0bf6b07-e141-4539-9dbb-1c8a54a5904c" />&nbsp;<img alt="page13image20558976" width="96.240000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/4afc7348-0aac-4c2d-9224-fa9e1651fcbe" /><img alt="page13image20559168" width="461.280000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/e8b54d17-2fa9-4062-a725-56e28f2442de" /></p><p>Bilirubin Level SGOT (AST) Levels</p><p>Mild Less than or equal More than ULN to 1.0x ULN</p><p>More than 1.0x&ndash;1.5x&nbsp;Any ULN</p><p>Modification of Starting Dose</p><p>None</p><p>None</p><p>Reduce Bortezomib TBM to 0.7 mg/m2&nbsp;in the first cycle. Consider dose escalation to 1.0 mg/m2&nbsp;or further dose reduction to 0.5 mg/m2&nbsp;in subsequent cycles based on patient tolerability.</p><p><img alt="page13image20559360" width="71.220000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/a6cbd32c-f8da-4940-83df-83f03fcd5952" />&nbsp;<img alt="page13image20559552" width="62.040000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/32667d5b-b1c9-4753-8e1e-878a3e0a34cb" />&nbsp;<img alt="page13image20559744" width="72.420000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f13bdc13-b39d-4f59-b282-d7f1ebba9778" />&nbsp;<img alt="page13image20559936" width="63.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/8a588b82-0aa5-46f2-9005-7d4187612aa9" />&nbsp;<img alt="page13image20560128" width="461.280000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6d7bebc8-4e48-4dad-a7a1-21abe6f6d143" /><img alt="page13image20560320" width="80.340000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/13e023f2-7307-417a-b2d2-ff9b4dcb4f3e" />&nbsp;<img alt="page13image20560512" width="70.860000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7994702a-95a9-410e-b27d-37d9c8df63b8" />&nbsp;<img alt="page13image20560704" width="55.920000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/6c6cfc44-4b8a-44b9-bda6-29478dbc1bbf" />&nbsp;<img alt="page13image20561280" width="104.940000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c51ebd03-f705-4aa0-b161-27287295be78" /><img alt="page13image20561472" width="461.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/cdeecc9b-53a4-42f0-93ff-53fc43852512" /></p><p>Moderate More than 1.5x&ndash;3x ULN</p><p>Any</p><p><img alt="page13image20561664" width="42.120000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/6c19c4d6-ec34-47da-a863-d3b555e49233" />&nbsp;<img alt="page13image20515840" width="84.000000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f554fa45-e73e-47f8-b774-9403a97addd2" />&nbsp;<img alt="page13image20519104" width="87.660000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e9721bc3-b2c3-464c-8783-1e25d925c13a" />&nbsp;<img alt="page13image20518144" width="80.040000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/94edac7b-aac7-4918-ac72-ef6922893c12" /><img alt="page13image20464000" width="0.480000" height="132.840000" src="blob:https://sdi.sfda.gov.sa/0c5a64ff-0766-48c1-b59e-5436bf832a14" />&nbsp;<img alt="page13image15191104" width="115.440010" height="132.840000" src="blob:https://sdi.sfda.gov.sa/fc3ffb60-41a6-44ce-a722-10a790e9c120" /></p><p>Severe</p><p>More than 3x ULN</p><p>Any</p><p><img alt="page13image20464768" width="84.660000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/255ddacf-f69f-4531-b040-c2cf44482ccb" /></p><p>Abbreviations: SGOT = serum glutamic oxaloacetic transaminase;</p><p><img alt="page13image20465344" width="295.500000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/dc560760-7fe2-478d-9d20-64303a653535" /></p><p>AST = aspartate aminotransferase; ULN = upper limit of the normal range.</p><p><img alt="page13image20465728" width="330.120000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/01fbec37-7612-43f8-b2a9-37609bd440b5" /><img alt="page13image20465920" width="0.479980" height="132.840000" src="blob:https://sdi.sfda.gov.sa/e88f16f2-70e8-45c6-ac0c-0a823ddbed62" />&nbsp;<img alt="page13image20466112" width="105.120000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/69ca0887-6067-4201-a462-a207b8f3a156" />&nbsp;<img alt="page13image20466304" width="94.740000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/1ae156d1-4aa6-465d-846a-bd3c9b479919" />&nbsp;<img alt="page13image20466496" width="67.500000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e60687a8-1d22-4aa0-b181-a788fcbe5b02" />&nbsp;<img alt="page13image20466688" width="97.740000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/5f76a92c-f14b-4c4b-99ab-b985b014d0b4" />&nbsp;<img alt="page13image20466880" width="90.360000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/336ca90c-040e-42f1-b778-f6705cf3425d" />&nbsp;<img alt="page13image20467072" width="71.460000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/543df69c-a464-4b49-9d53-f41b6d0584a1" />&nbsp;<img alt="page13image20467264" width="51.000000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/164006b7-19bd-48ca-9d79-caa1ee89b6e0" /></p><p>4.2.9 Administration Precautions</p><p><img alt="page13image20467648" width="155.220000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f09a58c7-ad66-4a85-aafd-9a40a97d69fa" /></p><p>The drug quantity contained in one vial (3.5 mg) may exceed the usual dose required. Caution should be used in calculating the dose to prevent (see section 4.2). When administered subcutaneously, sites for each injection (thigh or abdomen) should be rotated. New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, erythematous, or indurated.</p><p>If local injection site reactions occur following Bortezomib TBM administration subcutaneously, a less concentrated Bortezomib TBM solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously (see section 4.2). Alternatively, the intravenous route of administration should be considered (see section 4.2).</p><p>Bortezomib TBM is an antineoplastic. Procedures for proper handling and disposal should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to boron or to any of the excipients listed in section 6.1. Acute diffuse infiltrative pulmonary and pericardial disease.
When Bortezomib TBM is given in combination with other medicinal products, refer to their Summaries of Product Characteristics for additional contraindications.Bortezomib TBM is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib,
boron, or mannitol. Reactions have included anaphylactic reactions (see section 4.8).
Bortezomib TBM is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of Bortezomib TBM.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Peripheral Neuropathy</p><p>When bortezomib is given in combination with other medicinal products, the Summary of Product Characteristics of these other medicinal products must be consulted prior to initiation of treatment with Bortezomib TBM. When thalidomide is used, particular attention to pregnancy testing and prevention requirements is needed (see section 4.6).</p><p>Intrathecal administration<br />There have been fatal cases of inadvertent intrathecal administration of bortezomib. Bortezomib TBM is for intravenous or subcutaneous use. Bortezomib should not be administered intrathecally.</p><p>Gastrointestinal toxicity<br />Gastrointestinal toxicity, including nausea, diarrhoea, vomiting and constipation are very common with bortezomib treatment. Cases of ileus have been uncommonly reported (see section 4.8). Therefore, patients who experience constipation should be closely monitored.</p><p>Haematological toxicity<br />Bortezomib treatment is very commonly associated with haematological toxicities (thrombocytopenia, neutropenia and anaemia). In studies in patients with relapsed multiple myeloma treated with bortezomib and in patients with previously untreated MCL treated with bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BzR- CAP), one of the most common haematologic toxicity was transient thrombocytopenia. Platelets were lowest at Day 11 of each cycle of bortezomib treatment and typically recovered to baseline by the next cycle. There was no evidence of cumulative thrombocytopenia. The mean platelet count nadir measured was approximately 40% of baseline in the single-agent multiple myeloma studies and 50% in the MCL study. In patients with advanced myeloma the severity of thrombocytopenia was related to pre-treatment platelet count: for baseline platelet counts &lt; 75,000/&mu;l, 90% of 21 patients had a count :5 25,000/&mu;l during the study, including 14% &lt; 10,000/&mu;l; in contrast, with a baseline platelet count &gt; 75,000/&mu;l, only 14% of 309 patients had a count :5 25,000/&mu;l during the study.<br />In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade&nbsp;&ge;&nbsp;3 thrombocytopenia in the bortezomib treatment group (BzR-CAP) as compared to the non- bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]). The two treatment groups were similar with regard to the overall incidence of all-grade bleeding events (6.3% in the BzR-CAP group and 5.0% in the R- CHOP group) as well as Grade 3 and higher bleeding events (BzR-CAP: 4 patients [1.7%]; R-CHOP: 3 patients [1.2%]). In the BzR-CAP group, 22.5% of patients received platelet transfusions compared to 2.9% of patients in the R-CHOP group.<br />Gastrointestinal and intracerebral haemorrhage, have been reported in association with bortezomib treatment. Therefore, platelet counts should be monitored prior to each dose of bortezomib. Bortezomib therapy should be withheld when the platelet count is &lt; 25,000/&mu;l or, in the case of combination with melphalan and prednisone, when the platelet count is &le;30,000/&mu;l (see section 4.2). Potential benefit of the treatment should be carefully weighed against the risks, particularly in case of moderate to severe thrombocytopenia and risk factors for bleeding.<br />Complete blood counts (CBC) with differential and including platelet counts should be frequently monitored throughout treatment with Bortezomib. Platelet transfusion should be considered when clinically appropriate (see section 4.2).<br />In patients with MCL, transient neutropenia that was reversible between cycles was observed, with no evidence of cumulative neutropenia. Neutrophils were lowest at Day 11 of each cycle of</p><p><img alt="page14image20505408" width="373.260000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ecb78a78-0f64-47bb-8f2a-e4a37b0b3dce" /><img alt="page14image20505600" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/447c15b8-df70-4527-98a2-18e5e64b48f5" />&nbsp;<img alt="page14image20505792" width="205.860000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/bd434638-a295-49fe-8c9c-c09a2c4bea61" />&nbsp;<img alt="page14image20505984" width="0.720000" height="607.140000" src="blob:https://sdi.sfda.gov.sa/dcf6f701-11ed-4da1-acb4-0d5b7823f9a8" />&nbsp;<img alt="page14image20506176" width="109.080000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/8e304e1d-e69f-4bf1-92be-ffd0587bb867" /><img alt="page14image20506368" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/b1c1d3bd-13e0-4898-a5e8-83b654169b8b" /><img alt="page14image20506560" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/91fc291e-06de-4b86-af36-7d81220ad836" /><img alt="page14image20506752" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/0d4041a3-d4b2-4d99-a572-2dc04a7f540a" />&nbsp;<img alt="page14image20506944" width="228.480000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/3e28556c-0950-431c-812a-1295d15f410d" /><img alt="page14image20507136" width="113.340000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f0715015-51bb-41df-918d-43ff835e451c" />&nbsp;<img alt="page14image20507328" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/a9a6ff18-7a6b-4126-83ab-e67866c4d762" /><img alt="page14image20507520" width="434.340000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/89fc1de1-2637-45ff-9bc8-6411a645e26d" />&nbsp;<img alt="page14image20507712" width="106.020000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/6ad12151-630e-4d59-9c38-1a8d5d2aaf7d" /><img alt="page14image20507904" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/aa16822c-2e7e-428e-9986-8bf571bec522" /><img alt="page14image20508096" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/cb41a0d1-5afa-4e25-bf7f-368b6ba9aca1" /><img alt="page14image20508288" width="341.460000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4b9f1fa6-04dd-44c8-b670-08ac6ddc1328" />&nbsp;<img alt="page14image20508480" width="106.020000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b02e25e3-b497-42df-96c6-6bc5873141b7" /><img alt="page14image20508672" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/59f4d589-33de-46a2-9d8a-f01d26c56a54" /><img alt="page14image20508864" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/05770f93-4a4e-4d44-85d0-befd92053ad5" /><img alt="page14image20509056" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/fd51a671-aee4-4088-8206-8128ab6d178f" /><img alt="page14image20509248" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b13ac083-3494-4550-9e92-04f3976fe4a1" /><img alt="page14image20509440" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/1e71008d-d098-4dca-8596-3242be4a584c" /><img alt="page14image20509632" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/2e3faf94-53ae-4b5d-99b9-4bc28333ec76" /><img alt="page14image20509824" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/285e1de9-323a-4302-bae4-c3766d2045bc" /><img alt="page14image20510016" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/2613eec7-8f51-40b6-aa57-8f7af0ffa91f" /><img alt="page14image20510208" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/652b1288-7802-4db0-9d5c-0491fc90908e" /><img alt="page14image20510400" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/6ee64b8e-c796-46ce-9da9-ecd3d1e0ed16" /><img alt="page14image20510592" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e723d15f-a318-4d6d-913c-dcce774fbfbe" /><img alt="page14image20510784" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/48dcb036-1f86-4b7c-b6cb-dbd30e016c9d" /><img alt="page14image20510976" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b589ead2-c8d3-4c76-a5b3-52a87e96045e" /><img alt="page14image20511168" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b0605109-49e3-4741-b256-c6e3bd143a94" /><img alt="page14image20511360" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/39808012-9260-4d57-aa04-4dbf7fe3233c" /><img alt="page14image20511552" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/862cd347-b282-40bc-a521-1fe82a7c7d4b" /><img alt="page14image20511744" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f4babb6b-f69e-4968-a848-7d36d777c97e" /><img alt="page14image20511936" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/56a9a3e0-b8f3-4550-853e-e1ce3121c8f0" /><img alt="page14image20512128" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/b90eee48-6040-44e4-a177-ffaf5718361e" />&nbsp;<img alt="page14image20512320" width="135.960000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4a7a9f83-a6c5-4eb8-a9fd-8dbae752b41c" /><img alt="page14image20512512" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3d56a15d-4c16-4103-84ae-93a35a94b5de" /><img alt="page14image20477824" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/5fe87c5f-f5e0-461f-9ed5-e124051210b9" /><img alt="page14image20548032" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/04be1a43-c1be-461e-b803-08c556000732" /><img alt="page14image20547264" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/592bc4f8-a101-4efb-bf1f-69cb74ec726d" /><img alt="page14image20555520" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b53cd078-78a2-484d-bc83-d578382df504" />&nbsp;<img alt="page14image20576704" width="328.980000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ac303d59-aa5d-418c-91ae-0acf5706a265" /><img alt="page14image20865472" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/5edc5869-4e44-4816-9b69-da42552be161" /><img alt="page14image20480000" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/a436c702-a8cf-428d-902e-b06362cecf07" />&nbsp;<img alt="page14image20480192" width="171.060000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/d81c6b9d-985a-4a3b-a4d1-8563ecbd5239" /><img alt="page14image20480384" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/cacabdc0-7495-48c9-a2ad-c2ae8a55e4b2" /><img alt="page14image20480576" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bf09fcf9-b2d5-4332-af3b-bc903cce3633" /></p><p>sa-spc</p><p>Pg. 14</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page15image20387456" width="0.720000" height="657.720000" src="blob:https://sdi.sfda.gov.sa/08c43e56-5e11-40f5-8d00-332cfb4f4703" /></p><p>Bortezomib treatment and typically recovered to baseline by the next cycle. In study LYM-3002, colony stimulating factor support was given to 78% of patients in the BzR-CAP arm and 61% of patients in the R-CHOP arm. Since patients with neutropenia are at increased risk of infections, they should be monitored for signs and symptoms of infection and treated promptly. Granulocyte colony stimulating factors may be administered for haematologic toxicity according to local standard practice. Prophylactic use of granulocyte colony stimulating factors should be considered in case of repeated delays in cycle administration (see section 4.2).</p><p>Herpes zoster virus reactivation<br />Antiviral prophylaxis is recommended in patients being treated with Bortezomib.<br />In the Phase III study in patients with previously untreated multiple myeloma, the overall incidence of herpes zoster reactivation was more common in patients treated with Bortezomib+Melphalan+Prednisone compared with Melphalan+Prednisone (14% versus 4% respectively).<br />In patients with MCL (study LYM-3002), the incidence of herpes zoster infection was 6.7% in the BzR-CAP arm and 1.2% in the R-CHOP arm (see section 4.8).</p><p>Hepatitis B Virus (HBV) reactivation and infection<br />When rituximab is used in combination with Bortezomib, HBV screening must always be performed in patients at risk of infection with HBV before initiation of treatment. Carriers of hepatitis B and patients with a history of hepatitis B must be closely monitored for clinical and laboratory signs of active HBV infection during and following rituximab combination treatment with Bortezomib. Antiviral prophylaxis should be considered. Refer to the Summary of Product Characteristics of rituximab for more information.</p><p>Progressive multifocal leukoencephalopathy (PML)<br />Very rare cases with unknown causality of John Cunningham (JC) virus infection, resulting in PML and death, have been reported in patients treated with Bortezomib. Patients diagnosed with PML had prior or concurrent immunosuppressive therapy. Most cases of PML were diagnosed within 12 months of their first dose of Bortezomib. Patients should be monitored at regular intervals for any new or worsening neurological symptoms or signs that may be suggestive of PML as part of the differential diagnosis of CNS problems. If a diagnosis of PML is suspected, patients should be referred to a specialist in PML and appropriate diagnostic measures for PML should be initiated. Discontinue Bortezomib if PML is diagnosed.</p><p>Peripheral neuropathy<br />Treatment with Bortezomib is very commonly associated with peripheral neuropathy, which is predominantly sensory. However, cases of severe motor neuropathy with or without sensory peripheral neuropathy have been reported. The incidence of peripheral neuropathy increases early in the treatment and has been observed to peak during cycle 5.<br />It is recommended that patients be carefully monitored for symptoms of neuropathy such as a burning sensation, hyperesthesia, hypoesthesia, paraesthesia, discomfort, neuropathic pain or weakness.<br />In the Phase III study comparing Bortezomib administered intravenously versus subcutaneously, the incidence of Grade &ge;2 peripheral neuropathy events was 24% for the subcutaneous injection group and 41% for the intravenous injection group (p=0.0124). Grade &ge;3 peripheral neuropathy occurred in 6% of patients in the subcutaneous treatment group, compared with 16% in the intravenous treatment group (p=0.0264). The incidence of all grade peripheral neuropathy with Bortezomib administered intravenously was lower in the historical studies with Bortezomib administered intravenously than in study MMY-3021.<br />Patients experiencing new or worsening peripheral neuropathy should undergo neurological evaluation and may require a change in the dose, schedule or route of administration to</p><p><img alt="page15image20394560" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b4b07923-ecf1-48c0-8f4e-54cc0b5741f8" /><img alt="page15image20389760" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/a852b2e3-d787-4ca3-814a-1be4051ed7a9" /><img alt="page15image20396288" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/d86f3def-acc9-4895-8eab-3c519e2f642e" /><img alt="page15image20394368" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/2991f0d6-4034-4336-afd1-5a9d53ee8b60" /><img alt="page15image20041280" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/22e6d520-6162-4b0d-a00f-8884345e3cfa" /><img alt="page15image20040320" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f8a6b0e8-defd-4db5-ac5b-740c49ad1e66" />&nbsp;<img alt="page15image20046080" width="249.000000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/b7a6c772-c2e6-4e77-840d-b8cf5b1ba2d2" /><img alt="page15image20038400" width="139.620000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/1b5622c9-abcf-4e66-b1b7-5f5b65d970d0" />&nbsp;<img alt="page15image20044160" width="357.480000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/347776e2-bfd4-499b-ba30-7059c4b72130" /><img alt="page15image20046656" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/62c055f1-89dd-4268-b2eb-f0666a1d8664" /><img alt="page15image20037824" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ec1b7e65-1a4b-4e6d-b177-a88d5c397b31" /><img alt="page15image20039168" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/96e889fe-5fe6-43c3-9e4a-4b65553686cc" />&nbsp;<img alt="page15image20052608" width="59.580000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/2a30a589-20ff-4be2-ae16-37e1fa0757fc" /><img alt="page15image20040512" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/31a4a29e-edda-4064-9d93-4ecb15d654e6" />&nbsp;<img alt="page15image20052800" width="276.480000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/0402baf3-ffe1-4b2e-82cd-d6800852eaed" /><img alt="page15image20048960" width="225.420000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/9cd66b16-42a4-4ee8-81cb-75628cb34e23" />&nbsp;<img alt="page15image20043584" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/42e51f15-a49a-4491-a146-5836ad26c613" /><img alt="page15image20047808" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/9600dcc8-9366-4c86-8e30-d7427bcf1ce7" /><img alt="page15image20048768" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/812ebfc4-f100-4a34-9f33-aa3843cd8be6" /><img alt="page15image20048192" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e1e083cb-5a72-436a-8165-2ace9b481306" /><img alt="page15image20048576" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/19f184f2-0369-4232-b88e-4b0d3b34bc78" />&nbsp;<img alt="page15image20053760" width="221.160000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b3c89af9-b12e-4d7a-8a7b-c0d23834b1cb" /><img alt="page15image20041856" width="228.180000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7d16a5b9-61da-4240-8c5f-665c2d7ab203" />&nbsp;<img alt="page15image20046272" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b920b3c7-499b-435b-8a10-644667135647" /><img alt="page15image20049344" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/171cc138-60d3-4742-96bd-e691af5c4feb" /><img alt="page15image20051456" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0e669cd5-a443-4cfe-b743-53b47cdcad03" /><img alt="page15image20051648" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/75f98a14-0194-4f31-81d4-dc9fb5dff7ee" /><img alt="page15image20050496" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/7dc846c0-d0b3-497e-aa85-3497200413d9" /><img alt="page15image20050880" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/61fdacb4-f568-4843-8e0c-9ad9fa3c8104" /><img alt="page15image20050304" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/8cc6438b-c720-4eb6-9f06-50eef42d3805" />&nbsp;<img alt="page15image20047040" width="202.860000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3ac1274d-c58e-4302-a720-8368cfe358d6" />&nbsp;<img alt="page15image20042816" width="97.440000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3e69469f-527b-4db9-817f-72b87b986396" /><img alt="page15image20045312" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f4dd592b-9c8a-4590-8fbe-b58a2d36f047" /><img alt="page15image20042432" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c3ed9417-512b-48aa-ae40-27ca42b8ec88" /><img alt="page15image20041088" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/1ac1d116-aca6-482b-b1b3-43c5436ff649" />&nbsp;<img alt="page15image20050688" width="263.040000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/b5fea018-7712-4a0e-9829-6e598c96ba5c" /><img alt="page15image20049920" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/48a9902e-33ad-42a7-9181-3daa8deb892e" /><img alt="page15image20047616" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e151294f-96c6-435a-84d8-1bfebe261cc3" />&nbsp;<img alt="page15image20052416" width="44.880000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e4742943-61de-4e8d-a68e-0839c875ef01" /><img alt="page15image20044928" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/b07f1792-44b9-489e-8a90-ad84d40369a5" /><img alt="page15image20042240" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/822080cf-967d-4832-89ce-0a57dbe4e42f" /><img alt="page15image20050112" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/2fe9f5f2-11e0-466d-93e1-824a78f05903" /><img alt="page15image20039360" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ca6ccabd-a20b-4704-abc4-676290282197" /><img alt="page15image20040896" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/97c33b6f-0da4-4329-a901-1132deb33b6d" /><img alt="page15image20049728" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/9944bf26-38c7-4488-80f9-ef73363bb947" />&nbsp;<img alt="page15image20051264" width="178.140000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b84b9eed-2f50-40e6-b8dd-6417ebb9bf2b" /><img alt="page15image20051072" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/dfb65c00-c68f-4f8b-9c08-8b0fe47ebd53" /><img alt="page15image20038784" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bc3eb3db-6c9a-4d64-9974-7b85f053ed36" /></p><p>sa-spc</p><p>Pg. 15</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page16image20036800" width="0.720000" height="657.720000" src="blob:https://sdi.sfda.gov.sa/9a073bcf-ce08-4ff0-93e6-ae711bf1b3b9" /></p><p>subcutaneous (see section 4.2). Neuropathy has been managed with supportive care and other therapies.<br />Early and regular monitoring for symptoms of treatment-emergent neuropathy with neurological evaluation should be considered in patients receiving Bortezomib in combination with medicinal products known to be associated with neuropathy (e.g. thalidomide) and appropriate dose reduction or treatment discontinuation should be considered.</p><p>In addition to peripheral neuropathy, there may be a contribution of autonomic neuropathy to some adverse reactions such as postural hypotension and severe constipation with ileus. Information on autonomic neuropathy and its contribution to these undesirable effects is limited.</p><p>Seizures<br />Seizures have been uncommonly reported in patients without previous history of seizures or epilepsy. Special care is required when treating patients with any risk factors for seizures.</p><p>Hypotension<br />Bortezomib treatment is commonly associated with orthostatic/postural hypotension. Most adverse reactions are mild to moderate in nature and are observed throughout treatment. Patients who developed orthostatic hypotension on Bortezomib (injected intravenously) did not have evidence of orthostatic hypotension prior to treatment with Bortezomib. Most patients required treatment for their orthostatic hypotension. A minority of patients with orthostatic hypotension experienced syncopal events. Orthostatic/postural hypotension was not acutely related to bolus infusion of Bortezomib. The mechanism of this event is unknown although a component may be due to autonomic neuropathy. Autonomic neuropathy may be related to bortezomib or bortezomib may aggravate an underlying condition such as diabetic or amyloidotic neuropathy. Caution is advised when treating patients with a history of syncope receiving medicinal products known to be associated with hypotension; or who are dehydrated due to recurrent diarrhoea or vomiting. Management of orthostatic/postural hypotension may include adjustment of antihypertensive medicinal products, rehydration or administration of mineralocorticosteroids and/or sympathomimetics. Patients should be instructed to seek medical advice if they experience symptoms of dizziness, light-headedness or fainting spells.</p><p>Posterior Reversible Encephalopathy Syndrome (PRES)<br />There have been reports of PRES in patients receiving Bortezomib. PRES is a rare, often reversible, rapidly evolving neurological condition, which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. Brain imaging, preferably Magnetic Resonance Imaging (MRI), is used to confirm the diagnosis. In patients developing PRES, Bortezomib should be discontinued.</p><p>Heart failure<br />Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported during bortezomib treatment. Fluid retention may be a predisposing factor for signs and symptoms of heart failure. Patients with risk factors for or existing heart disease should be closely monitored.</p><p>Electrocardiogram investigations<br />There have been isolated cases of QT-interval prolongation in clinical studies, causality has not been established.</p><p>Pulmonary disorders<br />There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown aetiology such as pneumonitis, interstitial pneumonia, lung infiltration, and acute respiratory distress syndrome (ARDS) in patients receiving Bortezomib (see section 4.8). Some of these events have</p><p><img alt="page16image20034304" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/23fc743a-decf-45ab-beb4-02dcec5c23e6" />&nbsp;<img alt="page16image20035840" width="42.480000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/c5103c61-5d02-49a1-b092-7b7ba967c572" /><img alt="page16image20035264" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/bdff1738-6cb1-4008-af13-a18aaebf0814" /><img alt="page16image20036224" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/fdcb43bc-7dd0-4492-bc60-5da7394ffb5c" /><img alt="page16image20036032" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/9792f865-92b4-4fce-a787-eb436b6d59ef" />&nbsp;<img alt="page16image20035456" width="222.420000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/bd43be1c-5f4d-4a99-b052-eddf7416b07b" /><img alt="page16image20367616" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/f5b1db9b-cf75-46d6-99b9-887bc188d303" /><img alt="page16image20328256" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/b6e37d0d-abd4-41ed-850b-02c51ee41089" /><img alt="page16image20327296" width="355.860000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/efbb603b-6366-4f36-a6a2-1eb020c93098" />&nbsp;<img alt="page16image20316352" width="37.260000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/5a68bf5a-02fa-43fd-8690-d7c61fef512d" /><img alt="page16image20319040" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/be5acbac-d129-42fc-907a-a84e729bdcc6" /><img alt="page16image20321728" width="394.320000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/04128e30-039f-45bb-a941-be0916842daa" />&nbsp;<img alt="page16image20428480" width="56.220000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/edf29e60-2aef-4616-b8d7-8b8b8727c284" /><img alt="page16image20394176" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/d698c95d-be9a-4297-9e19-ccc197572d43" /><img alt="page16image20396096" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/8c4d8ab9-5223-48a4-8532-6e16a576e30a" /><img alt="page16image20392448" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/5af2fada-bbfa-44d4-9464-8618b3611b0e" /><img alt="page16image20233792" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/20dcf7f4-75a6-49df-8ff3-1ad4ad05cc95" /><img alt="page16image20238848" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/70825d92-1b5b-4283-b2d5-aba2888a2e5d" /><img alt="page16image20249792" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/eb97d66b-1199-44b0-a05e-3ec3c93caebd" /><img alt="page16image20188928" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/21847bc6-c8f2-473d-83f7-3b7427161a28" /><img alt="page16image20191424" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/af4f101a-f412-4837-9d2b-33e95ba261e4" /><img alt="page16image20190080" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/6ef7423e-1114-4ce9-aeb6-6228e651e817" /><img alt="page16image20196800" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/380d9c8e-fce5-4be2-9d75-8bc360cd4773" /><img alt="page16image20187968" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b98c993b-2ae3-4040-970c-54645e3e573d" /><img alt="page16image20283392" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/13a63f5b-7be7-40d0-af69-39c3f62cd641" /><img alt="page16image20311488" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4b050c82-b687-4db6-ab2f-227e47eaf4db" /><img alt="page16image20306688" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4a7e358e-784c-4d1f-b4b8-53dee6777892" />&nbsp;<img alt="page16image20300160" width="259.020000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/432692b5-dbae-4c5d-84b9-bf0ff383c67b" /><img alt="page16image20306112" width="247.440000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/1fe48971-1c39-40e2-9464-a26dcc0d6a12" />&nbsp;<img alt="page16image20305344" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c3be9919-0d93-49ca-b3ae-941ce1912c6b" /><img alt="page16image20266752" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/21ee623e-d615-498d-8d8a-7f83fd44a2a1" /><img alt="page16image19960320" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/8f13e4ca-2ea6-43be-93e5-0dae6ba5df52" /><img alt="page16image19959744" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/13baf7fc-53e0-4dd3-8518-e87241d1ff4d" />&nbsp;<img alt="page16image19960704" width="242.160000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e3f05918-96d7-4f71-8e6f-be471c5d9367" />&nbsp;<img alt="page16image19960512" width="55.860000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3024d7d7-588a-4598-ad3f-57e2882d907b" /><img alt="page16image19959360" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/f22a4e0c-3a44-41c2-8902-86b2b3e478ae" /><img alt="page16image19959168" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/13930c80-c4cb-4dd2-a32e-f85d342c5679" /><img alt="page16image19960128" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/b1de66fc-c410-413a-8777-efa220e4ae03" />&nbsp;<img alt="page16image19958592" width="223.860000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/586794a7-fde0-4609-a8de-945674d2ef34" /><img alt="page16image19959552" width="145.680000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/1e3af419-20e6-47c2-8224-1df0c9c9ba0e" />&nbsp;<img alt="page16image19958784" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/af7fe4a3-f15e-4ff7-aa85-b6faacde259b" />&nbsp;<img alt="page16image19958976" width="75.180000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c59124d4-81b3-42db-b6fc-fc4237fd5d84" />&nbsp;<img alt="page16image19958400" width="91.320000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/aee79bf1-465d-49fa-8679-1a831ee5546b" /><img alt="page16image19968768" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/197a86fe-ba3a-4c4a-b2fa-2f8f1412f6d8" /><img alt="page16image19959936" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/6ffbc10a-3b4f-4ba4-acd5-dc746be8d00c" /><img alt="page16image19955712" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/49efc25c-7fcf-47a6-a318-1aa81b49b8e4" /></p><p>sa-spc</p><p>Pg. 16</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page17image20009856" width="0.720000" height="670.380000" src="blob:https://sdi.sfda.gov.sa/4a7152e6-7799-4449-a361-b5bb5e2e5649" /></p><p>been fatal. A pre-treatment chest radiograph is recommended to serve as a baseline for potential post-treatment pulmonary changes.<br />In the event of new or worsening pulmonary symptoms (e.g., cough, dyspnoea), a prompt diagnostic evaluation should be performed and patients treated appropriately. The benefit/risk ratio should be considered prior to continuing Bortezomib therapy.</p><p>In a clinical trial, two patients (out of 2) given high-dose cytarabine (2 g/m2&nbsp;per day) by continuous infusion over 24 hours with daunorubicin and Bortezomib for relapsed acute myelogenous leukaemia died of ARDS early in the course of therapy, and the study was terminated. Therefore, this specific regimen with concomitant administration with high-dose cytarabine (2 g/m2&nbsp;per day) by continuous infusion over 24 hours is not recommended.</p><p>Renal impairment<br />Renal complications are frequent in patients with multiple myeloma. Patients with renal impairment should be monitored closely (see sections 4.2 and 5.2).</p><p>Hepatic impairment<br />Bortezomib is metabolised by liver enzymes. Bortezomib exposure is increased in patients with moderate or severe hepatic impairment; these patients should be treated with Bortezomib at reduced doses and closely monitored for toxicities (see sections 4.2 and 5.2).</p><p>Hepatic reactions<br />Rare cases of hepatic failure have been reported in patients receiving Bortezomib and concomitant medicinal products and with serious underlying medical conditions. Other reported hepatic reactions include increases in liver enzymes, hyperbilirubinaemia, and hepatitis. Such changes may be reversible upon discontinuation of bortezomib (see section 4.8).</p><p>Tumour lysis syndrome<br />Because bortezomib is a cytotoxic agent and can rapidly kill malignant plasma cells and MCL cells, the complications of tumour lysis syndrome may occur. The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.</p><p>Concomitant medicinal products<br />Patients should be closely monitored when given bortezomib in combination with potent CYP3A4- inhibitors. Caution should be exercised when bortezomib is combined with CYP3A4- or CYP2C19 substrates (see section 4.5).<br />Normal liver function should be confirmed and caution should be exercised in patients receiving oral hypoglycemics (see section 4.5).</p><p>Potentially immunocomplex-mediated reactions<br />Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly. Bortezomib should be discontinued if serious reactions occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In vitro studies indicate that bortezomib is a weak inhibitor of the cytochrome P450 (CYP) isozymes 1A2, 2C9, 2C19, 2D6 and 3A4. Based on the limited contribution (7%) of CYP2D6 to the metabolism of bortezomib, the CYP2D6 poor metaboliser phenotype is not expected to affect the overall disposition of bortezomib.</p><p>A drug-drug interaction study assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 35% (CI90% [1.032 to 1.772]) based on data from 12 patients. Therefore, patients should be closely monitored when given bortezomib in combination with potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir).</p><p>In a drug-drug interaction study assessing the effect of omeprazole, a potent CYP2C19 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 17 patients.<br />A drug-drug interaction study assessing the effect of rifampicin, a potent CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC reduction of 45% based on data from 6 patients. Therefore, the concomitant use of bortezomib with strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital and St. John&#39;s Wort) is not recommended, as efficacy may be reduced.</p><p>In the same drug-drug interaction study assessing the effect of dexamethasone, a weaker CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), there was no significant effect on the pharmacokinetics of bortezomib based on data from 7 patients.<br />A drug-drug interaction study assessing the effect of melphalan-prednisone on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 17% based on data from 21 patients. This is not considered clinically relevant.</p><p>During clinical trials, hypoglycemia and hyperglycemia were uncommonly and commonly reported in diabetic patients receiving oral hypoglycemics. Patients on oral antidiabetic agents receiving bortezomib treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contraception in males and females<br />Male and female patients of childbearing potential must use effective contraceptive measures during and for 3 months following treatment.</p><p>No clinical data are available for bortezomib with regard to exposure during pregnancy. The teratogenic potential of bortezomib has not been fully investigated.<br />In non-clinical studies, bortezomib had no effects on embryonal/foetal development in rats and rabbits at the highest maternally tolerated doses. Animal studies to determine the effects of bortezomib on parturition and post-natal development were not conducted (see section 5.3). Bortezomib should not be used during pregnancy unless the clinical condition of the woman requires treatment with bortezomib.</p><p>If bortezomib is used during pregnancy, or if the patient becomes pregnant while receiving this medicinal product, the patient should be informed of potential for hazard to the foetus.<br />Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. Thalidomide is contraindicated during pregnancy and in women of childbearing potential unless all the conditions of the thalidomide pregnancy prevention programme are met. Patients receiving bortezomib in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide. Refer to the Summary of Product Characteristics of thalidomide for additional information.</p><p>&nbsp;</p><p>&nbsp;</p><p>Breast-feeding</p><p>It is not known whether bortezomib is excreted in human milk. Because of the potential for serious adverse reactions in breast-fed infants, breast-feeding should be discontinued during treatment with Bortezomib.</p><p>&nbsp;</p><p>Fertility</p><p>Fertility studies were not conducted with Bortezomib (see section 5.3)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bortezomib TBM may&nbsp;have a moderate influence on the ability to drive and use machines. Bortezomib may be associated with fatigue very commonly, dizziness commonly, syncope uncommonly and orthostatic/postural hypotension or blurred vision commonly. Therefore, patients must be cautious when driving or using machines and should be advised not to drive or operate machinery if they experience these symptoms (see section 4.8)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a.&nbsp;Summary of the safety profile<br />Serious adverse reactions uncommonly reported during treatment with Bortezomib Injection include Peripheral Neuropathy, Hypotension, Cardiac Toxicity, Pulmonary Toxicity, Posterior Reversible Encephalopathy Syndrome (PRES), Gastrointestinal Toxicity, Thrombocytopenia/Neutropenia, Tumor Lysis Syndrome, Hepatic Toxicity.</p><p><img alt="page22image20005824" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/636e6539-15cc-4319-813c-a40ad793beb8" />&nbsp;<img alt="page22image20005248" width="76.980000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/fc3acda3-34c1-4b8f-aeda-a1bf409c826d" />&nbsp;<img alt="page22image20007552" width="124.560000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f2b9e75b-e88f-454a-99c1-1430fef5fbe2" /><img alt="page22image20005056" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/d72268af-6405-4f69-a4b0-44b1de3c9520" />&nbsp;<img alt="page22image20006016" width="256.620000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/d75d1f1e-7aac-46c4-814b-5aee68af0e8f" /><img alt="page22image20006400" width="181.680000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/15b8a2e5-8584-4e5b-a68d-bce289859c7b" />&nbsp;<img alt="page22image20005440" width="377.460000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/c141d6e0-13f9-4517-9d4a-334602a8bdbc" />&nbsp;<img alt="page22image20006976" width="60.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/8ff4fe36-6daa-4248-96f8-0fbfccccf33e" /><img alt="page22image20006784" width="441.840000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/5cd3f6b7-8287-4195-a6ef-cef8d7ea7b57" />&nbsp;<img alt="page22image20007360" width="244.980000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b8689860-6b59-4004-a7de-c87c35893ea3" />&nbsp;<img alt="page22image20006592" width="64.740000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/fb8fa4c6-3f7f-4e3f-8bb5-1f3beea78c8a" />&nbsp;<img alt="page22image20007744" width="0.720000" height="101.220000" src="blob:https://sdi.sfda.gov.sa/e67ddc18-c0ae-44f9-9f36-d8f1dbd9cd50" /><img alt="page22image20007936" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/555b6017-64f8-4895-99bd-2c69491a2716" /><img alt="page22image20008128" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e515c919-2e8c-412c-a0bb-bc7b2e881e9f" />&nbsp;<img alt="page22image20008320" width="54.660000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/fedb902d-b5ee-482e-84ae-7082c22d4b60" /><img alt="page22image20008896" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/f347faed-0900-4a68-bfb2-5fd3077b3a67" /><img alt="page22image20008704" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b75f62f4-c438-4e17-97b0-06bd304d48e7" /><img alt="page22image20009088" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/44c75268-af2b-4919-86f5-915d91c9b4c8" /><img alt="page22image20009664" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e893d794-434c-4b7f-bae2-aa7fcb5be4e2" />&nbsp;<img alt="page22image20019072" width="263.640000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/2288fc94-a191-4698-85f3-3b40b8006425" />&nbsp;<img alt="page22image20009280" width="35.460000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f8fe701f-4be3-459f-bcb1-7721e22f139a" />&nbsp;<img alt="page22image20019264" width="0.720000" height="50.640000" src="blob:https://sdi.sfda.gov.sa/3aed634f-fec9-4d59-ba94-71fa43b8d49e" /><img alt="page22image20019648" width="122.880000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/138474cf-ebe9-450f-85a8-0ca8d5503fc5" />&nbsp;<img alt="page22image20020032" width="318.960000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/6b85a07a-53bb-4b6a-8471-e2d79b1a0d44" /><img alt="page22image20020416" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/a5e9e0bf-43a9-4f09-8cd3-4b4fef7909f0" />&nbsp;<img alt="page22image20020800" width="73.560000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/76d4dbe5-f984-455d-ba87-e28bab650bea" />&nbsp;<img alt="page22image20020608" width="0.720000" height="151.800000" src="blob:https://sdi.sfda.gov.sa/fa76ee70-a249-4e8e-9c2c-cc8e2577ac90" />&nbsp;<img alt="page22image20321344" width="82.800000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e6e25e64-4017-44ea-ab7e-f2f11c0333d3" /><img alt="page22image20320192" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/233bdedb-525e-4308-a6b5-5f8e13c3f704" />&nbsp;<img alt="page22image20327680" width="86.100000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/33e72a95-5794-408d-8e61-2b4a7d123e38" />&nbsp;<img alt="page22image20322112" width="63.540000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ee4aa742-5bca-4fac-b8ee-3e43b607eded" /><img alt="page22image20318080" width="410.220000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f032e121-3773-404f-a822-0172dd917ca9" />&nbsp;<img alt="page22image20319808" width="274.860000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/00e5c54b-061f-47d2-b57b-1b8fe02b1f7c" />&nbsp;<img alt="page22image20318272" width="41.520000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/9b9c5e29-c307-43c0-963b-3cd61bec6074" /><img alt="page22image20328640" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/119f0da7-b4aa-483b-8252-38f92701cb1e" />&nbsp;<img alt="page22image20317120" width="248.280000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/08d112c8-585c-42b7-813c-cb947d3e6eb3" />&nbsp;<img alt="page22image20316544" width="0.720000" height="88.560000" src="blob:https://sdi.sfda.gov.sa/1754685e-537f-4cbf-9d79-e3f5b4f1d0cb" /><img alt="page22image20318848" width="329.760000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/032df3cc-57ac-48f8-a094-38cda4f182b4" />&nbsp;<img alt="page22image20320768" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/ac835f0f-9e2a-4cf2-82d9-91fdd15372c1" /><img alt="page22image20316736" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/826ca6cc-8674-46ac-80ff-75d96789d875" /><img alt="page22image20319616" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c8af60ef-dd31-44e0-8709-650c6d76fc3e" />&nbsp;<img alt="page22image20319232" width="275.880000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/902e1ffe-387c-4273-88ed-43c87af8653f" /><img alt="page22image20322880" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3b901d4b-ff62-4d87-b429-3600290b1337" />&nbsp;<img alt="page22image20317312" width="269.640000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/c3e77656-651b-4c89-b7aa-bdbf218739d4" /></p><p>sa-spc</p><p>Pg. 22</p><p>System Organ Class<br />Infections and infestations</p><p>Incidence</p><p>Common</p><p>Rare</p><p>Very Common Common Uncommon</p><p>Uncommon Rare</p><p>Uncommon</p><p>Adverse reaction</p><p>Herpes zoster (inc disseminated &amp; ophthalmic), Pneumonia*, Herpes simplex*, Fungal infection*</p><p>Meningitis (inc bacterial), Epstein-Barr virus infection, Genital herpes, Tonsillitis, Mastoiditis, Post viral fatigue syndrome</p><p>Thrombocytopenia*, Neutropenia*, Anaemia* Leukopenia*, Lymphopenia*<br />Pancytopenia*, Febrile neutropenia, Coagulopathy*, Leukocytosis*, Lymphadenopathy, Haemolytic anaemia#</p><p>Angioedema#, Hypersensitivity*<br />Anaphylactic shock, Amyloidosis, Type III immune complex mediated reaction<br />Cushing&#39;s syndrome*, Hyperthyroidism*, Inappropriate</p><p>Bortezomib for injection 3.5mg/vial</p><p>The most commonly reported adverse reactions during treatment with Bortezomib Injection are nausea, diarrhoea, constipation, vomiting, fatigue, pyrexia, thrombocytopenia, anaemia, neutropenia, peripheral neuropathy (including sensory), headache, paraesthesia, decreased appetite, dyspnoea, rash, herpes zoster and myalgia.</p><p>b.&nbsp;Tabulated summary of adverse reactions<br />Multiple Myeloma<br />Undesirable effects in Table 7 were considered by the investigators to have at least a possible or probable causal relationship to Bortezomib Injection. These adverse reactions are based on an integrated data set of 5,476 patients of whom 3,996 were treated with Bortezomib Injection at 1.3 mg/m2&nbsp;and included in Table&nbsp;87.<br />Overall, Bortezomib Injection was administered for the treatment of multiple myeloma in 3,974 patients.<br />Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are defined as: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable</p><p>effects are presented in order of decreasing seriousness. Table&nbsp;8 7has been generated using Version 14.1 of the MedDRA.<br />Post-marketing adverse reactions not seen in clinical trials are also included.</p><p>Table&nbsp;87: Adverse reactions in patients with Multiple Myeloma treated with Bortezomib Injection as single agent or in combination</p><p><img alt="page23image20417920" width="439.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/1ef10900-9933-49cb-8af3-097144246c6a" /><img alt="page23image20423104" width="439.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/0b3ac7aa-9381-47b3-8806-41dee12e90ee" /></p><table><tbody><tr><td><p>Uncommon</p></td><td><p>Infection*, Bacterial infections*, Viral infections*, Sepsis (inc septic shock)*, Bronchopneumonia, Herpes virus infection*, Meningoencephalitis herpetic#, Bacteraemia (inc staphylococcal), Hordeolum, Influenza, Cellulitis, Device related infection, Skin infection*, Ear infection*, Staphylococcal infection, Tooth infection*</p></td></tr></tbody></table><p><img alt="page23image20430208" width="0.480000" height="75.900000" src="blob:https://sdi.sfda.gov.sa/ea257aa8-99b2-4809-acf8-2b1e14c47e13" /></p><table><tbody><tr><td><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td><p>Rare</p></td><td><p>Neoplasm malignant, Leukaemia plasmacytic, Renal cell carcinoma, Mass, Mycosis fungoides, Neoplasm benign*</p></td></tr></tbody></table><p>Blood and lymphatic system<br />disorders</p><p>Immune system disorders</p><p>Endocrine</p><p><img alt="page23image20429248" width="352.200000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/89177a7c-56b0-49bc-8835-6c10575dea18" />&nbsp;<img alt="page23image20423488" width="352.200000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/661b932f-af23-4b35-9a52-9ced44e24bfe" /></p><table><tbody><tr><td><p>Rare</p></td><td><p>Disseminated intravascular coagulation, Thrombocytosis*, Hyperviscosity syndrome, Platelet disorder NOS, Thrombocytopenic purpura, Blood disorder NOS, Haemorrhagic diathesis, Lymphocytic infiltration</p></td></tr></tbody></table><p><img alt="page23image20428864" width="0.480000" height="50.640000" src="blob:https://sdi.sfda.gov.sa/72fb998c-e112-457d-9a14-7285134421d6" />&nbsp;<img alt="page23image20421184" width="352.200000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/92e24f91-5759-442e-b348-67b4530acc9e" /><img alt="page23image20410176" width="439.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/282d2a2e-6dc7-4382-879b-158745b24cd9" />&nbsp;<img alt="page23image20411520" width="87.720000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/43697f7e-6cde-4777-9807-d46fcb9e5ebd" />&nbsp;<img alt="page23image20407104" width="80.820000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/0fd12fe6-bccb-4aa2-a42c-503da95d562e" /><img alt="page23image20412864" width="269.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/9dbfbf5c-9d94-4433-9e40-3fe8183f332c" /></p><p>sa-spc</p><p>Pg. 23</p><p>System Organ Class<br />disorders</p><p>Metabolism and nutrition disorders</p><p>Incidence</p><p>Rare<br />Very Common Common</p><p>Adverse reaction</p><p>antidiuretic hormone secretion<br />Hypothyroidism<br />Decreased appetite<br />Dehydration, Hypokalaemia*, Hyponatraemia*, Blood glucose abnormal*, Hypocalcaemia*, Enzyme abnormality*</p><p>Mood disorders and disturbances*, Anxiety disorder*, Sleep disorders and disturbances*<br />Mental disorder*, Hallucination*, Psychotic disorder*, Confusion*, Restlessness</p><p>Suicidal ideation*, Adjustment disorder, Delirium, Libido decreased<br />Neuropathies*, Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia*</p><p>Motor neuropathy*, Loss of consciousness (inc syncope), Dizziness*, Dysgeusia*, Lethargy, Headache*</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page24image19923136" width="439.920000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/b48f8f4d-9af9-4790-a4fa-9129c99c67e7" /><img alt="page24image19923712" width="439.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/390668d2-7f54-4bd5-b35a-1d42077cb635" /><img alt="page24image19922944" width="352.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5cb8b17a-f5c9-4069-80c8-af8ce4234915" /><img alt="page24image19923904" width="439.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/25d37019-3ad7-4e0d-bb34-1f82aa689e53" /><img alt="page24image19924096" width="352.200000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/2e70940c-ee9b-4f66-b74b-53bdc2219d6c" /></p><table><tbody><tr><td><p>Uncommon</p></td><td><p>Tumour lysis syndrome, Failure to thrive*, Hypomagnesaemia*, Hypophosphataemia*, Hyperkalaemia*, Hypercalcaemia*, Hypernatraemia*, Uric acid abnormal*, Diabetes mellitus*, Fluid retention</p></td></tr><tr><td><p>Rare</p></td><td><p>Hypermagnesaemia*, Acidosis, Electrolyte imbalance*, Fluid overload, Hypochloraemia*, Hypovolaemia, Hyperchloraemia*, Hyperphosphataemia*, Metabolic Disorder, Vitamin B complex deficiency, Vitamin B12 deficiency, Gout, Increased appetite, Alcohol intolerance</p></td></tr></tbody></table><p><img alt="page24image19926784" width="0.480000" height="50.640000" src="blob:https://sdi.sfda.gov.sa/fd71b250-9d44-4310-880c-64f94e979fc9" />&nbsp;<img alt="page24image19953536" width="0.480000" height="63.240000" src="blob:https://sdi.sfda.gov.sa/1be84ee8-5463-4634-a9d0-b89ae41af32f" /></p><p>Psychiatric disorders</p><p>Nervous disorders</p><p>Common Uncommon Rare<br />Very Common Common</p><p><img alt="page24image19953920" width="352.200000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/76faf0ec-795a-457a-8fde-6f64fe25153e" />&nbsp;<img alt="page24image19949888" width="352.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/bac51b27-6509-4ce4-8b17-4800f3ceb598" /><img alt="page24image19954112" width="439.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/8b7d5c8d-88fe-47cb-849d-6697d44b730f" /></p><p>system</p><p><img alt="page24image20034880" width="352.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c506c78f-3987-47cd-84ca-63be891c64d5" /></p><table><tbody><tr><td><p>Uncommon</p></td><td><p>Tremor, Peripheral sensorimotor neuropathy, Dyskinesia*, Cerebellar coordination and balance disturbances*, Memoryloss (exc dementia)*, Encephalopathy*, Posterior Reversible Encephalopathy Syndrome#, Neurotoxicity, Seizure disorders*, Post herpetic neuralgia, Speech disorder*, Restless legs syndrome, Migraine, Sciatica, Disturbance in</p><p>attention, Reflexes abnormal*, Parosmia</p></td></tr><tr><td><p>Rare</p></td><td><p>Cerebral haemorrhage*, Haemorrhage intracranial (inc subarachnoid) *, Brain oedema, Transient ischaemic attack, Coma, Autonomic nervous system imbalance, Autonomic</p><p>neuropathy, Cranial palsy*, Paralysis*, Paresis*, Presyncope, Brain stem syndrome, Cerebrovascular disorder, Nerve root<br />lesion, Psychomotor hyperactivity, Spinal cord compression, Cognitive disorder NOS, Motor dysfunction, Nervous system disorder NOS, Radiculitis, Drooling, Hypotonia</p></td></tr></tbody></table><p><img alt="page24image20033920" width="0.480000" height="101.220000" src="blob:https://sdi.sfda.gov.sa/62e5d9ed-0555-452c-ade5-4bebdc22eba4" />&nbsp;<img alt="page24image20033536" width="0.480000" height="139.140000" src="blob:https://sdi.sfda.gov.sa/22aef4b0-bfac-4178-9327-989136e4d77f" /></p><p>Eye disorders</p><p>Common Uncommon</p><p>Rare</p><p>Eye swelling*, Vision abnormal*, Conjunctivitis*<br />Eye haemorrhage*, Eyelid infection*, Eye inflammation*, Diplopia, Dry eye*, Eye irritation*, Eye pain, Lacrimation increased, Eye discharge<br />Corneal lesion*, Exophthalmos, Retinitis, Scotoma, Eye disorder (inc. eyelid) NOS, Dacryoadenitis acquired,</p><p><img alt="page24image20034112" width="352.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/38f02b7d-3ef0-45ae-90ec-0bf98077a53b" />&nbsp;<img alt="page24image20049536" width="352.200000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ccfe0577-1d36-4526-ade1-1ae4c9f2d9e5" /><img alt="page24image19990208" width="87.720000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e683cd4b-7e30-4ce0-89cc-9ffe4ea8967f" />&nbsp;<img alt="page24image19988480" width="80.820000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/825c2175-170a-45d3-89f2-db597fb9fb5c" />&nbsp;<img alt="page24image19989440" width="269.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/9e18b892-7cc5-4777-b554-ed406dae484d" /></p><p>sa-spc</p><p>Pg. 24</p><p>System Organ Class</p><p>Ear and labyrinth disorders</p><p>Incidence</p><p>Common Uncommon</p><p>Rare</p><p>Adverse reaction</p><p>Photophobia, Photopsia, Optic neuropathy#, Different degrees of visual impairment (up to blindness)*<br />Vertigo*<br />Dysacusis (inc tinnitus) *,Hearing impaired (up to and inc deafness), Ear discomfort*</p><p>Ear haemorrhage, Vestibular neuronitis, Ear disorder NOS</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page25image20351616" width="439.920000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/79c221e4-5fbe-4b1f-8848-e78b77b2fb8c" /><img alt="page25image20351808" width="439.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e5683115-e8ce-4e84-959d-2bf546c425e0" /><img alt="page25image20352000" width="439.920000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/2559e61a-a451-4c84-9257-8935ace9935d" /><img alt="page25image20352192" width="352.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d50b367f-ad47-470c-8d00-1ae963879ec4" />&nbsp;<img alt="page25image20352384" width="352.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f4e9297f-2eb4-46ea-82a1-167d345b68b6" /></p><table><tbody><tr><td rowspan="2" colspan="1"><p>Cardiac disorders</p></td><td><p>Uncommon</p></td><td><p>Cardiac tamponade#, Cardio-pulmonary arrest*, Cardiac fibrillation (inc atrial), Cardiac failure (inc left and right ventricular)*, Arrhythmia*, Tachycardia*, Palpitations, Angina pectoris, Pericarditis (inc pericardial effusion)*, Cardiomyopathy*, Ventricular dysfunction*, Bradycardia</p></td></tr><tr><td><p>Rare</p></td><td><p>Atrial flutter, Myocardial infarction*, Atrioventricular block*,<br />Cardiovascular disorder (inc cardiogenic shock), Torsade de pointes, Angina unstable, Cardiac valve disorders*, Coronary</p><p>artery insufficiency, Sinus arrest</p></td></tr></tbody></table><p>V ascular disorders</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Common</p><p>Rare Common</p><p>Hypotension*, Orthostatic hypotension, Hypertension*</p><p>Peripheral embolism, Lymphoedema, Pallor, Erythromelalgia, Vasodilatation, Vein discolouration, Venous insufficiency<br />Dyspnoea*, Epistaxis, Upper/lower respiratory tract infection*, Cough*</p><table><tbody><tr><td><p>Uncommon</p></td><td><p>Cerebrovascular accident#, Deep vein thrombosis*, Haemorrhage*, Thrombophlebitis (inc superficial), Circulatory collapse (inc hypovolaemic shock), Phlebitis, Flushing*,</p><p>Haematoma (inc perirenal)*, Poor peripheral circulation*, Vasculitis, Hyperaemia (inc ocular)*</p></td></tr></tbody></table><p><img alt="page25image20355456" width="0.480000" height="75.900000" src="blob:https://sdi.sfda.gov.sa/db39279d-5900-4a54-8f64-8444a25da7be" />&nbsp;<img alt="page25image20355840" width="439.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ba56ea60-4760-4bad-9470-6a00cd312c8e" /></p><table><tbody><tr><td><p>Uncommon</p></td><td><p>Pulmonary embolism, Pleural effusion, Pulmonary oedema (inc acute), Pulmonary alveolar haemorrhage#, Bronchospasm, Chronic obstructive pulmonary disease*, Hypoxaemia*, Respiratory tract congestion*, Hypoxia, Pleurisy*, Hiccups, Rhinorrhoea, Dysphonia, Wheezing</p></td></tr><tr><td><p>Rare</p></td><td><p>Respiratory failure, Acute respiratory distress syndrome, Apnoea, Pneumothorax, Atelectasis, Pulmonary hypertension, Haemoptysis, Hyperventilation, Orthopnoea, Pneumonitis, Respiratory alkalosis, Tachypnoea, Pulmonary fibrosis, Bronchial disorder*, Hypocapnia*, Interstitial lung disease, Lung infiltration, Throat tightness, Dry throat,Increased upper airway secretion, Throat irritation, Upper airway cough syndrome</p></td></tr></tbody></table><p><img alt="page25image20357376" width="0.480000" height="63.240000" src="blob:https://sdi.sfda.gov.sa/d9a1ab6c-8187-45b9-a98b-f23962b25474" />&nbsp;<img alt="page25image20357760" width="0.480000" height="101.220000" src="blob:https://sdi.sfda.gov.sa/83357c4a-648d-46c6-a0e1-3ce04c7cc32f" /></p><p>Gastrointestinal disorders</p><p>Very Common</p><p>Uncommon</p><p>Nausea and vomiting symptoms*, Diarrhoea*, Constipation</p><p>Pancreatitis (inc chronic)*, Haematemesis, Lip swelling*, Gastrointestinal obstruction (inc small intestinal</p><table><tbody><tr><td><p>Common</p></td><td><p>Gastrointestinal haemorrhage (inc mucosal)*, Dyspepsia, Stomatitis*, Abdominal distension, Oropharyngeal pain*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder*, Flatulence</p></td></tr></tbody></table><p><img alt="page25image20358912" width="0.480000" height="50.640000" src="blob:https://sdi.sfda.gov.sa/41c6476b-3ef8-4d50-baf5-32c475e77ece" />&nbsp;<img alt="page25image20359296" width="87.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/170249fb-13f8-4a83-af43-c7d282fd12df" />&nbsp;<img alt="page25image20359488" width="80.820000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/256798e2-b103-4521-a725-983eec00bc2b" />&nbsp;<img alt="page25image20359680" width="269.940000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/59bbb6d6-95b3-4ec4-99ba-9bdccd393195" /></p><p>sa-spc</p><p>Pg. 25</p><p>System Organ Class</p><p>Incidence</p><p>Adverse reaction</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page26image20143040" width="439.920000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/72c2ea2f-480a-46a2-8a99-63352ff466da" /></p><table><tbody><tr><td rowspan="2" colspan="1">&nbsp;</td><td>&nbsp;</td><td><p>obstruction, ileus)*, Abdominal discomfort, Oral ulceration*, Enteritis*,<br />Gastritis*, Gingival bleeding, Gastrooesophageal reflux disease*, Colitis (inc clostridium difficile)*, Colitis ischaemic#, Gastrointestinal inflammation*, Dysphagia, Irritable bowel syndrome, Gastrointestinal disorder NOS, Tongue coated, Gastrointestinal motility disorder*, Salivary gland disorder*</p></td></tr><tr><td><p>Rare</p></td><td><p>Pancreatitis acute, Peritonitis*, Tongue oedema*, Ascites, Oesophagitis, Cheilitis, Faecal incontinence, Anal sphincter atony, Faecaloma*, Gastrointestinal ulceration and</p><p>perforation*, Gingival hypertrophy, Megacolon, Rectal discharge, Oropharyngeal blistering*, Lip pain, Periodontitis, Anal fissure, Change of bowel habit, Proctalgia, Abnormal faeces</p></td></tr></tbody></table><p>Hepatobiliary disorders</p><p>Skin subcutaneous tissue disorders</p><p>and</p><p>Common Uncommon Rare</p><p>Common</p><p>Hepatic enzyme abnormality*<br />Hepatotoxicity (inc liver disorder), Hepatitis*, Cholestasis Hepatic failure, Hepatomegaly, Budd-Chiari syndrome, Cytomegalovirus hepatitis, Hepatic haemorrhage, Cholelithiasis<br />Rash*, Pruritus*, Erythema, Dry skin</p><p><img alt="page26image20145152" width="352.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b86e17cb-f5f8-48e3-bfa8-947bf2de7217" />&nbsp;<img alt="page26image20146496" width="352.200000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/4ed5037d-3c38-44ec-a64d-d1809ee77175" /><img alt="page26image20146304" width="439.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/7696cff6-7ae5-43ca-aa18-750c10724bc4" /></p><table><tbody><tr><td><p>Uncommon</p></td><td><p>Erythema multiforme, Urticaria, Acute febrile neutrophilic dermatosis, Toxic skin eruption, Toxic epidermal necrolysis#, Stevens-Johnson syndrome#, Dermatitis*, Hair disorder*,</p><p>Petechiae, Ecchymosis, Skin lesion, Purpura, Skin mass*, Psoriasis, Hyperhidrosis, Night sweats, Decubitus ulcer#, Acne*, Blister*, Pigmentation disorder*</p></td></tr><tr><td><p>Rare</p></td><td><p>Skin reaction, Jessner&#39;s lymphocytic infiltration, Palmarplantar erythrodysaesthesia syndrome, Haemorrhage subcutaneous, Livedo reticularis, Skin induration, Papule, Photosensitivity reaction, Seborrhoea, Cold sweat, Skin</p><p>disorder NOS, Erythrosis, Skin ulcer, Nail disorder</p></td></tr></tbody></table><p><img alt="page26image20148416" width="0.480000" height="88.560000" src="blob:https://sdi.sfda.gov.sa/b611e259-8f77-4046-b36e-418a4613cc49" />&nbsp;<img alt="page26image20149952" width="0.480000" height="75.900000" src="blob:https://sdi.sfda.gov.sa/78bd5a73-ee7f-46a3-b3c5-9572428e14f2" /></p><p>Musculoskeletal and connective tissue disorders</p><p>Renal and urinary disorders</p><p>Reproductive</p><p>Very Common Common Uncommon</p><p>Common</p><p>Rare Uncommon</p><p>Musculoskeletal pain*<br />Muscle spasms*, Pain in extremity, Muscular weakness Muscle twitching, Joint swelling, Arthritis*, Joint stiffness, Myopathies*,Sensation of heaviness</p><p>Renal impairment*</p><p>Bladder irritation<br />Vaginal haemorrhage, Genital pain*, Erectile dysfunction,</p><p><img alt="page26image20147648" width="352.200000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/948c9d51-ad79-4ba7-a359-b950d3b797b8" />&nbsp;<img alt="page26image20138624" width="352.200000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/55ccd677-9757-4e48-bb40-787492dbc9b2" /></p><table><tbody><tr><td><p>Rare</p></td><td><p>Rhabdomyolysis, Temporomandibular joint syndrome, Fistula, Joint effusion, Pain in jaw, Bone disorder, Musculoskeletal and connective tissue infections and inflammations*, Synovial cyst</p></td></tr></tbody></table><p><img alt="page26image20149376" width="0.480000" height="50.640000" src="blob:https://sdi.sfda.gov.sa/59bbc742-93c9-4f3d-87a3-2a948f053ec0" /></p><table><tbody><tr><td><p>Uncommon</p></td><td><p>Renal failure acute, Renal failure chronic*, Urinary tract infection*, Urinary tract signs and symptoms*, Haematuria*, Urinary retention, Micturition disorder*, Proteinuria, Azotaemia, Oliguria*, Pollakiuria</p></td></tr></tbody></table><p><img alt="page26image20150720" width="0.480000" height="50.640000" src="blob:https://sdi.sfda.gov.sa/b4ad0a5b-65d8-4e10-b2cb-0591f9f6af97" />&nbsp;<img alt="page26image20146880" width="439.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b6aed577-484c-4d1a-825e-2ea479bc6196" />&nbsp;<img alt="page26image20152064" width="87.720000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/5da9d85b-4158-44ae-9c6e-f3e39cef6e4b" />&nbsp;<img alt="page26image19963776" width="80.820000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/54314f22-3c75-4e56-aa09-842dec4841cb" /><img alt="page26image19971840" width="269.940000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/620ea4a7-2e8d-4e8f-aa24-6ff518c3da2b" /></p><p>sa-spc</p><p>Pg. 26</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page27image20169856" width="439.920000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/5dff56db-d132-41ed-a0c5-577f4d9bad63" /></p><p>System Organ Class<br />system and breast</p><p>disorders</p><p>General disorders and administration site conditions</p><p>Investigations</p><p>Injury, poisoning and procedural complications</p><p>Surgical and medical procedures</p><p>Incidence</p><p>Rare</p><p>Very Common Common</p><p>Adverse reaction</p><p>Testicular disorder*, Prostatitis, Breast disorder female, Epididymal tenderness, Epididymitis, Pelvic pain, Vulval ulceration</p><p>Pyrexia*, Fatigue, Asthenia<br />Oedema (inc peripheral), Chills, Pain*, Malaise*</p><p><img alt="page27image20168896" width="439.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/78c227b1-43c3-4d44-8b2b-693585acade1" /></p><table><tbody><tr><td><p>Congenital, familial and genetic<br />disorders</p></td><td><p>Rare</p></td><td><p>Aplasia, Gastrointestinal malformation, Ichthyosis</p></td></tr></tbody></table><p><img alt="page27image20180224" width="352.200000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/8198422c-005b-4eee-b0e6-8a00a1b0af83" /></p><table><tbody><tr><td><p>Uncommon</p></td><td><p>General physical health deterioration*, Face oedema*, Injection site reaction*, Mucosal disorder*, Chest pain, Gait disturbance, Feeling cold, Extravasation*, Catheter related complication*, Change in thirst*, Chest discomfort, Feeling of body temperature change*, Injection site pain*</p></td></tr><tr><td><p>Rare</p></td><td><p>Death (inc sudden), Multi-organ failure, Injection site haemorrhage*, Hernia(inc hiatus)*, Impaired healing*, Inflammation, Injection site phlebitis*, Tenderness, Ulcer, Irritability, Non-cardiac chest pain, Catheter site pain, Sensation of foreign body</p></td></tr></tbody></table><p><img alt="page27image20179648" width="0.480000" height="75.900000" src="blob:https://sdi.sfda.gov.sa/bf23ae7c-5413-4afb-95fa-6a4e0f9f192a" />&nbsp;<img alt="page27image20182528" width="0.480000" height="63.240000" src="blob:https://sdi.sfda.gov.sa/c7913831-b71e-42b3-bc28-cdd928133fcf" /></p><p>Common Uncommon</p><p>Uncommon Rare</p><p>Rare</p><p>Weight decreased<br />Hyperbilirubinaemia*, Protein analyses abnormal*, Weight increased, Blood test abnormal*,C-reactive protein increased</p><p>Fall, Contusion<br />Transfusion reaction, Fractures*, Rigors*, Face injury, Joint injury*, Burns, Laceration, Procedural pain, Radiation injuries*<br />Macrophage activation</p><p><img alt="page27image20184256" width="352.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1e64d4d4-78be-407a-b42f-d3e27502f0c0" /></p><table><tbody><tr><td><p>Rare</p></td><td><p>Blood gases abnormal*, Electrocardiogram abnormalities (inc QT prolongation)*, International normalised ratio abnormal*, Gastric pH decreased, Platelet aggregation increased, Troponin I increased, Virus identification and serology*, Urine analysis abnormal*</p></td></tr></tbody></table><p><img alt="page27image20172928" width="0.480000" height="63.300000" src="blob:https://sdi.sfda.gov.sa/441f2d86-135f-44fa-a999-136774a7e13a" />&nbsp;<img alt="page27image20184448" width="352.200000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4e647466-8b69-454c-9be0-77b8df3ce832" /><img alt="page27image20176192" width="439.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/6ca97801-0506-4324-acc1-c62fe6b88710" />&nbsp;<img alt="page27image20169664" width="87.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/863f23bd-19f7-4513-b658-c77f7dbb7577" />&nbsp;<img alt="page27image20178304" width="80.820000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/76e553c7-24da-4b1c-97b3-b0f969e9902d" /><img alt="page27image20170624" width="269.940000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/24337e0f-bb94-4957-b2ad-6d04280513cd" /></p><p>NOS=not otherwise specified<br />* Grouping of more than one MedDRA preferred term.<br /># Postmarketing adverse reaction<br />Mantle Cell Lymphoma (MCL)<br />The safety profile of Bortezomib Injection in 240 MCL patients treated with Bortezomib Injection at 1.3 mg/m2&nbsp;in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BzR-CAP) versus 242 patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] was relatively consistent to that observed in patients with multiple myeloma with main differences described below. Additional adverse drug reactions identified associated with the use of the combination therapy (BzR-CAP) were hepatitis B infection (&lt; 1%) and myocardial ischaemia (1.3%). The similar incidences of these events in both treatment arms, indicated that these adverse drug reactions are not attributable to Bortezomib Injection alone. Notable differences in the MCL patient population as compared to patients in the multiple myeloma studies were a &ge; 5% higher incidence of the haematological adverse reactions (neutropenia,</p><p><img alt="page27image20176960" width="139.560000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/ef06e9da-bcd0-48fa-8014-ed45ab154a21" /></p><p>sa-spc</p><p>Pg. 27</p><p>Bortezomib for injection 3.5mg/vial</p><p>thrombocytopenia, leukopenia, anemia, lymphopenia), peripheral sensory neuropathy, hypertension, pyrexia, pneumonia, stomatitis, and hair disorders.<br />Adverse drug reactions identified as those with a &ge; 1% incidence, similar or higher incidence in the BzR-CAP arm and with at least a possible or probable causal relationship to the components of the BzR-CAP arm, are listed in Table 8 below. Also included are adverse drug reactions identified in the BzR-CAP arm that were considered by investigators to have at least a possible or probable causal relationship to Bortezomib Injection based on historical data in the multiple myeloma studies.</p><p>Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are defined as: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Table 8 has been generated using Version 16 of the MedDRA.</p><p>Table 8 Adverse reactions in patients with Mantle Cell Lymphoma treated with BzR-CAP</p><p><img alt="page28image20090048" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d5b88a76-18a0-4d07-9a0a-d3cbc98d9875" /></p><p>System Organ Class</p><p>Infections and infestations</p><p>Blood and lymphatic system disorders</p><p>Immune system disorders</p><p>Metabolism and nutrition disorders</p><p>Psychiatric disorders Nervous system disorders</p><p>Eye disorders<br />Ear and labyrinth disorders</p><p>Cardiac disorders</p><p>Incidence</p><p>Very Common</p><p>Uncommon Very Common</p><p>Uncommon Common Uncommon Very Common Common</p><p>Uncommon Common<br />Very Common</p><p>Uncommon Common Common Uncommon</p><p>Adverse reaction</p><p>Pneumonia*</p><p>Hepatitis B, Infection*, Bronchopneumonia Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia*</p><p>Pancytopenia*<br />Hypersensitivity*<br />Anaphylactic reaction<br />Decreased appetite<br />Hypokalaemia*, Blood glucose abnormal*, Hyponatraemia*, Diabetes mellitus*, Fluid retention</p><p>Tumour lysis syndrome<br />Sleep disorders and disturbances*<br />Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia*</p><p>Autonomic nervous system imbalance<br />Vision abnormal*<br />Dysacusis (inc tinnitus)*<br />Vertigo*, Hearing impaired (up to and inc deafness)</p><p><img alt="page28image20089664" width="445.500000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/f4c3c94e-115e-48d0-9d43-dca21900a963" /></p><table><tbody><tr><td><p>Common</p></td><td><p>Sepsis (inc septic shock)*, Herpes zoster (inc disseminated &amp; ophthalmic), Herpes virus infection*, Bacterial infections*, Upper/lower respiratory tract infection*, Fungal infection*, Herpes simplex*</p></td></tr></tbody></table><p><img alt="page28image20099072" width="0.480000" height="63.240000" src="blob:https://sdi.sfda.gov.sa/b29df902-1e60-474f-a8bc-d0d3f2240f39" />&nbsp;<img alt="page28image20087168" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ae0883f5-cea5-4794-af42-3ce3d371e97d" />&nbsp;<img alt="page28image20099264" width="308.700000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/34c00870-4dfb-41d0-81b3-0372aed9c7c8" /><img alt="page28image20087360" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/3df4f052-2ffe-4aa3-9166-5a7e3a02bbd2" />&nbsp;<img alt="page28image20087552" width="308.700000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c9946b64-e1bd-4721-bb40-06a7443cc7ad" /><img alt="page28image20087936" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b3d64b58-9374-4439-81c5-e4be1d16c1c6" />&nbsp;<img alt="page28image20087744" width="308.700000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/9b4f9fc2-1a89-42e1-9fc4-45bc2a75e1a4" /><img alt="page28image20088128" width="308.700000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c7a5803c-5208-4f88-b339-f2db6f02e803" />&nbsp;<img alt="page28image20088320" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/389faf2b-f5d3-4ff7-b50d-61a673de6ffc" /><img alt="page28image20088896" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/07d15b42-267a-4259-b608-356974d5a7ee" /></p><table><tbody><tr><td><p>Common</p></td><td><p>Neuropathies*, Motor neuropathy*, Loss of consciousness (inc syncope), Encephalopathy*, Peripheral sensorimotor neuropathy, Dizziness*, Dysgeusia*, Autonomic neuropathy</p></td></tr></tbody></table><p><img alt="page28image20090240" width="0.480000" height="66.120000" src="blob:https://sdi.sfda.gov.sa/792890eb-2cfd-4f73-bd24-66c9cad8b8dc" />&nbsp;<img alt="page28image20090432" width="445.500000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/9132188d-df3d-4e50-9271-c46e04979ed2" /><img alt="page28image20091008" width="445.500000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/4764977d-541f-4500-b17c-5fc5486dfceb" />&nbsp;<img alt="page28image20090816" width="308.700000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/be920e62-70e1-488c-902f-1feef692596f" /></p><table><tbody><tr><td><p>Common</p></td><td><p>Cardiac fibrillation (inc atrial), Arrhythmia*, Cardiac failure (inc left and right ventricular)*, Myocardial ischaemia, V entricular dysfunction*</p></td></tr></tbody></table><p><img alt="page28image20091584" width="0.480000" height="50.640000" src="blob:https://sdi.sfda.gov.sa/eef34367-2d48-4739-a1eb-d6623bc78460" /></p><p>Uncommon</p><p>Cardiovascular disorder (inc cardiogenic</p><p><img alt="page28image20092928" width="136.800000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f0cfc930-b71f-4816-99d0-802407bc392c" />&nbsp;<img alt="page28image20091968" width="86.340000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/3f685042-8d1b-4ae4-a759-51f7fd7d0d1d" />&nbsp;<img alt="page28image20092352" width="220.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/0d2727e9-7474-4532-a135-c9067643dc84" /></p><p>sa-spc</p><p>Pg. 28</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page29image19989824" width="445.500000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/03000c1a-3aff-42a5-8be9-d5fe6fd5ab38" /><img alt="page29image20020992" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/b41f1f2d-30e5-4566-bad7-d83ae146550a" /></p><p>Vascular disorders</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Gastrointestinal disorders</p><p>Hepatobiliary disorders</p><p>Skin and subcutaneous tissue<br />disorders<br />Musculoskeletal and connective</p><p>tissue disorders<br />Renal and urinary disorders General disorders and administration site conditions<br />Investigations</p><p>Common</p><p>Common Uncommon</p><p>Very Common</p><p>Uncommon Common Uncommon Very Common Common</p><p>Common</p><p>Common<br />Very Common Common</p><p>shock)<br />Hypertension*, Hypotension*, Orthostatic hypotension<br />Dyspnoea*, Cough*, Hiccups<br />Acute respiratory distress syndrome, Pulmonary embolism, Pneumonitis, Pulmonary hypertension, Pulmonary oedema (inc acute) Nausea and vomiting symptoms*, Diarrhoea*, Stomatitis*, Constipation</p><p>Colitis (inc clostridium difficile)* Hepatotoxicity (inc liver disorder) Hepatic failure<br />Hair disorder*</p><p>Pruritus*, Dermatitis*, Rash*</p><p>Muscle spasms*, Musculoskeletal pain*, Pain in extremity</p><p>Urinary tract infection*<br />Pyrexia*, Fatigue, Asthenia<br />Oedema (inc peripheral), Chills, Injection site reaction*, Malaise*<br />Hyperbilirubinaemia*, Protein analyses</p><p><img alt="page29image20076928" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/7abd23b4-6d35-46e3-ba35-87c134b9baea" />&nbsp;<img alt="page29image20077312" width="308.700000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c49fc6dc-034c-4c6e-b6b9-60eca0752500" /><img alt="page29image20075968" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f7ce3f90-4f05-4aab-b696-7bedbea5595b" /></p><table><tbody><tr><td><p>Common</p></td><td><p>Gastrointestinal haemorrhage (inc mucosal)*, Abdominal distension, Dyspepsia, Oropharyngeal pain*, Gastritis*, Oral ulceration*, Abdominal discomfort, Dysphagia, Gastrointestinal inflammation*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder*</p></td></tr></tbody></table><p><img alt="page29image20078080" width="0.480000" height="88.560000" src="blob:https://sdi.sfda.gov.sa/bc8475f9-3a6f-427c-b836-1b2bf3768282" />&nbsp;<img alt="page29image20072128" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4d28d0c1-c36f-49a2-bfdc-285651216e37" />&nbsp;<img alt="page29image20076736" width="308.700000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/530c7923-078b-4fc0-936b-a9fee1178923" /><img alt="page29image20083072" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/601232ab-1198-4939-a4d0-18824a973298" />&nbsp;<img alt="page29image20074048" width="308.700000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2c0b1a07-c94c-49e9-a28c-8f6437cc8a69" /><img alt="page29image20075776" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2fd31207-ac1a-4cc2-9a8a-293e1f78787a" /><img alt="page29image20075008" width="445.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a2ea5158-d928-4bdc-9ea7-dbb2a42b6485" /><img alt="page29image20075392" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/de197355-341a-4a22-a6ad-9954570b009c" />&nbsp;<img alt="page29image20077888" width="308.700000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1230eb4d-94e5-4367-8ca3-20230f132095" /><img alt="page29image20073472" width="445.500000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/af15d5de-f46d-4d59-bd3d-4c34c4d5223b" /></p><p>Common<br />* Grouping of more than one MedDRA preferred term.</p><p>abnormal*, increased</p><p>Weight</p><p>decreased,</p><p>Weight</p><p><img alt="page29image20083264" width="136.800000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/2c6109e3-d5ad-49ba-9347-ac2f0fa63122" />&nbsp;<img alt="page29image20072512" width="86.340000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b423ccd4-b19d-4537-8b13-4068f31d39ef" />&nbsp;<img alt="page29image20073856" width="220.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/eecd9a3d-9ff7-408e-989b-2dc3d632a8f6" /></p><p>c.&nbsp;Description of selected adverse reactions<br />Herpes zoster virus reactivation<br />Multiple Myeloma<br />Antiviral prophylaxis was administered to 26% of the patients in the Bz+M+P arm. The incidence of herpes zoster among patients in the Bz+M+P treatment group was 17% for patients not administered antiviral prophylaxis compared to 3% for patients administered antiviral prophylaxis.&nbsp;Mantle cell lymphoma</p><p>Antiviral prophylaxis was administered to 137 of 240 patients (57%) in the BzR-CAP arm. The incidence of herpes zoster among patients in the BzR-CAP arm was 10.7% for patients not administered antiviral prophylaxis compared to 3.6% for patients administered antiviral prophylaxis (see section 4.4).</p><p>Hepatitis B Virus (HBV) reactivation and infection</p><p>Mantle cell lymphoma</p><p>HBV infection with fatal outcomes occurred in 0.8% (n=2) of patients in the non- Bortezomib Injection treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP) and 0.4% (n=1) of patients receiving Bortezomib Injection in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BzR-CAP). The overall incidence of</p><p><img alt="page29image20079232" width="139.620000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/693da8b2-1e82-4d1c-8dec-d0bf5894ec7d" />&nbsp;<img alt="page29image20077120" width="225.420000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/34abac20-b970-494b-9ef2-b3275fe97f76" /></p><p>sa-spc</p><p>Pg. 29</p><p>Bortezomib for injection 3.5mg/vial</p><p>hepatitis B infections was similar in patients treated with BzR-CAP or with R-CHOP (0.8% vs 1.2% respectively).</p><p>Peripheral neuropathy in combination regimens</p><p>Multiple Myeloma</p><p>In trials in which Bortezomib Injection was administered as induction treatment in combination with dexamethasone (study IFM- 2005-01), and dexamethasone-thalidomide (study MMY-3010), the incidence of peripheral neuropathy in the combination regimens is presented in the table 9 below:</p><p>Table 9: Incidence of peripheral neuropathy during induction treatment by toxicity and treatment discontinuation due to peripheral neuropathy</p><p><img alt="page30image20098880" width="209.520000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/35edbf29-6387-42af-ac3d-68341981e019" />&nbsp;<img alt="page30image20098112" width="447.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d2ffdd80-73a7-4fc5-85e2-992dc4a34b21" /></p><p>IFM-2005-01</p><p>MMY-3010</p><table><tbody><tr><td>&nbsp;</td><td><p>vincristine, doxorubicin, dexamethasone (N=239)</p></td><td><p>Bortezomib Injection, dexamethasone (N=239)</p></td><td><p>thalidomide, dexamethasone (N=126)</p></td><td><p>Bortezomib Injection, thalidomide, dexamethasone (N=130)</p></td></tr></tbody></table><p>Incidence of PN (%)<br />All GradePN<br />&ge; Grade 2 PN<br />&ge; Grade 3 PN<br />Discontinuation &lt;1 2 1 5 due to PN (%)</p><p>PN=peripheral neuropathy</p><p>Note: Peripheral neuropathy included the preferred terms: neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy.</p><p>Mantle cell lymphoma</p><p>In study LYM-3002 in which Bortezomib Injection was administered with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CAP), the incidence of peripheral neuropathy in the combination regimens is presented in the table 10 below:<br />Table 10: Incidence of peripheral neuropathy in study LYM-3002 by toxicity and treatment discontinuation due to peripheral neuropathy</p><p><img alt="page30image20097920" width="84.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/196968bd-2059-4907-80c6-d6caff5f182e" />&nbsp;<img alt="page30image20101760" width="250.680000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/0f99289c-dccc-4a52-9452-deca0acfd06c" />&nbsp;<img alt="page30image20102144" width="112.320000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/9a6a6b1e-744f-4e2e-b135-59219932579e" /></p><p>3 15</p><p>12 45 2 31 0 5</p><p><img alt="page30image20102912" width="84.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/599eb2ba-0845-45e0-936a-c7760e37f399" />&nbsp;<img alt="page30image20102720" width="250.680000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/53c3a157-7a10-49a7-b138-ff5e23a53887" />&nbsp;<img alt="page30image20102528" width="112.320000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2ec2c3fe-6726-44d8-8656-b57d4ea1a4c3" /></p><p>1 10 &lt; 1 5</p><p><img alt="page30image20093696" width="84.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/36a9f89a-cad0-4b50-b4f5-91fb15ece25d" />&nbsp;<img alt="page30image20098304" width="250.680000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1bd06f67-efa8-4294-a145-1dbe15a0f2bc" />&nbsp;<img alt="page30image20169088" width="112.320000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c45a8af7-ea8a-4094-b2ff-891c136361f1" />&nbsp;<img alt="page30image20183104" width="84.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/bf690992-a1a9-4a19-b9e3-6457141659f4" /><img alt="page30image20169472" width="250.680000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/36425bda-b3e4-4750-8ecd-6cb4698d2ed1" />&nbsp;<img alt="page30image20173888" width="112.320000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8ec59079-da02-48f1-8bb8-b6dbd2b0bb88" />&nbsp;<img alt="page30image20184832" width="81.060000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/64f65318-b956-48dc-bced-743b8f2ae46a" />&nbsp;<img alt="page30image20172160" width="83.460000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/7bab221d-44bb-4c46-bc0b-baada16ebbfd" />&nbsp;<img alt="page30image20176384" width="84.720000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ad667704-afcf-48e3-8408-ef4f40210aa9" />&nbsp;<img alt="page30image20119552" width="111.360000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/ebe3a2e6-7ed7-44c3-ab6c-4168ea56e46c" /><img alt="page30image20138240" width="84.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/53380a59-81c6-40d3-83a1-5abd6f9b8911" />&nbsp;<img alt="page30image20137280" width="447.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/99f1cf7c-0bdc-42cd-b9dd-06495be911e6" /></p><p>IFM-2005-01<br />Bortezomib Injection , rituximab, cyclophosphamide, doxorubicin, and prednisone,BzR-CAP (N=240)</p><p>MMY-3010<br />rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP (N=242)</p><p>29 9 4 &lt;1</p><p><img alt="page30image20138048" width="447.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/c6763525-e2ed-486f-9138-5bae11fbda80" /><img alt="page30image20137088" width="447.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/d76f7260-ba93-4325-84f3-8e1db1c81038" /></p><p>Incidence of PN (%) All GradePN<br />&ge; Grade 2 PN<br />&ge; Grade 3 PN Discontinuation</p><p>30 18 8 2</p><p><img alt="page30image20136512" width="447.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/a0cca34a-6cd7-40d7-a025-6ae587897dde" /><img alt="page30image20139392" width="447.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/8783c787-0058-45c1-94be-2c7249f9b224" /><img alt="page30image20137664" width="447.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/4addda30-a5d8-40ba-bc30-9cbdb5c15199" /><img alt="page30image20139200" width="447.720000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/0e2140ad-e28a-4e32-a903-469317999431" /></p><p>due to PN (%)<br />PN=peripheral neuropathy<br />Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy</p><p><img alt="page30image20139584" width="81.060000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/6cca9868-594d-4e75-9564-dac1f66f82ff" />&nbsp;<img alt="page30image20139776" width="184.560000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/9d2fcdf7-5944-4d77-a2cc-e468306b383f" />&nbsp;<img alt="page30image19965888" width="180.660000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d60cc092-8076-4f0a-a213-5468e2c9df53" /></p><p>sa-spc</p><p>Pg. 30</p><p>Bortezomib for injection 3.5mg/vial</p><p>Elderly MCL patients</p><p>42.9% and 10.4% of patients in the BzR-CAP (Bortezomib Injection, rituximab, cyclophosphamide, doxorubicin, and prednisone) arm were in the range 65-74 years and &ge; 75 years of age, respectively. Although in patients aged &ge; 75 years, both BzR-CAP and R-CHOP were less tolerated, the serious adverse event rate in the BzR-CAP groups was 68%, compared to 42% in the R-CHOP group.</p><p>Notable differences in the safety profile of Bortezomib Injection administered subcutaneously versus intravenously as single agent<br />In the Phase III study patients who received Bortezomib Injection subcutaneously compared to intravenous administration had 13% lower overall incidence of treatment emergent adverse reactions that were Grade 3 or higher in toxicity, and a 5% lower incidence of discontinuation of Bortezomib Injection. The overall incidence of diarrhoea, gastrointestinal and abdominal pain, asthenic conditions, upper respiratory tract infections and peripheral neuropathies were 12%-15% lower in the subcutaneous group than in the intravenous group. In addition, the incidence of Grade 3 or higher peripheral neuropathies was 10% lower, and the discontinuation rate due to peripheral neuropathies 8% lower for the subcutaneous group as compared to the intravenous group.</p><p>Six percent of patients had an adverse local reaction to subcutaneous administration, mostly redness. Cases resolved in a median of 6 days, dose modification was required in two patients. Two (1%) of the patients had severe reactions; 1 case of pruritus and 1 case of redness.<br />The incidence of death on treatment was 5% in the subcutaneous treatment group and 7% in the intravenous treatment group. Incidence of death from &ldquo;Progressive disease&rdquo; was 18% in the subcutaneous group and 9% in the intravenous group.</p><p>Retreatment of patients with relapsed multiple myeloma</p><p>In a study in which Bortezomib Injection retreatment was administered in 130 patients with relapsed multiple myeloma, who previously had at least partial response on a Bortezomib Injection -containing regimen, the most common all-grade adverse events occurring in at least 25% of patients were thrombocytopenia (55%), neuropathy (40%), anaemia (37%), diarrhoea (35%), and constipation (28%). All grade peripheral neuropathy and grade &ge; 3 peripheral neuropathy were observed in 40% and 8.5% of patients, respectively.</p><p>&nbsp;</p><p>To reports any side effect(s):<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the competent authority in Saudi Arabia as per details below:</p><p><img alt="page32image20828864" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0b03ee35-fe86-43cb-b6e2-d31ccbd224c5" />&nbsp;<img alt="page32image20836928" width="131.940000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/53c66afb-d719-4c04-bf2d-5d4d33adeeb4" />&nbsp;<img alt="page32image20830976" width="58.920000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/7ff7d44e-6d31-4ef5-a333-832f4a690bcf" />&nbsp;<img alt="page32image20824256" width="58.920000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/45e3b233-01f7-43f1-be3b-025293fe27d9" /><img alt="page32image20833664" width="441.840000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/f94e2944-b142-4ae0-9fd8-dda52e83ab86" /><img alt="page32image20827520" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7106f74e-2f89-4f17-afb8-e6d028a768d5" /><img alt="page32image20825024" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/02eb3edc-197a-4639-9559-047e13f9de93" /><img alt="page32image20828288" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/15334d13-cfa6-47b0-84c6-58ab6f343140" /><img alt="page32image20837312" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/2f6827c9-7cc6-4f0c-9120-55e67b2daf55" /><img alt="page32image20833472" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b13b00b2-d9cc-4b17-b080-74d9da3a9edb" /><img alt="page32image20829632" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c47d0e65-6bfd-41f4-adef-a5397f566f38" />&nbsp;<img alt="page32image20835008" width="250.560000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/6294a8d0-2933-43f9-aab5-935eb9f5d0fe" /><img alt="page32image20837120" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/efba89f5-5130-4271-a518-5befd7782c2e" /><img alt="page32image20835392" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/6db73830-ed6e-4b39-a2c7-bbbc0ec3cb6e" />&nbsp;<img alt="page32image20834624" width="87.360000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/964f1e85-49ed-45f2-a87f-10ef8cce50e6" />&nbsp;<img alt="page32image20826944" width="139.620000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/96b1c01b-cde8-4ebb-83da-677c73def5f1" /><img alt="page32image20825216" width="139.620000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ac8ef535-bc43-4d19-9968-0fc4d092b7b9" />&nbsp;<img alt="page32image20832320" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/70df20de-7dcf-4fed-b72c-63b888d50bd6" /><img alt="page32image20830016" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/efed6ba4-5bb9-4d4b-a8cf-6824111b794b" /><img alt="page32image20824064" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/8c626a1d-c7f8-4e5d-8da8-4f9aa241c7ff" /><img alt="page32image20833088" width="373.020000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/51309b34-1d63-4500-bde2-5041ed3611ed" />&nbsp;<img alt="page32image20830592" width="148.200000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/66006e60-9797-4a93-8534-2ec58520c63a" />&nbsp;<img alt="page32image20832896" width="148.200000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/1192a947-d3ea-4b3d-97bd-b1aab72599e2" /><img alt="page32image20829248" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/4ef81e9b-2fcb-4c62-af50-83e496d9ebe0" /><img alt="page32image20832128" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/17405638-3508-472c-8695-6f9b1e0f6b05" />&nbsp;<img alt="page32image20831936" width="66.300000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4efd7421-1349-4bde-baf3-a131f1b76d51" />&nbsp;<img alt="page32image20831168" width="98.340000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c413de88-58cf-4469-8eba-4a6d87b3138a" />&nbsp;<img alt="page32image20832512" width="98.340000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e1bf007f-9141-44b8-8cd0-d749834cf40b" /><img alt="page32image20832704" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/acbee94d-e9d9-47ac-9887-7f80f589de94" /><img alt="page32image20830208" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/df4eb21d-a320-484e-b18f-789a85c1595d" /><img alt="page32image20831552" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/5c278bdb-92f5-49f3-a2d5-7bacf1e0b03f" />&nbsp;<img alt="page32image20833280" width="89.220000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/fd18d5f4-b490-40fa-a3b0-f288116f7193" />&nbsp;<img alt="page32image20831744" width="127.020000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/238285e8-6fc3-4eb6-a0e4-0ec548bf54bd" /></p><p>&nbsp;The National Pharmacovigilance Centre (NPC)</p><ul><li><p>- &nbsp;Fax: +966-11-205-7662</p></li><li><p>- &nbsp;Call NPC at +966-11-2038222, Ext 2317-2356-2340</p></li><li><p>- &nbsp;SFDA Call Centre: 19999</p></li><li><p>- &nbsp;E-mail: npc.drug@sfda.gov.sa</p></li><li><p>- &nbsp;Website: https://ade.sfda.gov.sa/</p></li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><p><img alt="page32image20838464" width="226.320000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/3a6401ff-52e5-493a-b1c8-836e06fb801a" />&nbsp;<img alt="page32image20836160" width="123.540000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/3aa84b3a-ae1f-4a67-a213-860b9316ef8b" />&nbsp;<img alt="page32image20835200" width="250.320000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/4c564a95-4ed1-42c9-9e14-167ff5cfab13" />&nbsp;<img alt="page32image20834048" width="132.540000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/427dc359-a403-4baa-bc9c-b9d6775d1852" /><img alt="page32image20836544" width="152.160000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/08d1abb1-ba46-4e62-8041-8e26ffbe653e" />&nbsp;<img alt="page32image20834432" width="160.980000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/069fb149-2b8a-49b1-ada7-83b18f665b52" />&nbsp;<img alt="page32image20836352" width="283.200000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/16343c0d-9e69-4a31-9ed5-889e387e9bd2" />&nbsp;<img alt="page32image20835776" width="105.540000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a70767d8-1d16-4b5b-8f45-007155acaac4" /><img alt="page32image20837888" width="319.380000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a1e07479-fa96-4def-92e9-87246c7efa08" />&nbsp;<img alt="page32image20835584" width="128.580000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/aa741f06-cc24-4f0d-a0ce-8e5750b7c90d" />&nbsp;<img alt="page32image20838272" width="134.160000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/3f4ff20d-f227-4e5b-bcb3-e0080b16bff6" />&nbsp;<img alt="page32image20834816" width="98.460000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/83f75bf9-ff8e-4f7b-92c0-a6fb57ffbdcb" /><img alt="page32image20839232" width="136.860000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/977a9b0e-84dc-41cb-b2af-f2b56de0f2de" /><img alt="page32image20833856" width="0.720000" height="184.140000" src="blob:https://sdi.sfda.gov.sa/6f44cbc9-e766-45d0-b467-1c3ba236458e" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients, overdose more than twice the recommended dose has been associated with the acute onset of symptomatic hypotension and thrombocytopenia with fatal outcomes. For preclinical cardiovascular safety pharmacology studies, see section 5.3.<br />There is no known specific antidote for bortezomib overdose. In the event of an overdose, the patient&#39;s vital signs should be monitored and appropriate supportive care given to maintain blood pressure (such as fluids, pressors, and/or inotropic agents) and body temperature (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bortezomib is a proteasome inhibitor. It is specifically designed to inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the turnover of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death.</p><p>Bortezomib is highly selective for the proteasome. At 10 &mu;M concentrations, bortezomib does not inhibit any of a wide variety of receptors and proteases screened and is more than 1,500-fold more selective for the proteasome than for its next preferable enzyme. The kinetics of proteasome inhibition were evaluated in vitro, and bortezomib was shown to dissociate from the proteasome with a t% of 20 minutes, thus demonstrating that proteasome inhibition by bortezomib is reversible. Bortezomib mediated proteasome inhibition affects cancer cells in a number of ways, including, but not limited to, altering regulatory proteins, which control cell cycle progression and nuclear factor kappa B (NF-kB) activation. Inhibition of the proteasome results in cell cycle arrest and apoptosis. NF-kB is a transcription factor whose activation is required for many aspects of tumourigenesis, including cell growth and survival, angiogenesis, cell-cell interactions, and metastasis. In myeloma, bortezomib affects the ability of myeloma cells to interact with the bone marrow microenvironment. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types and that cancer cells are more sensitive to the pro-apoptotic effects of proteasome inhibition than normal cells. Bortezomib causes reduction of tumour growth in vivo in many preclinical tumour models, including multiple myeloma.</p><p>Data from in vitro, ex-vivo, and animal models with bortezomib suggest that it increases osteoblast differentiation and activity and inhibits osteoclast function. These effects have been observed in patients with multiple myeloma affected by an advanced osteolytic disease and treated with bortezomib.</p><p>&nbsp;</p><p>&nbsp;</p><p>Clinical efficacy in previously untreated multiple myeloma<br />A prospective Phase III, international, randomised (1:1), open-label clinical study (MMY-3002 VISTA) of 682 patients was conducted to determine whether Bortezomib (1.3 mg/ m2m2 injected intravenously) in combination with melphalan (9 mg/m2) and prednisone (60 mg/m2) resulted in improvement in time to progression (TTP) when compared to melphalan (9 mg/m2) and prednisone (60 mg/m2) in patients with previously untreated multiple myeloma. Treatment was administered for a maximum of 9 cycles (approximately 54 weeks) and was discontinued early for disease progression or unacceptable toxicity. The median age of the patients in the study was 71 years, 50% were male, 88% were Caucasian and the median Karnofsky performance status score for the patients was 80. Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105 g/l, and a median platelet count of 221.5 x 109/l. Similar proportions of patients had creatinine clearance :5 30 ml/min (3% in each arm).<br />At the time of a pre-specified interim analysis, the primary endpoint, time to progression, was met and patients in the M+P arm were offered Bz+M+P treatment. Median follow-up was 16.3 months. The final survival update was performed with a median duration of follow-up of 60.1 months. A statistically significant survival benefit in favour of the Bz+M+P treatment group was observed (HR=0.695; p=0.00043) despite subsequent therapies including Bortezomib-based regimens. Median survival for the Bz+M+P treatment group was 56.4 months compared to 43.1 for the M+P treatment group. Efficacy results are presented in Table 11:</p><p><img alt="page34image20939904" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e6da83d8-ff2a-4426-a5fd-1a975068532b" /><img alt="page34image20952384" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/ac45e5cb-9028-4be7-88bb-c3586d512609" /><img alt="page34image20949312" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/5a293f3f-efd6-47df-a983-94a4687042b4" /><img alt="page34image20943936" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/6aa557cb-4f36-481f-9182-77bf1e18c192" /><img alt="page34image20943744" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/ca48f18f-0dd5-4ae9-8eae-88f1be22b928" /><img alt="page34image20946816" width="441.840000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/fe499871-9332-4db8-a900-afaec8bcbba5" />&nbsp;<img alt="page34image20947584" width="127.380000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0ab90223-2d46-4728-b9c8-29835341defe" />&nbsp;<img alt="page34image20938752" width="109.680000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/d1da98df-c3c3-4b1a-8325-2f3d1ebdc242" /><img alt="page34image20953920" width="109.680000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/f4759d6e-c21f-423a-a32f-b62f4354ee27" />&nbsp;<img alt="page34image20948160" width="288.420000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/4783d525-d4bf-4626-bad2-2b7ab44d72f6" />&nbsp;<img alt="page34image20944896" width="147.780000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/bae4b2f0-cbb8-450e-b2ee-d440a50d9c72" /><img alt="page34image20954112" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/fb7c9538-ade9-48cf-8089-ceb0d995de7c" /><img alt="page34image20949504" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/36357c2f-414d-415f-9566-54bb86800379" />&nbsp;<img alt="page34image20947776" width="262.140000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/87ddf00a-239d-407f-bcfb-12f5a77dcf3e" /><img alt="page34image20951808" width="176.160000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/9fce8c6b-5243-4cc5-83a5-cc1c977fee39" />&nbsp;<img alt="page34image20952960" width="222.720000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/2ead8f4d-0bdc-4f21-809d-f999c111bfb1" />&nbsp;<img alt="page34image20942208" width="63.480000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/46df736c-ea6a-4ff3-bd3d-47e9cfcd1a64" />&nbsp;<img alt="page34image20941440" width="127.320000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/e84a7e5b-6339-4f39-b758-e5ae40590818" /><img alt="page34image20948544" width="260.280000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/c012bba4-457f-44ef-aa2d-5cccaf60e392" />&nbsp;<img alt="page34image20949696" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/63e2da82-3737-48f9-ab69-78cc84adeff8" /><img alt="page34image20938944" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/f981748b-06e2-4013-96bb-6f3ee81c180c" /><img alt="page34image20947392" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/25a90c46-c519-44ed-b0c5-901d7619a93d" /><img alt="page34image20928704" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/33d72db8-1f47-46c9-86c8-abbcc8ee5712" /><img alt="page34image20928128" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/8f811e6c-8153-4716-bb5d-fed17039a5ec" /><img alt="page34image20925632" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/f7f783b2-e99b-4913-a56a-2f6f15b59dc5" /><img alt="page34image20931008" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a0502730-f8aa-4701-a8d1-77f93cb0e067" /><img alt="page34image20929280" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/411375ff-d626-4bd0-a744-528b827a2888" /><img alt="page34image20931776" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/fbee5073-b15d-4a77-92b3-a50f02046982" /><img alt="page34image20928896" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/88c76efc-2725-4631-be82-124f22bd6845" />&nbsp;<img alt="page34image20927360" width="247.320000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/6bb0c52f-c54e-4d24-a930-a5d14660a024" /><img alt="page34image20923328" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/caae68bc-62f9-4c23-aca4-dde44b5fd712" /><img alt="page34image20929664" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/208b36a9-1df9-469f-9eeb-6a3fbc5ab789" /><img alt="page34image20924096" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/436f2f22-5362-43c9-8f38-b14027fe997d" /><img alt="page34image20932544" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/e0b05f5a-82ed-40d1-9cbd-d209c21acc23" /><img alt="page34image20924480" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/adc54d35-7dd2-4711-b1f6-6e74b7c51925" /><img alt="page34image20924672" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/1aec61a9-7940-4177-ac18-1f564faf1d73" />&nbsp;<img alt="page34image20923712" width="261.120000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/b5bb128d-7c9e-443d-a7ae-bb37e3d0b3ec" /></p><p>Table 11: Efficacy results following the final survival update to VISTA study</p><p><img alt="page34image20925056" width="336.300000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/55653c3a-b359-4395-b5fd-13e976cc7b03" /><img alt="page34image20922944" width="463.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b73059d4-9c81-429a-803d-7eba89c152cc" /></p><p>Efficacy endpoint Time to progression&nbsp;Events n (%)</p><p>Mediana&nbsp;(95% CI) Hazard ratiob&nbsp;(95% CI)</p><p>p-valuec<br />Progression-free survival&nbsp;Events n (%)</p><p>Mediana&nbsp;(95% CI) Hazard ratiob&nbsp;(95% CI)</p><p>p-value&nbsp;c<br />Overall survival*&nbsp;Events (deaths) n (%)</p><p>Mediana&nbsp;(95% CI) Hazard ratiob&nbsp;(95% CI)</p><p>Vc+M+P n=344</p><p>101 (29) 20.7 mo (17.6, 24,7)</p><p>135 (39) 18.3 mo (16.6, 21.7)</p><p>176 (51.2)<br />56.4 mo (52.8, 60.9)</p><p>M+P n=338</p><p>152 (45) 15.0 mo (14.1, 17.9)</p><p>0.54 (0.42, 0.70) 0.000002</p><p>190 (56) 14.0 mo (11.1, 15.0)</p><p>0.61 (0.49, 0.76) 0.00001</p><p>211 (62.4)<br />43.1 mo (35.3, 48.3)</p><p>0.695 (0.567, 0.852)</p><p><img alt="page34image20932736" width="75.960000" height="0.959990" src="blob:https://sdi.sfda.gov.sa/3e23262b-2f3c-4aeb-8f8d-1557f2e236c4" />&nbsp;<img alt="page34image20929856" width="67.380000" height="0.959990" src="blob:https://sdi.sfda.gov.sa/213a9185-91db-41f5-a103-a738ac399f6a" />&nbsp;<img alt="page34image20927936" width="50.040000" height="0.959990" src="blob:https://sdi.sfda.gov.sa/7581719f-50c8-45e8-84ac-80b53f93cf26" />&nbsp;<img alt="page34image20926976" width="463.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/427aa63b-5479-412f-adf2-fa706c2df2ca" />&nbsp;<img alt="page34image20926400" width="86.160000" height="0.959990" src="blob:https://sdi.sfda.gov.sa/b725fb1f-c30f-4e6b-a711-b80f3dc5ede4" /><img alt="page34image20930432" width="52.680000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f36c4814-6875-4bf6-8886-0ad1ae7428e6" />&nbsp;<img alt="page34image20929088" width="34.440000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/827f804f-76a3-4b3d-9803-a4e72549ddd5" />&nbsp;<img alt="page34image20928512" width="34.440000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/cd924b37-6197-4943-878c-efd36a818e68" />&nbsp;<img alt="page34image20931392" width="463.920000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8a5b384e-328e-4886-b148-6d6485d5f933" />&nbsp;<img alt="page34image20925248" width="82.620000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/720d6124-ad2a-452e-889e-7b8d755d20b4" />&nbsp;<img alt="page34image20922752" width="82.620000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/fde30e6e-6ce1-4fda-8a00-db26eb155fc6" /><img alt="page34image20929472" width="76.080000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/fd104ab3-219c-44c7-aa11-858daeb55b95" />&nbsp;<img alt="page34image20713984" width="463.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/94a71fea-cac1-4e38-86ad-e468e4512ceb" />&nbsp;<img alt="page34image20710720" width="96.480000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/c51f1e0f-be0d-4b3c-ba7e-dcb9fc93a459" />&nbsp;<img alt="page34image20712832" width="47.040000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/c73b9327-ae88-4c51-a1f0-2407cc9d73d9" /><img alt="page34image20717248" width="463.920000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/47ca916d-5b4a-48e4-bee1-4d5b528bc240" />&nbsp;<img alt="page34image20711488" width="37.500000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/1f888b15-6bb3-48ec-9944-c09f219b6edb" />&nbsp;<img alt="page34image20716096" width="34.020000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/59a2581c-c237-4198-92d4-5ddb55b967aa" /><img alt="page34image20715904" width="463.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/270c304a-df42-4155-bd74-e7debcf0e4e8" />&nbsp;<img alt="page34image20717824" width="108.480000" height="0.960010" src="blob:https://sdi.sfda.gov.sa/a974424a-fcd7-457b-9aea-db24cc4a09f9" />&nbsp;<img alt="page34image20716672" width="52.680000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/3d9b3afd-acb1-4f51-b796-59cdfd9529f8" />&nbsp;<img alt="page34image20722048" width="34.440000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/752837ac-fe93-423d-81ca-7c3b9b9d1bcc" />&nbsp;<img alt="page34image20712064" width="34.440000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/20538949-5c89-48f3-a6e4-9ed4460de8e6" /><img alt="page34image20712256" width="463.920000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/d5a40b91-5df4-45e7-95cc-93df994393c3" />&nbsp;<img alt="page34image20718016" width="82.620000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e5873f55-57a4-4f3b-9004-fd444b71541b" />&nbsp;<img alt="page34image20718400" width="81.780000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/8b870475-b2d2-4a33-b890-ef1528da0a34" />&nbsp;<img alt="page34image20720896" width="76.080000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/f5cf5dac-7ff0-463b-b217-8bb3dc407cc2" /><img alt="page34image20709568" width="463.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/0a6c6601-70f1-4bb3-8ff6-b13937c28d20" />&nbsp;<img alt="page34image20720320" width="96.480000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/65765940-2b7f-4948-9602-766f3a2d4b10" />&nbsp;<img alt="page34image20713408" width="47.040000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/69117231-9a2e-4d0c-b8c6-e2e240805764" /><img alt="page34image20710528" width="463.920000" height="0.480000" src="blob:https://sdi.sfda.gov.sa/d47060b8-ae7a-41bd-8597-642c6e38da23" />&nbsp;<img alt="page34image20713024" width="32.520000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/cf837bc0-ab8a-41a4-9bb0-3dd7412e596c" />&nbsp;<img alt="page34image20717632" width="36.840000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/0e883dd2-4512-4af1-8d4c-bd41fe2cadfa" /><img alt="page34image20715136" width="463.920000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/06663078-c487-409e-8148-145f8f39283b" />&nbsp;<img alt="page34image20709376" width="74.760000" height="0.959990" src="blob:https://sdi.sfda.gov.sa/b63b0c31-ce3f-437a-bcfb-72fb8f088ed6" />&nbsp;<img alt="page34image20713792" width="87.660000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/1d03802f-f9a5-4aa2-9a40-4c6a81a4c9d1" />&nbsp;<img alt="page34image20718784" width="42.000000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/1e48fba9-c1fe-4484-9e62-e7f4d53f8c58" />&nbsp;<img alt="page34image20721472" width="41.280000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e76ede81-0174-4a12-9214-e1cb6ec97873" /><img alt="page34image20711296" width="463.860000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/ed1350d3-72b7-4e53-b30a-338823a4f1d8" />&nbsp;<img alt="page34image20710144" width="82.620000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/98efb172-e776-42de-a909-fc52522a2175" />&nbsp;<img alt="page34image20713216" width="82.620000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b39f45ee-8681-489f-b967-fbd3ff647c9a" />&nbsp;<img alt="page34image20720128" width="76.260000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/d77e239c-603d-4583-9b80-ecedb711e602" /><img alt="page34image20716288" width="463.380000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/e216cd8e-81e3-46bc-983f-e9316dbd25f6" />&nbsp;<img alt="page34image20715328" width="96.480000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1c5c6bba-12ef-4f9f-a52f-7debb5f3978d" />&nbsp;<img alt="page34image20719936" width="57.180000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/b243c77a-98ee-43b8-a46c-7a2d30f916d8" /><img alt="page34image20711104" width="191.400000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/efaeb67f-3425-4068-8858-68a467c2191c" />&nbsp;<img alt="page34image20709760" width="271.020000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2ae26e6b-88d1-48fd-b0fd-3d7bdb6fe58f" /></p><p>sa-spc</p><p>Pg. 34</p><p>Bortezomib for injection 3.5mg/vial</p><p><img alt="page35image20381248" width="463.380000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/8eb128b7-370b-4b33-8cd2-6418fb943a32" />&nbsp;<img alt="page35image20368192" width="0.720000" height="674.280000" src="blob:https://sdi.sfda.gov.sa/8da5a6e4-e4fe-4680-85cd-43505561c7b3" /></p><p>p-valuec&nbsp;Response rate</p><p>populatione&nbsp;n=668</p><p>CRf&nbsp;n (%)</p><p>PRf&nbsp;n (%) nCR n (%)</p><p>CR+PRf&nbsp;n (%) p-valued</p><p>Reduction in serum M-protein</p><p>populationg&nbsp;n=667<br />&ge;90% n (%)<br />Time to first response in CR + PR&nbsp;Median</p><p>Mediana&nbsp;response duration</p><p>CRf</p><p>CR+PRf</p><p>Time to next therapy</p><p>Events n (%)<br />Mediana&nbsp;(95% CI) Hazard ratiob&nbsp;(95% CI)</p><p>p-valuec</p><p>Clinical efficacy and safety</p><p>Multiple Myeloma</p><p>n=337</p><p>102 (30) 136 (40)</p><p>5 (1) 238 (71)</p><p>n=336</p><p>151 (45) 1.4 mo</p><p>24.0 mo 19.9 mo</p><p>224 (65.1)<br />27.0 mo (24.7, 31.1)</p><p>0.00043</p><p>&lt; 10-10</p><p>n=331</p><p>12 (4) 103 (31)</p><p>0 115 (35)</p><p>n=331</p><p><img alt="page35image20371648" width="32.520000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/87d2a0d3-4b4d-4298-8aa7-f30ecee32953" />&nbsp;<img alt="page35image20371072" width="34.020000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1a7858fd-3d86-4a4f-addd-604cdbca211a" />&nbsp;<img alt="page35image20381440" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/704ef8b2-79a1-4c69-88c5-cdd8fb9af0ce" />&nbsp;<img alt="page35image20366272" width="60.240000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/385c520b-d710-46d0-b4ce-98bac3f24fd2" />&nbsp;<img alt="page35image20376064" width="76.500000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/1db992f8-07cb-406b-b890-3e8a48286315" /><img alt="page35image20377216" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/71e561c9-106a-4c1a-acf1-f7801acf0c17" />&nbsp;<img alt="page35image20367040" width="34.440000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2e985a14-9169-4f41-9125-5d5dab5d9b46" />&nbsp;<img alt="page35image20366464" width="42.240000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8ac0d996-09b1-4db0-ae9f-aea55cd141ee" /><img alt="page35image20375296" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/df629806-e9d0-44bf-aa6a-082c1919a85e" />&nbsp;<img alt="page35image20365696" width="34.440000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/9e910d47-5b60-40fa-abbc-181c8a3ef08f" />&nbsp;<img alt="page35image20373568" width="34.440000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/efb72e98-569c-4a02-9267-277ff9045581" />&nbsp;<img alt="page35image20380672" width="41.160000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2d896811-d959-4a88-ac34-38b287dfc991" /><img alt="page35image20373760" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/8473d5bc-be84-48aa-b506-8d70a20cbf81" />&nbsp;<img alt="page35image20372224" width="43.680000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5db6a59f-7a64-44b9-951d-5ac4fe313b3c" /><img alt="page35image20370304" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/2dd7e1a2-640a-450a-afc5-47291e526cc2" />&nbsp;<img alt="page35image20374912" width="34.440000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/e0ab2d48-fd6f-4ed9-8224-f3fc7fabc467" />&nbsp;<img alt="page35image20372032" width="33.720000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/4b222295-6076-4fa6-a790-93a8024fe953" />&nbsp;<img alt="page35image20377984" width="60.480000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/db5131d1-ce4c-49d0-aab5-1443de6e7b4c" /><img alt="page35image20372416" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f62d8ff4-cdbf-4e78-bbe8-4b86083fbdc3" />&nbsp;<img alt="page35image20380480" width="34.980000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/fe870d7c-c6a0-4752-baab-86c553d874ed" /><img alt="page35image20368768" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/5f1bca82-bc01-4a23-b234-e4be0c0fc3f4" />&nbsp;<img alt="page35image20378560" width="131.460000" height="0.959960" src="blob:https://sdi.sfda.gov.sa/cda3a624-e93d-4d3a-ad75-0245b0ff876a" />&nbsp;<img alt="page35image20367232" width="77.040000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/d561466b-5cfe-44cb-bced-3100896f1193" /><img alt="page35image20369152" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/a7b596f1-25b4-4379-a4d9-15b5121053f4" /></p><p>34 (10) 4.2 mo</p><p>12.8 mo 13.1 mo</p><p>260 (76.9)<br />19.2 mo (17.0, 21.0)</p><p><img alt="page35image20376448" width="49.200000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/13033d18-ab00-4584-8c3b-b77c8eff7298" />&nbsp;<img alt="page35image20321536" width="34.440000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/c1a7e61b-32d7-4054-826b-cce577ffa1d0" />&nbsp;<img alt="page35image20318464" width="463.380000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/418f3bb6-4dc3-41a5-9c5a-46f7d91de779" />&nbsp;<img alt="page35image20317504" width="145.860000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/14beb903-f1ac-4ec3-9b67-a1acd242c7e0" /><img alt="page35image20316928" width="463.380000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/ba940716-82b2-480c-a281-ff4bc11b1132" /><img alt="page35image20345024" width="463.380000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/a72411eb-b453-41dc-91a9-ea4ec0644e08" />&nbsp;<img alt="page35image20333504" width="117.840000" height="0.959960" src="blob:https://sdi.sfda.gov.sa/39fd847d-42f6-47b0-b86f-cc35584026bb" /><img alt="page35image20341376" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/39afd3e8-d038-48cd-a32c-751d28ee2a89" />&nbsp;<img alt="page35image20343104" width="33.060000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/daa36078-10af-4ac2-a7ba-12bd679a04cf" />&nbsp;<img alt="page35image20332928" width="33.060000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/c86fbfea-8bec-4e38-930a-c1ccdbb1c6f3" /><img alt="page35image20422144" width="463.380000" height="0.480040" src="blob:https://sdi.sfda.gov.sa/514b86a0-cb1c-49f4-8647-a72811cb12ee" />&nbsp;<img alt="page35image20446784" width="33.060000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/f5dae17e-0840-48f4-975d-5cc7efd532e8" />&nbsp;<img alt="page35image20443520" width="33.060000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/80d27343-839b-41f3-be3c-2d03c413fe06" />&nbsp;<img alt="page35image20435648" width="34.560000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/df1185a7-a463-4c43-aea5-310d6d48f948" /><img alt="page35image20446400" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/9c43e047-dd34-4fc2-bb8d-d271c30e298f" />&nbsp;<img alt="page35image20385344" width="90.300000" height="0.960020" src="blob:https://sdi.sfda.gov.sa/19c7a4b0-b002-4c53-8131-1f809b1bae2e" />&nbsp;<img alt="page35image19989248" width="52.680000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/6513398a-202e-4028-9371-a4e672fbf032" />&nbsp;<img alt="page35image19989632" width="42.000000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/481c8138-d2e9-417e-ab10-d02b55bad66b" />&nbsp;<img alt="page35image19988864" width="42.000000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/cf676f9e-2c76-4939-8e19-68232b3be704" /><img alt="page35image19990784" width="463.380000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/51678ab5-38f7-4fff-a65c-e99d2378ca2a" />&nbsp;<img alt="page35image19989056" width="82.620000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/dab142ff-1ed4-4405-aac5-cf85bdc08551" />&nbsp;<img alt="page35image19990976" width="82.620000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/9f7e5261-7988-4756-aa7f-acfadb17673b" />&nbsp;<img alt="page35image19988672" width="76.260000" height="0.480010" src="blob:https://sdi.sfda.gov.sa/3689153f-9e47-43df-b247-0c4c46c03c43" /><img alt="page35image19993664" width="463.380000" height="0.479980" src="blob:https://sdi.sfda.gov.sa/60207896-46e0-428c-8b01-d3c2414ecfec" /></p><p>0.557 (0.462, 0.671) &lt; 0.000001</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p><img alt="page50image20767168" width="49.500000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c266dc07-faad-4a13-a3c4-2c0e0733357e" /></p><p>Following intravenous bolus administration of a 1.0 mg/ m2&nbsp;and 1.3 mg/ m2&nbsp;dose to 11 patients with multiple myeloma and creatinine clearance values greater than 50 ml/min, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/ml, respectively. In subsequent doses, mean maximum observed plasma concentrations ranged from 67 to 106 ng/ml for the</p><p>1.0 mg/ m2&nbsp;dose and 89 to 120 ng/ml for the 1.3 mg/ m2&nbsp;dose.<br />Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m2&nbsp;dose to patients with multiple myeloma (n=14 in the intravenous group, n=17 in the subcutaneous group), the total systemic exposure after repeat dose administration (AUClast) was equivalent for subcutaneous and intravenous administrations. The Cmax after subcutaneous administration (20.4 ng/ml) was lower than intravenous (223 ng/ml). The AUClast geometric mean ratio was 0.99 and 90% confidence intervals were 80.18%-122.80%.</p><p>&nbsp;</p><p>&nbsp;</p><p>Metabolism</p><p>In vitro&nbsp;studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolised via cytochrome P450 enzymes, 3A4, 2C19, and 1A2. The major metabolic pathway is deboronation to form two deboronated metabolites that subsequently undergo hydroxylation to several metabolites. Deboronated-bortezomib metabolites are inactive as 26S proteasome inhibitors.</p><p>&nbsp;</p><p>&nbsp;</p><p>Elimination</p><p>The mean elimination half-life (t1/2) of bortezomib upon multiple dosing ranged from 40-193 hours. Bortezomib is eliminated more rapidly following the first dose compared to subsequent doses. Mean total body clearances were 102 and 112 l/h following the first dose for doses of 1.0 mg/ m2&nbsp;and 1.3 mg/ m2, respectively, and ranged from 15 to 32 l/h and 18 to 32 l/h following subsequent doses for doses of 1.0 mg/ m2&nbsp;and 1.3 mg/ m2, respectively.</p><p>Special populations</p><p>Hepatic impairment</p><p>The effect of hepatic impairment on the pharmacokinetics of bortezomib was assessed in a Phase I study during the first treatment cycle, including 61 patients primarily with solid tumors and varying degrees of hepatic impairment at bortezomib doses ranging from 0.5 to 1.3 mg/ m2.<br />When compared to patients with normal hepatic function, mild hepatic impairment did not alter dose-normalised bortezomib AUC. However, the dose-normalised mean AUC values were increased by approximately 60% in patients with moderate or severe hepatic impairment. A lower starting dose is recommended in patients with moderate or severe hepatic impairment, and those patients should be closely monitored (see section 4.2, Table 6).</p><p>Renal impairment</p><p>A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCL) into the following groups: Normal (CrCL &ge; 60 ml/min/1.73 m2, n=12), Mild (CrCL=40-59 ml/min/1.73 m2, n=10), Moderate (CrCL=20-39 ml/min/1.73 m2, n=9), and Severe (CrCL &lt; 20 ml/min/1.73 m2, n=3). A group of dialysis patients who were dosed after dialysis was also included in the study (n=8).</p><p>Patients were administered intravenous doses of 0.7 to 1.3 mg/ m2&nbsp;of Bortezomib twice weekly. Exposure of Bortezomib (dose-normalised AUC and Cmax) was comparable among all the groups (see section 4.2).</p><p>Age</p><p>The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3mg/m2&nbsp;doses to 104 pediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). Based on a population pharmacokinetic analysis, clearance of bortezomib increased with increasing body surface area</p><p><img alt="page51image20160960" width="438.240000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/813c56d4-80d9-451e-b22d-0ce427cbc5ae" />&nbsp;<img alt="page51image20164992" width="263.760000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/e2551ccd-4339-498c-a7f3-14b44ea0139d" />&nbsp;<img alt="page51image20165376" width="56.340000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c12d6c88-4096-4bd5-b1d2-c5707f285430" /><img alt="page51image20162496" width="114.660000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/000ee8f4-4bb9-4d7f-ae50-bfcaf2d00be6" />&nbsp;<img alt="page51image20163456" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/d4d8916f-e39d-4b03-a0aa-a3dc41541b8b" /><img alt="page51image20156352" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/9e43984f-5fd9-4045-b4c1-6cab484ded9b" />&nbsp;<img alt="page51image20161920" width="32.100000" height="0.539920" src="blob:https://sdi.sfda.gov.sa/59170b48-a15b-43f4-9faf-886d572fce4e" />&nbsp;<img alt="page51image20160384" width="52.560000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/7bd76c63-2d25-4728-a6cc-5a2bd5f849ee" />&nbsp;<img alt="page51image20158272" width="0.720000" height="151.740000" src="blob:https://sdi.sfda.gov.sa/78dedd43-ce30-4316-a612-256ef172e2cc" /><img alt="page51image20154240" width="400.500000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/e54f421f-fbe3-4a42-917c-cac5a44b6c56" /><img alt="page51image20159040" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/8e1cae82-ff67-422f-b8c9-7a0dc909600d" /><img alt="page51image20161152" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/08f5696f-2f2c-40d3-a8d3-8e9c7812e863" /><img alt="page51image20161536" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/232b8dae-c376-4b3d-b5ca-c057f312d0d5" />&nbsp;<img alt="page51image20160000" width="86.760000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/93738ea1-f38f-4857-86ef-79d572698de2" /><img alt="page51image20156928" width="355.080000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/357ab100-444f-44ae-a3ac-73639a2d3028" /><img alt="page51image20165568" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/8b599c6e-6cb7-42bb-8f88-abf190718737" />&nbsp;<img alt="page51image20145536" width="256.020000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/92a88cb3-f320-4e69-ba51-200d6d6e615a" /><img alt="page51image20141696" width="441.840000" height="0.540040" src="blob:https://sdi.sfda.gov.sa/c71bdfee-c973-4108-8d4e-6fc8b6765659" /><img alt="page51image20142848" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/7492e15f-6d57-4585-bd0c-f07ae87ae361" /><img alt="page51image20136704" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/0eaddc20-cee6-4a6a-8c45-2ac9cbee9284" /><img alt="page51image20140928" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/bf0681ab-d6ad-4ef9-bc87-f625bf276ceb" /><img alt="page51image20145728" width="362.880000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/98000b63-d66b-4a4c-a8e0-2d462f9de044" />&nbsp;<img alt="page51image20151872" width="51.960000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/90e92b35-c785-4516-b914-e0725e7a20b1" />&nbsp;<img alt="page51image20142080" width="0.720000" height="404.760000" src="blob:https://sdi.sfda.gov.sa/ef53f38d-4314-498a-9d0b-ea8d9f23d973" />&nbsp;<img alt="page51image20140352" width="145.200000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/8d21e32a-6331-4e8b-82ed-f7ed14293ce0" /><img alt="page51image20141888" width="287.580000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/089a1c5b-e44f-419b-a64c-af5c4d2aabe3" />&nbsp;<img alt="page51image20141504" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/6da84f6b-e6a1-4587-9216-76377f0c5b2f" /><img alt="page51image20140544" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/370148d7-0ae4-4323-bee3-59bfe0daba9d" /><img alt="page51image20142656" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/494d548f-dbd9-4564-80cf-f05f6826d772" />&nbsp;<img alt="page51image20141120" width="261.420000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/657d136e-7487-4cca-81b7-9292bb54f27e" /><img alt="page51image20140160" width="86.460000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/226d761d-990c-4e07-8068-4ec07bbb3258" />&nbsp;<img alt="page51image20137856" width="88.320000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/d841483d-779c-4e1d-a050-7c29b4354ffc" />&nbsp;<img alt="page51image20141312" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/21227f3c-4fe5-446f-aa13-1b25a543ad8d" /><img alt="page51image20140736" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/81c0819f-b354-4978-ba9b-f0883b718ab5" /><img alt="page51image20145344" width="366.360000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ff5e20d4-8e89-4fb4-8784-616d4f2b4f2e" /><img alt="page51image20137472" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/c3b6ba33-34b1-49c8-ad4e-37cb1b987e70" /><img alt="page51image20144384" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/18082977-6617-438b-92e7-569ed5a469d4" /><img alt="page51image20135936" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/ae78fde2-8b8b-49eb-b498-db46c1931f08" /><img alt="page51image20142464" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/2f4593f1-2085-45cf-bb1e-e7fff557fd21" />&nbsp;<img alt="page51image20139968" width="277.320000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/c148c613-91e9-4ee3-a311-a45a95c86b09" /><img alt="page51image20136320" width="79.080000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/355b4748-d5d7-4e6c-9383-0a7e57a7194f" />&nbsp;<img alt="page51image20139008" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/99ad7539-b239-413f-b192-4e4d71fba99d" /><img alt="page51image20136896" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/5827ed82-5267-442c-a8b0-474d73be87e3" /><img alt="page51image20138816" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/0728519c-f9f8-4363-a5ad-9af236b99db0" /><img alt="page51image20377792" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/d1a664ef-2206-422b-8e9f-5e23acd1cef2" /><img alt="page51image20368000" width="369.120000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/2dde04d0-996e-4c16-8e63-2a7d78bc4250" /><img alt="page51image20378176" width="441.840000" height="0.539990" src="blob:https://sdi.sfda.gov.sa/fb3f3f65-3c2c-4702-b417-662c6672c35c" /><img alt="page51image20374336" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/8ca2900e-4c3f-49e9-abbb-f9d27b57b4a7" />&nbsp;<img alt="page51image20379328" width="74.520000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/a651eeca-d440-4326-aaf0-4ea19e07ed33" /><img alt="page51image20375104" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/99452739-4d44-458a-b0a7-556cf7f3be1a" /><img alt="page51image20379904" width="441.840000" height="0.539980" src="blob:https://sdi.sfda.gov.sa/2eecbbe9-e291-4cbe-8abf-1096f458fbe1" /><img alt="page51image20366080" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/dbfc6ac1-3ad2-438a-812a-7a8c5edef066" /><img alt="page51image20365888" width="441.840000" height="0.540010" src="blob:https://sdi.sfda.gov.sa/bf744185-92db-49c1-9f51-73f1f4dc46f9" /></p><p>sa-spc</p><p>Pg. 51</p><p>Bortezomib for injection 3.5mg/vial</p><p>(BSA). Geometric mean (%CV) clearance was 7.79 (25%) L/hr/ m2, volume of distribution at steadystate was 834 (39%) L/ m2, and the elimination half-life was 100 (44%) hours. After correcting for the BSA effect, other demographics such as age, body weight and sex did not have clinically significant effects on bortezomib clearance. BSA normalized clearance of bortezomib in pediatric patients was similar to that observed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bortezomib was positive for clastogenic activity (structural chromosomal aberrations) in the in vitro chromosomal aberration assay using Chinese hamster ovary (CHO) cells at concentrations as low as 3.125 &mu;g/ml, which was the lowest concentration evaluated. Bortezomib was not genotoxic when tested in the in vitro mutagenicity assay (Ames assay) and in vivo micronucleus assay in mice. Developmental toxicity studies in the rat and rabbit have shown embryo-fetal lethality at maternally toxic doses, but no direct embryo-foetal toxicity below maternally toxic doses. Fertility studies were not performed but evaluation of reproductive tissues has been performed in the general toxicity studies. In the 6-month rat study, degenerative effects in both the testes and the ovary have been observed. It is, therefore, likely that bortezomib could have a potential effect on either male or female fertility. Peri- and postnatal development studies were not conducted.</p><p>In multi-cycle general toxicity studies conducted in the rat and monkey, the principal target organs included the gastrointestinal tract, resulting in vomiting and/or diarrhoea; haematopoietic and lymphatic tissues, resulting in peripheral blood cytopenias, lymphoid tissue atrophy and haematopoietic bone marrow hypocellularity; peripheral neuropathy (observed in monkeys, mice and dogs) involving sensory nerve axons; and mild changes in the kidneys. All these target organs have shown partial to full recovery following discontinuation of treatment.</p><p>&nbsp;</p><p>Based on animal studies, the penetration of bortezomib through the blood-brain barrier appears to be limited, if any and the relevance to humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol (PFG)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product is packed in 10 mL USP Type -1 glass vial stoppered with 13 mm rubber stoppers and sealed with 13 mm aluminium seals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bortezomib is a cytotoxic agent. Therefore, caution should be used during handling and preparation of Bortezomib TBM. Use of gloves and other protective clothing to prevent skin contact is recommended.<br />Aseptic technique must be strictly observed throughout the handling of Bortezomib TBM, since it contains no preservative. There have been fatal cases of inadvertent intrathecal administration of bortezomib. Bortezomib TBM is for intravenous or subcutaneous use. Bortezomib TBM should not be administered intrathecally.</p><p>Instructions for reconstitution<br />Bortezomib TBM must be reconstituted by a healthcare professional.<br />Intravenous injection<br />Each 10 ml vial of Bortezomib TBM must be carefully reconstituted with 3.5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper. Dissolution of the lyophilized powder is completed in less than 2 minutes.<br />After reconstitution, each ml solution contains 1 mg bortezomib. The reconstituted solution is clear and colourless, with a final pH of 4 to 7.<br />The reconstituted solution must be inspected visually for particulate matter and discolouration prior to administration. If any discolouration or particulate matter is observed, the reconstituted solution must be discarded.</p><p>Subcutaneous injection</p><p>Each 10 ml vial of Bortezomib TBM must be carefully reconstituted with 1.4 ml of sodium chloride 9 mg/ml (0.9%) solution for injection, by using a syringe of the appropriate size, without removing the vial stopper. Dissolution of the lyophilised powder is completed in less than 2 minutes.<br />After reconstitution, each ml solution contains 2.5 mg bortezomib. The reconstituted solution is clear and colourless, with a final pH of 4 to 7. The reconstituted solution must be inspected visually for particulate matter and discolouration prior to administration. If any discolouration or particulate matter is observed, the reconstituted solution must be discarded.</p><p>Disposal<br />Bortezomib TBM is for single use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company, Sudair Industrial Zone, Sudair,
Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>